<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2023.1196774</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>Acinetobacter baumannii</italic> in the critically ill: complex infections get complicated</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Cavallo</surname> <given-names>Ilaria</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/2325699/overview"/>
</contrib>
<contrib contrib-type="author"><name><surname>Oliva</surname> <given-names>Alessandra</given-names></name><xref rid="aff2" ref-type="aff"><sup>2</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/437114/overview"/>
</contrib>
<contrib contrib-type="author"><name><surname>Pages</surname> <given-names>Rebecca</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/2264536/overview"/>
</contrib>
<contrib contrib-type="author"><name><surname>Sivori</surname> <given-names>Francesca</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/2288270/overview"/>
</contrib>
<contrib contrib-type="author"><name><surname>Truglio</surname> <given-names>Mauro</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/1301886/overview"/>
</contrib>
<contrib contrib-type="author"><name><surname>Fabrizio</surname> <given-names>Giorgia</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref></contrib>
<contrib contrib-type="author"><name><surname>Pasqua</surname> <given-names>Martina</given-names></name><xref rid="aff3" ref-type="aff"><sup>3</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/500905/overview"/>
</contrib>
<contrib contrib-type="author"><name><surname>Pimpinelli</surname> <given-names>Fulvia</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/1809594/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Di Domenico</surname> <given-names>Enea Gino</given-names></name><xref rid="aff3" ref-type="aff"><sup>3</sup></xref><xref rid="c001" ref-type="corresp"><sup>&#x002A;</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/326638/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Public Health and Infectious Diseases, Sapienza University of Rome</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Biology and Biotechnology "C. Darwin" Sapienza University of Rome</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff>
<author-notes>
<fn id="fn0001" fn-type="edited-by">
<p>Edited by: Axel Cloeckaert, Institut National de recherche pour l&#x2019;agriculture, l&#x2019;alimentation et l&#x2019;environnement (INRAE), France</p>
</fn>
<fn id="fn0002" fn-type="edited-by">
<p>Reviewed by: Wasan Katip, Chiang Mai University, Thailand; Veronica Godoy, Northeastern University, United States</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Enea Gino Di Domenico, <email>enea.didomenico@uniroma1.it</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1196774</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>03</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>06</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2023 Cavallo, Oliva, Pages, Sivori, Truglio, Fabrizio, Pasqua, Pimpinelli and Di Domenico.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Cavallo, Oliva, Pages, Sivori, Truglio, Fabrizio, Pasqua, Pimpinelli and Di Domenico.</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p><italic>Acinetobacter baumannii</italic> is increasingly associated with various epidemics, representing a serious concern due to the broad level of antimicrobial resistance and clinical manifestations. During the last decades, <italic>A. baumannii</italic> has emerged as a major pathogen in vulnerable and critically ill patients. Bacteremia, pneumonia, urinary tract, and skin and soft tissue infections are the most common presentations of <italic>A. baumannii</italic>, with attributable mortality rates approaching 35%. Carbapenems have been considered the first choice to treat <italic>A. baumannii</italic> infections. However, due to the widespread prevalence of carbapenem-resistant <italic>A. baumannii</italic> (CRAB), colistin represents the main therapeutic option, while the role of the new siderophore cephalosporin cefiderocol still needs to be ascertained. Furthermore, high clinical failure rates have been reported for colistin monotherapy when used to treat CRAB infections. Thus, the most effective antibiotic combination remains disputed. In addition to its ability to develop antibiotic resistance, <italic>A. baumannii</italic> is also known to form biofilm on medical devices, including central venous catheters or endotracheal tubes. Thus, the worrisome spread of biofilm-producing strains in multidrug-resistant populations of <italic>A. baumannii</italic> poses a significant treatment challenge. This review provides an updated account of antimicrobial resistance patterns and biofilm-mediated tolerance in <italic>A. baumannii</italic> infections with a special focus on fragile and critically ill patients.</p>
</abstract>
<kwd-group>
<kwd><italic>Acinetobacter baumannii</italic></kwd>
<kwd>cancer</kwd>
<kwd>biofilm</kwd>
<kwd>skin and soft-tissue infections</kwd>
<kwd>colistin</kwd>
<kwd>carbapenem</kwd>
<kwd>crab</kwd>
<kwd>cefiderocol</kwd>
</kwd-group>
<contract-sponsor id="cn1">Italian Ministry of Health</contract-sponsor>
<counts>
<fig-count count="2"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="234"/>
<page-count count="17"/>
<word-count count="16867"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Infectious Agents and Disease</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="sec1" sec-type="intro">
<title>Introduction</title>
<p><italic>Acinetobacter baumannii</italic> is an opportunistic pathogen causing severe nosocomial infections (<xref ref-type="bibr" rid="ref68">Gonzalez-Villoria and Valverde-Garduno, 2016</xref>; <xref ref-type="bibr" rid="ref124">Morris et al., 2019</xref>). The global estimated incidence rate of <italic>A. baumannii</italic> infections is approximately 1 million cases annually, with high crude mortality rates, particularly in critically ill patients (<xref ref-type="bibr" rid="ref155">Peleg et al., 2008</xref>; <xref ref-type="bibr" rid="ref114">Magill et al., 2014</xref>; <xref ref-type="bibr" rid="ref108">Lob et al., 2016</xref>; <xref ref-type="bibr" rid="ref159">Piperaki et al., 2019</xref>; <xref ref-type="bibr" rid="ref112">Ma and McClean, 2021</xref>). Over the last 30&#x2009;years, <italic>A. baumannii</italic> has emerged as one of the most troublesome pathogens for healthcare institutions, but it rarely causes disease outside of the healthcare setting (<xref ref-type="bibr" rid="ref222">Wong et al., 2017</xref>). The clinical significance of <italic>A. baumannii</italic> has been raised due to its ability to acquire antibiotic resistance and tolerate desiccation. Indeed, multidrug-resistant (MDR), extensively drug-resistant (XDR), and <italic>A. baumannii</italic> isolates resistant to all clinically available antibiotics (pan-drug resistant&#x2014;PDR) have been reported worldwide (<xref ref-type="bibr" rid="ref159">Piperaki et al., 2019</xref>; <xref ref-type="bibr" rid="ref220">Weinberg et al., 2020</xref>). The rates of MDR are approximately four times higher than those described for other major nosocomial pathogens (<xref ref-type="bibr" rid="ref71">Hamidian and Nigro, 2019</xref>). Currently, 45% of all <italic>A. baumannii</italic> isolates are classified as MDR, with peaks of 70% in South America, Asia, and Europe (<xref ref-type="bibr" rid="ref65">Giammanco et al., 2017</xref>; <xref ref-type="bibr" rid="ref71">Hamidian and Nigro, 2019</xref>). These observations place <italic>A. baumannii</italic> among the most problematic nosocomial ESKAPE (<italic>Enterococcus faecium</italic>, <italic>Staphylococcus aureus</italic>, <italic>Klebsiella pneumoniae</italic>, <italic>Acinetobacter baumannii</italic>, <italic>Pseudomonas aeruginosa</italic>, and <italic>Enterobacter</italic> spp) pathogens, and a &#x201C;high priority&#x201D; by the World Health Organization (WHO) and Centers for Disease Control and Prevention [CDC; <xref ref-type="bibr" rid="ref1002">Tacconelli et al., 2018</xref>; <xref ref-type="bibr" rid="ref196">Tiku, 2022</xref>].</p>
<p>The ability to acquire antibiotic resistance, the environmental persistence, along with the absence of identified toxins in its genome suggest that the virulence potential of <italic>A. baumannii</italic> resides in the ability to survive for prolonged periods throughout a hospital environment (<xref ref-type="bibr" rid="ref221">Whiteway et al., 2022</xref>). Indeed, adhering to plastics allows <italic>A. baumannii</italic> to colonize endotracheal tubes or central venous catheters, thus increasing its persistence and transmission in hospitalized patients (<xref ref-type="bibr" rid="ref155">Peleg et al., 2008</xref>; <xref ref-type="bibr" rid="ref169">Roca et al., 2012</xref>). In particular, <italic>A. baumannii</italic> has been demonstrated to grow as a biofilm on different materials, including health-care-associated equipment, porcelain, stainless steel, rubber, endotracheal tubes, polycarbonate plastic, and polypropylene plastic (<xref ref-type="bibr" rid="ref69">Greene et al., 2016a</xref>,<xref ref-type="bibr" rid="ref70">b</xref>). Biofilm formation contributes significantly to establishing medical-device-associated infections conferring a high desiccation resistance and survival of <italic>A. baumannii</italic> isolates (<xref ref-type="bibr" rid="ref163">Pour et al., 2011</xref>; <xref ref-type="bibr" rid="ref69">Greene et al., 2016a</xref>,<xref ref-type="bibr" rid="ref70">b</xref>). Recent reports also suggested that biofilm-producing <italic>A. baumannii</italic> strains are commonly isolated from intensive care units and in oncological patients (<xref ref-type="bibr" rid="ref229">Zeighami et al., 2019</xref>; <xref ref-type="bibr" rid="ref7">Asaad et al., 2021</xref>; <xref ref-type="bibr" rid="ref42">Di Domenico et al., 2021</xref>; <xref ref-type="bibr" rid="ref173">Roy et al., 2022</xref>). MDR <italic>A. baumannii</italic> (MDRAB) forms robust biofilms, both in the wound and on occlusive dressings in the skin and soft-tissue infections (<xref ref-type="bibr" rid="ref193">Thompson et al., 2014</xref>). Notably, <italic>A. baumannii</italic> exhibits several adhesive and protective elements that significantly contribute to the formation and maintenance of biofilms, thus increasing tolerance to environmental stressors (<xref ref-type="bibr" rid="ref69">Greene et al., 2016a</xref>,<xref ref-type="bibr" rid="ref70">b</xref>). Biofilm is also important to the virulence of <italic>A. baumannii</italic> because it facilitates horizontal gene transfer (HGT) of antibiotic-resistance mobile elements while physically protecting bacteria from the immune system (<xref ref-type="bibr" rid="ref51">Eze et al., 2018</xref>; <xref ref-type="bibr" rid="ref73">Harding et al., 2018</xref>).</p>
<p>Infections caused by MDRAB in immunocompromised individuals result from complex relationships between several factors, including <italic>A. baumannii</italic> pathogenicity, the fitness costs of resistance, the site-specific microflora composition of the human host, and the selective forces following clinical interventions such as antibiotic therapy. Therefore, understanding the consequences of mutations driving antibiotic resistance and the worrisome convergence of virulent traits, including biofilm production, has important implications for controlling the spread of <italic>A. baumannii</italic> and developing novel treatment strategies in critically ill patients.</p>
<p>This review provides an updated analysis of antimicrobial resistance mechanisms and biofilm-mediated tolerance in <italic>A. baumannii</italic>. Moreover, we discuss current therapeutic options for carbapenem-resistant <italic>A. baumannii</italic> (CRAB) infections, with a special focus on fragile and critically ill patients.</p>
</sec>
<sec id="sec2">
<title>Virulence and pathogenicity</title>
<p>Various studies have revealed that <italic>A. baumannii</italic> owns more human virulence potential than other <italic>Acinetobacter</italic> spp. In particular, <italic>A. baumannii</italic> resists macrophage uptake and grows better at 37&#x00B0;C than other species (<xref ref-type="bibr" rid="ref192">Tayabali et al., 2012</xref>). Some elements, such as the outer membrane proteins (OMP), secretion systems, immunity interaction, or adhesion to the host cells, are highly characterized by virulence and pathogenicity in <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="ref124">Morris et al., 2019</xref>; <xref ref-type="bibr" rid="ref196">Tiku, 2022</xref>).</p>
<sec id="sec3">
<title>Outer membrane proteins and outer membrane vesicles</title>
<p>Outer membrane proteins (OMPs) are a class of integral membrane proteins anchored in the outer membrane with a &#x03B2;-barrel structure. OmpA is one of the most abundant porins in the outer membrane of <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="ref148">Park et al., 2011</xref>; <xref ref-type="bibr" rid="ref207">Uppalapati et al., 2020</xref>). OmpA is connected to the diaminopimelic acid of the peptidoglycan by two conserved residues (Asp271 and Arg286) in its periplasmic C-terminal domain (<xref ref-type="bibr" rid="ref149">Park et al., 2012</xref>.). These characteristics give OmpA high stability in the membrane and the capability to fight against harsh environments (<xref ref-type="bibr" rid="ref123">Moon et al., 2012</xref>). Indeed, being exposed to the outside of the bacterial cell OmpA provides the first line of contact between the bacterium and its surroundings. Given its central position, OmpA acts as an adhesion factor in virulence, channels for the uptake of nutrients, siderophore receptors, and enzymes such as proteases and lipases. Three OMPs were identified as fibronectin-binding proteins, such as OmpA, TonB-dependent copper receptor, and 34&#x2009;kDa Omp (<xref ref-type="bibr" rid="ref184">Smani et al., 2012</xref>). OmpA forms a non-selective channel in bacterial outer membranes that permits the passage of ions and other solutes (<xref ref-type="bibr" rid="ref188">Sugawara and Nikaido, 2012</xref>; <xref ref-type="bibr" rid="ref32">Confer and Ayalew, 2013</xref>). Furthermore, OmpA contributes to the antimicrobial resistance of <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="ref188">Sugawara and Nikaido, 2012</xref>; <xref ref-type="bibr" rid="ref183">Smani et al., 2014</xref>). Indeed, disrupting the OmpA gene decreases the minimal inhibitory concentrations (MICs) of aztreonam, chloramphenicol, and nalidixic acid by 8, 8, and 2.7-fold, respectively. This data suggests that OmpA participates in the extrusion of antibiotics from the periplasmic space through the outer membrane and couples with inner membrane efflux systems (<xref ref-type="bibr" rid="ref183">Smani et al., 2014</xref>). In <italic>A. baumannii</italic>, OmpA serves multiple functions, both <italic>in vitro</italic> and <italic>in vivo,</italic> including adherence to epithelia, induction of epithelial cell death, drug resistance, channels for the uptake of nutrients, siderophore receptors, binding to factor H (<xref ref-type="bibr" rid="ref28">Choi et al., 2005</xref>, <xref ref-type="bibr" rid="ref27">2008</xref>; <xref ref-type="bibr" rid="ref60">Gaddy et al., 2009</xref>; <xref ref-type="bibr" rid="ref96">Kim et al., 2009</xref>). OmpA enhances the survival and persistence of <italic>A. baumannii</italic> by facilitating biofilm formation (<xref ref-type="bibr" rid="ref60">Gaddy et al., 2009</xref>; <xref ref-type="bibr" rid="ref182">Shin et al., 2009</xref>). In particular, outer membrane receptor proteins are significantly upregulated in biofilm than in planktonic cultures (<xref ref-type="bibr" rid="ref182">Shin et al., 2009</xref>). Moreover, it has been reported that overexpression of OmpA represents a significant risk factor for pneumonia, bacteremia, and enhanced mortality in patients infected with <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="ref177">S&#x00E1;nchez-Encinales et al., 2017</xref>). In <italic>A. baumannii</italic>, virulence factors, including OmpA and certain tissue-degrading enzymes, are delivered to host cells via OMVs (<xref ref-type="bibr" rid="ref90">Jin et al., 2011</xref>). OMVs are spherical elements with a 20&#x2013;200&#x2009;nm diameter, secreted by various Gram-negative pathogenic bacteria (<xref ref-type="bibr" rid="ref99">Kulp and Kuehn, 2010</xref>). They mainly comprise lipopolysaccharide (LPS), outer membrane and periplasmic proteins, phospholipids, and nucleic acids, representing delivery vehicles for bacterial effectors to host cells (<xref ref-type="bibr" rid="ref47">Ellis and Kuehn, 2010</xref>). OMVs are central in delivering <italic>A. baumannii</italic> virulence factors, including OmpA, and certain tissue-degrading enzymes, such as proteases and phospholipases (<xref ref-type="bibr" rid="ref104">Lee et al., 2017</xref>). Furthermore, OmpA has the highest content in OMVs, which is involved in the mitochondrial decomposition of the host&#x2019;s cell apoptosis (<xref ref-type="bibr" rid="ref28">Choi et al., 2005</xref>; <xref ref-type="bibr" rid="ref197">Tiku et al., 2021</xref>).</p>
</sec>
<sec id="sec4">
<title>Phospholipase</title>
<p>Phospholipases are lipolytic enzyme essential for phospholipid metabolism and a major virulence factor in many Gram-negative bacteria. Phospholipids are the primary building blocks of biological membranes and a carbon and energy source in the human host. In <italic>A. baumannii</italic>, have been identified two phospholipases C (A1S_0043 and A1S_2055) and three phospholipases D (PLD1, PLD2, PLD3), all with substrate specificity toward the eukaryotic membrane component phosphatidylcholine (PC; <xref ref-type="bibr" rid="ref57">Flores-D&#x00ED;az et al., 2016</xref>). PC is abundant in eukaryotic membranes representing 50% of all phospholipids and increasing up to 80% in the lung and tracheobronchial secretions (<xref ref-type="bibr" rid="ref67">Girod et al., 1992</xref>; <xref ref-type="bibr" rid="ref17">Bernhard et al., 2001</xref>; <xref ref-type="bibr" rid="ref201">Tomaras et al., 2003</xref>) Experimental evidence suggests that it may serve as a nutrient source during lung infections by pathogens like <italic>Pseudomonas aeruginosa</italic> and <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="ref120">McConnell et al., 2013</xref>; <xref ref-type="bibr" rid="ref189">Sun et al., 2014</xref>; <xref ref-type="bibr" rid="ref142">&#x00D6;zarslan et al., 2023</xref>). Phospholipids&#x2019; degradation compromises the stability of host cell membranes, interfering with cellular signaling, thus resulting in changes in the host immune response (<xref ref-type="bibr" rid="ref57">Flores-D&#x00ED;az et al., 2016</xref>). In particular, the 1,2-diacylglycerol released by cellular phospholipases C plays roles in modifying biophysical membrane properties, including charge, fluidity, and permeability, and can recruit cytosolic proteins that induce spatial reorganization of signaling complexes, which in turn affect diverse cellular processes (<xref ref-type="bibr" rid="ref200">Toker, 2005</xref>; <xref ref-type="bibr" rid="ref57">Flores-D&#x00ED;az et al., 2016</xref>). Consequently, products generated by bacterial phospholipases could affect the immune response and promote the infection&#x2019;s establishment or progression (<xref ref-type="bibr" rid="ref210">van der Meer-Janssen et al., 2010</xref>). In <italic>A. baumannii,</italic> phospholipases D concertedly promote serum resistance, epithelial cell invasion, and <italic>in vivo</italic> pathogenesis (<xref ref-type="bibr" rid="ref87">Jacobs et al., 2010</xref>; <xref ref-type="bibr" rid="ref187">Stahl et al., 2015</xref>). Interestingly, PLD1 and PLD2 appear to result from a gene duplication characterized by the HxKx4Dx6GSxN (HKD) pattern similar to eukaryotic cells and required for catalytic activity (<xref ref-type="bibr" rid="ref187">Stahl et al., 2015</xref>). Despite their similarity, PLD2 is more important for invasion and virulence than the other two PLDs (<xref ref-type="bibr" rid="ref87">Jacobs et al., 2010</xref>; <xref ref-type="bibr" rid="ref187">Stahl et al., 2015</xref>). Since phospholipases are conserved across numerous strains of <italic>A. baumannii</italic> and are essential for host invasion, they may represent promising targets for developing enzyme inhibitors and potential vaccine candidates to limit the impacts on human diseases (<xref ref-type="bibr" rid="ref57">Flores-D&#x00ED;az et al., 2016</xref>).</p>
</sec>
<sec id="sec5">
<title>Protein secretion systems</title>
<p>The Type II secretion system (T2SS) is a two-step process, dependent on the general secretory pathway (Sec) or the Twin-arginine (Tat) system for substrate translocation to the periplasm before secretion in the extracellular environment (<xref ref-type="bibr" rid="ref219">Weber et al., 2017</xref>). The T2SS was first described in <italic>A. baumannii</italic> ATCC17978, with the specific apparatus encoded by genes designated, general secretory pathway (GspA-O), located in six separate operons (<xref ref-type="bibr" rid="ref44">Eijkelkamp, 2014</xref>). Secretion of type II effector proteins includes enzymes such as lipase, elastase, alkaline phosphatase, and phospholipases, which are essential for <italic>A. baumannii</italic> virulence (<xref ref-type="bibr" rid="ref46">Elhosseiny and Attia, 2018</xref>). In <italic>A. baumannii</italic>, major T2SS effectors include the metalloendopeptidase, CpaA, and the lipases, LipA and LipH (<xref ref-type="bibr" rid="ref91">Johnson et al., 2016</xref>; <xref ref-type="bibr" rid="ref219">Weber et al., 2017</xref>). Secretion of CpaA and LipA requires specific membrane-associated chaperones CpaB and LipB (<xref ref-type="bibr" rid="ref230">Zheng et al., 2013</xref>; <xref ref-type="bibr" rid="ref72">Harding, 2016</xref>). In particular, LipA contributes to extracellular lipolytic activity by using long-chain fatty acids as carbon sources for growth and may use fatty acids derived through lipid hydrolysis as signaling molecules allowing bacterial escape from innate immunity (<xref ref-type="bibr" rid="ref91">Johnson et al., 2016</xref>; <xref ref-type="bibr" rid="ref104">Lee et al., 2017</xref>). In addition, CpaA is a zinc-dependent metalloendopeptidase forming an active complex with its chaperone (CpaAB), essential for secretion. It targets the common coagulation pathway by interfering with fibrinogen, factor XII and factor V, disrupting blood clotting and allowing the dissemination and colonization of <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="ref214">Waack et al., 2018</xref>; <xref ref-type="bibr" rid="ref208">Urusova et al., 2019</xref>). Moreover, mutations in gspD and lipA showed a significant virulence reduction in both <italic>G. mellonella</italic> and murine models (<xref ref-type="bibr" rid="ref72">Harding, 2016</xref>; <xref ref-type="bibr" rid="ref91">Johnson et al., 2016</xref>).</p>
<p>Previous studies showed that <italic>A. baumannii</italic> strains produce a type VI secretion system (T6SS) involved in interbacterial competition (<xref ref-type="bibr" rid="ref55">Fitzsimons et al., 2018</xref>). The T6SS is a complex nanomachine structurally and mechanistically analogous to an intracellular membrane-attached contractile phage tail (<xref ref-type="bibr" rid="ref30">Cianfanelli et al., 2016</xref>). T6SS is an efficient weapon that can inject toxic effectors into the extracellular environment or directly into eukaryotic or prokaryotic cells (<xref ref-type="bibr" rid="ref30">Cianfanelli et al., 2016</xref>). In addition, this system is implicated in bacterial competition and DNA uptake released by the prey cells, which promotes horizontal gene transfer (HGT; <xref ref-type="bibr" rid="ref219">Weber et al., 2017</xref>). Indeed, HGT plays a significant role in the spread of antibiotic resistance cassettes and pathogenicity islands. Therefore, the potential involvement of T6SS in acquiring antibiotic resistance in <italic>A. baumannii</italic> has attracted considerable attention (<xref ref-type="bibr" rid="ref219">Weber et al., 2017</xref>). It remains to be determined what, if any, benefit the T6SS may provide to <italic>A. baumannii</italic> during infection. In particular, <italic>G. mellonella</italic> infected with <italic>A. baumannii</italic> defective for the T6SS did not succumb to infection as quickly as did worms infected with the wild-type but were killed to the same extent at later time points (<xref ref-type="bibr" rid="ref166">Repizo et al., 2015</xref>).</p>
</sec>
</sec>
<sec id="sec6">
<title>Multiple antibiotic-resistance mechanisms</title>
<p>Increasing reports of the hospital- and community-acquired MDRAB infections are accumulating worldwide (<xref ref-type="bibr" rid="ref8">Assimakopoulos et al., 2019</xref>; <xref ref-type="bibr" rid="ref66">Girija and Priyadharsini, 2019</xref>; <xref ref-type="bibr" rid="ref37">Darby et al., 2023</xref>; <xref ref-type="bibr" rid="ref117">Mangioni et al., 2023</xref>). In addition to its intrinsic resistance to antibiotics, <italic>A. baumannii</italic> can acquire new functions by HGT, enabling rapid dissemination and maintenance of resistance genes between different isolates (<xref ref-type="bibr" rid="ref39">Decr&#x00E9;, 2012</xref>). Indeed, the European Centre for Disease Prevention and Control&#x2019;s (ECDC) reported that from 2012 to 2020 in Europe, there had been an increase of 3.4% of <italic>A. baumannii</italic> strains resistant to fluoroquinolones, aminoglycosides, and carbapenems and an alarming rise of 11.3% (217 to 2,451 isolates) in Italy only.</p>
<sec id="sec7">
<title>Fluoroquinolones</title>
<p>The quinones/fluoroquinolones are antibiotics that inhibit two enzymes involved in DNA synthesis: DNA gyrases and Topoisomerase IV. <italic>A. baumannii</italic> has genetic mutations providing resistance. Mutations in the <italic>gyrA</italic> and <italic>parC</italic> genes of the DNA gyrase subunit and Topoisomerase IV subunit C play a major role in conferring direct antibiotic resistance (<xref ref-type="bibr" rid="ref172">Roy et al., 2021</xref>). Other important antibiotic resistance mechanisms of <italic>A. baumannii</italic> involve efflux pumps, permeability defects, and alteration of the target site (<xref rid="fig1" ref-type="fig">Figure 1</xref>). More generally, three resistance-nodulation cell division (RND)-family efflux pump systems, such as AdeABC, AdeFGH, and AdeIJK, and the multi-antimicrobial extrusion protein family (MATE) efflux pump in <italic>A. baumannii</italic> are overexpressed due to amino acid substitutions in their regulatory genes (<xref ref-type="bibr" rid="ref54">Fernandez and Hancock, 2013</xref>; <xref ref-type="bibr" rid="ref189">Sun et al., 2014</xref>; <xref ref-type="bibr" rid="ref37">Darby et al., 2023</xref>). These two systems allow a broad spectrum of antibiotic resistance to aminoglycoside, chloramphenicol, erythromycin, tetracycline, and tigecycline (<xref ref-type="bibr" rid="ref115">Magnet et al., 2001</xref>; <xref ref-type="bibr" rid="ref58">Fournier et al., 2006</xref>; <xref ref-type="bibr" rid="ref212">Vila et al., 2007</xref>). The plasmid-encoded <italic>qepA</italic> gene is an efflux pump belonging to the major facilitator superfamily that decreases susceptibility to hydrophilic fluoroquinolones, especially ciprofloxacin (<xref ref-type="bibr" rid="ref88">Jacoby et al., 2014</xref>). With less antibiotic resistance efficiency, mutations in the aminoglycoside transferase AAC(6&#x2032;)-Ib-Cr by Tryp102Arg and Asp179Typ substitution permit N-acetylation modification of two fluoroquinolones (ciprofloxacin and norfloxacin; <xref ref-type="bibr" rid="ref172">Roy et al., 2021</xref>; <xref ref-type="bibr" rid="ref211">Venkataramana et al., 2022</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>The main antibiotics resistance mechanisms of <italic>Acinetobacter baumannii.</italic> The resistance mechanisms are divided into six categories. <bold>(A)</bold> The permeability defects are due to porins modification, such as the carbapenem-associated outer membrane protein (CarO) and the OMP family. <bold>(B)</bold> The one-step or two-step drug extrusion from the cytosol to the outer membrane via the efflux pumps family. Among them, the resistance-nodulation-division superfamily (RND-superfamily) takes over the drug from the cytoplasm or the periplasm by its AdeABC, AdeIJK, or AdeFGH efflux pumps system. The major facilitator superfamily (MFS; e.g., TetA, TetB, CmlA, CraA, AmvA, AbaF), the multidrug and toxic compound extrusion (MATE) transporter family (e.g., AbeM), and the small multidrug resistance (SMR) transporter (e.g., AbeS) are H+ and Na+&#x2009;coupled multidrug efflux pumps at the inner membrane. <bold>(C)</bold> The hydrolysis of &#x03B2;-lactam antibiotics by &#x03B2;-lactamases. <italic>Acinetobacter baumannii</italic> &#x03B2;-lactamases are classified into four molecular classes: class A (e.g., TEM, GES, PER, CTX-M, SCO, VEB, KPC, CRAB enzyme family), class B (e.g., IMP, VIM, NDM, SIM enzyme family), class C (e.g., Amp family) and class D (e.g., OXA subgroups enzyme family). <bold>(D)</bold> The complete loss of LPS by inactivating the lipid A biosynthesis genes (<italic>lpxA, lpxC</italic>, and <italic>lpxD</italic>) results in colistin resistance. <bold>(E)</bold> The aminoglycoside-modifying enzymes classified in three class acetyltransferases [e.g., AAC3, AAC(6&#x2032;)], adenyltransferases [e.g., ANT(2&#x2033;), ANT(3&#x2033;)], and phosphotransferases [e.g., APH(3&#x2033;), APH(3&#x2032;)]. <bold>(F)</bold> The alteration of targeted sites of TetM confers ribosomal protection against tetracycline, and GyrA subunit modification of DNA gyrase confers resistance to quinolone.</p>
</caption>
<graphic xlink:href="fmicb-14-1196774-g001.tif"/>
</fig>
</sec>
<sec id="sec8">
<title>Aminoglycosides</title>
<p>The aminoglycosides antibiotic family inhibits protein synthesis by binding to the 16S ribosomal RNA of the 30S ribosome, with high affinity. Two main mechanisms, involving aminoglycoside modifying enzymes and RNA 16S methylase modification, are associated with increased resistance. Several reports reviewing clinical <italic>A. baumannii</italic> isolates find a match in genes coding for aminoglycosides enzymes modification <italic>ant(3&#x2033;)-I, aac(3)-I, aph(3&#x2032;)-I, aac(6&#x2032;)-Ib</italic> and <italic>aph(3&#x2032;)-IIb</italic>; and a gene coding for an rRNA 16S methylase <italic>armA</italic> allowing a high antibiotic resistance (<xref ref-type="bibr" rid="ref130">Nie et al., 2014</xref>; <xref ref-type="bibr" rid="ref75">Hasani et al., 2016</xref>).</p>
</sec>
<sec id="sec9">
<title>&#x03B2;-lactam resistance in <italic>Acinetobacter baumannii</italic></title>
<p>Carbapenems are the most important class of antibiotics against <italic>A. baumannii</italic> and, generally, for Gram-positive and negative isolates (<xref ref-type="bibr" rid="ref121">Meletis, 2016</xref>). Indeed, carbapenems are considered the drugs of choice to treat <italic>A. baumannii</italic> infections and the first-line agents for empirical therapy in areas with low rates of resistant strains (<xref ref-type="bibr" rid="ref146">Pandey and Cascella, 2022</xref>). However, different mechanisms of &#x03B2;-lactam resistance have been described resulting in overexpression of OXA &#x03B2;-lactamases and chromosomal cephalosporinases, which have been classified as <italic>Acinetobacter</italic>-derived cephalosporinases (ADCs; <xref ref-type="bibr" rid="ref153">Paton et al., 1993</xref>). The ADCs overexpression is caused by an insertion sequence (ISAba1) close to these resistance genes (<xref ref-type="bibr" rid="ref77">Heritier et al., 2006</xref>). The first ADC gene was reported in Spain in 2000 (<xref ref-type="bibr" rid="ref18">Bou and Mart&#x00ED;nez-Beltr&#x00E1;n, 2000</xref>). Currently, several variants have been described worldwide conferring resistance against penicillins, extended-spectrum cephalosporins, monobactam (aztreonam), and &#x03B2;-lactamase inhibitors (sulbactam; <xref ref-type="bibr" rid="ref171">Rodr&#x00ED;guez-Mart&#x00ED;nez et al., 2010</xref>; <xref ref-type="bibr" rid="ref194">Tian et al., 2011</xref>; <xref ref-type="bibr" rid="ref100">Kuo et al., 2015</xref>; <xref ref-type="bibr" rid="ref84">Ingti et al., 2020</xref>). The extensive use of carbapenems has been regarded as one of the main risk factors promoting the emergence and spread of MDRAB (<xref ref-type="bibr" rid="ref61">Garnacho-Montero et al., 2015</xref>). The most effective resistance mechanism is the acquisition of carbapenem-hydrolyzing enzymes. In CRABs, the most common are class D oxacillinases (OXA type) &#x03B2;-lactamases classified in subgroups, with more than 400 OXA-type enzymes identified. Specifically, OXA-23, OXA-24, OXA-51, and OXA-58 subgroups are widespread in <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="ref49">Evans et al., 2013</xref>). Nevertheless, other &#x03B2;-lactamases classes are involved in carbapenem resistance, such as class A &#x03B2;-lactamases and class B metallo-&#x03B2;-lactamases (MBLs; <xref ref-type="bibr" rid="ref185">Smet et al., 2008</xref>). OXA-type &#x03B2;-lactamases (especially OXA-23) have also been commonly detected in cefiderocol-resistant <italic>A. baumannii</italic> clinical isolates (<xref ref-type="bibr" rid="ref86">Iregui et al., 2020</xref>; <xref ref-type="bibr" rid="ref97">Kohira et al., 2020</xref>; <xref ref-type="bibr" rid="ref1">Abdul-Mutakabbir et al., 2021</xref>; <xref ref-type="bibr" rid="ref226">Yamano et al., 2021</xref>). Moreover, PER-like &#x03B2;-lactamases and, to a lesser extent, NDM &#x03B2;-lactamases have been shown to contribute to a decreased susceptibility to cefiderocol (<xref ref-type="bibr" rid="ref161">Poirel et al., 2021</xref>). Therefore, combined factors, including the presence of &#x03B2;-lactamases such as NDM-like enzymes, modification of the penicillin-binding proteins (target gene PBP-3), permeability defects associated with efflux overexpression and reduced expression or mutation of genes involved in the ion transport, might contribute to resistance to cefiderocol in <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="ref116">Malik et al., 2020</xref>; <xref ref-type="bibr" rid="ref218">Wang et al., 2022</xref>). More seldom is the presence of mutations affecting iron transport genes (<italic>pirA</italic> and <italic>piuA</italic>) in cefiderocol-resistant <italic>A. baumannii</italic> isolates (<xref ref-type="bibr" rid="ref116">Malik et al., 2020</xref>). The <italic>pirA</italic> and <italic>piuA</italic> genes encode components of the pyoverdine and ferric iron uptake systems, respectively. Cefiderocol is transported across the outer cell membrane via iron transporters; thus, mutations in these genes may reduce antibiotic susceptibility. Nevertheless, the finding that mutations in these iron transport genes are relatively rare in <italic>A. baumannii</italic> isolates may suggest that iron acquisition is central to <italic>A. baumannii</italic> survival and, at the same time, genes involved in drug efflux, cell envelope modification, and cell wall biosynthesis may be more efficient in providing resistance to cefiderocol (<xref ref-type="bibr" rid="ref125">Moyni&#x00E9; et al., 2017</xref>).</p>
</sec>
<sec id="sec10">
<title>The emergence of colistin resistance in multidrug-resistant isolates</title>
<p>The increase in colistin treatments after the rise of CRAB has led to a critical emergence of resistant strains, particularly in the hospital environment (<xref ref-type="bibr" rid="ref94">Katip et al., 2021a</xref>,<xref ref-type="bibr" rid="ref95">b</xref>). The first recorded case of a colistin-resistant <italic>Acinetobacter</italic> sp. was in 1949 in the Czech Republic (<xref ref-type="bibr" rid="ref190">Sun et al., 2020</xref>). Currently, the high-resistant clonal lineage of <italic>A. baumannii</italic> has been described across 12&#x2009;hospitals in Italy, Greece, and Spain, with resistance rates for colistin of 50% (<xref ref-type="bibr" rid="ref133">Nowak et al., 2017</xref>). Moreover, 42% of <italic>A. baumannii</italic> isolates causing bloodstream infections in intensive care unit (ICU) patients from a Greek hospital have been found resistant to colistin and directly linked to fulminant septic shock and high mortality (<xref ref-type="bibr" rid="ref147">Papathanakos et al., 2020</xref>). Despite that discovery, the resistance mechanisms to colistin in <italic>A. baumannii</italic> are only partially understood. Colistin is positively charged and interacts electrostatically with the negatively charged phosphate groups of lipid A, the LPS component of Gram-negative bacilli outer membrane. Colistin&#x2019;s binding causes displacement of calcium (Ca<sup>2+</sup>) and magnesium (Mg<sup>2+</sup>) ions, associated with lipid A phosphoresters, thus affecting the stability of the LPS molecules. Subsequently, colistin inserts its hydrophobic terminal acyl fatty chain, causing disruption and permeabilization of the outer membrane. When permeabilization occurs, colistin penetrates the outer membrane, affecting the integrity of the inner membrane&#x2019;s phospholipid bilayer, leading to membrane destabilization and cell death (<xref ref-type="bibr" rid="ref167">Rhouma et al., 2016</xref>; <xref ref-type="bibr" rid="ref132">Novovi&#x0107; and Jov&#x010D;i&#x0107;, 2023</xref>). Unlike Gram-negative bacteria such as <italic>Salmonella</italic> spp., <italic>Escherichia coli, Klebsiella pneumoniae,</italic> and <italic>Pseudomonas aeruginosa</italic>, <italic>A. baumannii</italic> does not possess a PhoP/PhoQ two-component system. The primary polymyxin resistance mechanisms in <italic>A. baumannii</italic> relies on the PmrA/PmrB two-component system. The PmrA/PmrB is a major regulatory system implied in the lipid A modification (<xref ref-type="bibr" rid="ref79">Hua et al., 2020</xref>) and is well-characterized in <italic>E. coli</italic>, <italic>P. aeruginosa,</italic> or <italic>K. pneumoniae</italic> (<xref ref-type="bibr" rid="ref24">Chen and Groisman, 2013</xref>). The histidine-kinase PmrB sensor reacts to various stress conditions, such as low Mg<sup>2+</sup> and Ca<sup>2+</sup> concentrations, acid pH, and high Fe<sup>3+</sup> concentrations (<xref rid="fig2" ref-type="fig">Figure 2</xref>).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Model for activation of the polymyxin resistance PmrA/PmrB two-component system in <italic>Acinetobacter baumannii</italic>. Resistance to polymyxins can be induced in response to various stress conditions, such as low Mg2+ and Ca2+ concentrations, acidic pH, and high Fe3+ concentrations, which activate the two-component system PmrA/PmrB. Once activated, PmrA/PmrB upregulates <italic>pmrC</italic> gene expression, which encodes lipid A phosphoethanolamine (PEtN) transferase that promotes the addition of PEtN to lipid A. PmrC upregulates <italic>naxD</italic>, which codes for an N-acetylhexosamine deacetylase involved in the deacetylation of the &#x03B2;-galactosamine and Lipid A modification. Alternatively, overexpression of the <italic>eptA</italic> gene, homolog to PmrC, promotes the addition of the cationic pEtN moiety to the lipid A of LPS. Lastly, the plasmid-mediated mobile colistin resistance (<italic>mcr</italic>) genes encode a phosphoethanolamine transferase that adds PEtN to lipid A residues lowering the binding affinity of colistin to its target site.</p>
</caption>
<graphic xlink:href="fmicb-14-1196774-g002.tif"/>
</fig>
<p>In Gram-negative bacteria, resistance to polymyxins results mostly from LPS modifications, which is the drug target. These modifications originate from the addition of cationic groups such as 4-amino-L-arabinose (L-Ara4N) and/or phosphoethanolamine (PEtN) on the lipid A (<xref ref-type="bibr" rid="ref50">Ezadi et al., 2019</xref>). Unlike Enterobacterales, <italic>A. baumannii</italic> lacks all the genes of the <italic>arn</italic> operon required for L-Ara4N biosynthesis. Consequently, colistin resistance is caused by the addition of PEtN to the lipid A on position 1 or 4&#x2032; by the chromosomally-encoded EptA-like phosphoethanolamine transferase by the <italic>pmrC</italic> gene (<xref ref-type="bibr" rid="ref48">El-Sayed Ahmed et al., 2020</xref>).</p>
<p>Mutations in the PmrAB system have been found in a large number of colistin-resistant <italic>A. baumannii</italic> isolates. These mutations constitutively activate the PmrAB regulatory system, which in turn, upregulates the expression of the operon <italic>pmrCAB</italic> (<xref ref-type="bibr" rid="ref2">Adams et al., 2009</xref>). The self-regulation of the <italic>pmrCAB</italic> transcription enables the modification of lipid A (<xref ref-type="bibr" rid="ref136">Olaitan et al., 2014</xref>). The colistin resistance-related mutations in the coding sequence for the amino acids Pro102 and Ile13 of PmrA and Pro233, Thr235, and Gln270 of PmrB caused an overactivity of PmrA. These mutations in <italic>pmrA</italic> were located in the sulfatase domain, while in <italic>pmrB</italic> were in the histidine kinase domain. Mutations in <italic>pmrA</italic>-<italic>pmrB</italic> promote phosphorylation of the PmrB receptor kinase, activating PmrA. The activated PmrA modulates the expression of the <italic>pmrC</italic> gene that encodes the phosphoethanolamine transferase that catalyzes the addition of PEtN to the 1&#x2032;- or 4&#x2032;-phosphate group of lipid A (<xref ref-type="bibr" rid="ref190">Sun et al., 2020</xref>). Another study, analyzing the genetic determinants associated with colistin resistance in <italic>A. baumannii</italic> isolates collected from various regions of Greece, identified additional mutations in PmrB (Glu140 or Leu178) and PmrA (Lys172 or Asp10) genes (<xref ref-type="bibr" rid="ref145">Palmieri et al., 2020</xref>). Besides, PmrA also regulates the <italic>naxD</italic> transcription coding for an N-acetylhexosamine deacetylase which is involved in the deacetylation of the &#x03B2;-galactosamine modifying the Lipid A (<xref ref-type="bibr" rid="ref2">Adams et al., 2009</xref>; <xref ref-type="bibr" rid="ref122">Moffatt et al., 2010</xref>; <xref ref-type="bibr" rid="ref107">Llewellyn et al., 2012</xref>; <xref ref-type="bibr" rid="ref40">Deveson Lucas et al., 2018</xref>; <xref ref-type="bibr" rid="ref190">Sun et al., 2020</xref>; <xref ref-type="bibr" rid="ref82">Ilsan et al., 2021</xref>).</p>
<p>Recently, a plasmid-mediated resistance to polymyxin has been described in Enterobacterales. The <italic>mcr</italic> (mobile colistin resistance) genes also encode a phosphoethanolamine transferase that adds PEtN to lipid A (<xref ref-type="bibr" rid="ref150">Partridge et al., 2018</xref>). The <italic>mcr-1</italic> remains the predominant plasmid-mediated colistin resistance gene, while <italic>mcr</italic>-2, -3, -4, -5, -6, -7, and -8 have been detected in isolates from animals, humans, and different environments worldwide. Currently, 56 <italic>mcr</italic> variant sequences are available in GenBank (<xref ref-type="bibr" rid="ref150">Partridge et al., 2018</xref>). The <italic>mcr</italic> genes initially found in Enterobacterales, have been only recently described on <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="ref113">Ma et al., 2019</xref>; <xref ref-type="bibr" rid="ref3">Al-Kadmy et al., 2020</xref>), for which resistance to polymyxin was previously restricted to chromosome-encoded elements (<xref ref-type="bibr" rid="ref89">Jeannot et al., 2017</xref>; <xref ref-type="bibr" rid="ref160">Poirel et al., 2017</xref>; <xref ref-type="bibr" rid="ref150">Partridge et al., 2018</xref>).</p>
<p>More recently, a colistin-resistant mutation has also been shown in <italic>A. baumannii</italic> by insertion into the <italic>hns</italic> gene, an H-NS family transcriptional regulator. That mutation alters the expression of more than 150 genes, including the <italic>eptA</italic> gene. Overexpression of this LPS modifying enzyme codes for EptA, a PEtN transferase homolog to PmrC, which confer colistin resistance (<xref ref-type="bibr" rid="ref40">Deveson Lucas et al., 2018</xref>; <xref ref-type="bibr" rid="ref204">Trebosc et al., 2019</xref>; <xref ref-type="bibr" rid="ref145">Palmieri et al., 2020</xref>; <xref ref-type="bibr" rid="ref82">Ilsan et al., 2021</xref>).</p>
<p>Instead of lipid A modification, <italic>A. baumannii</italic> can acquire resistance to colistin due to the complete loss of LPS by inactivating the lipid A biosynthesis genes (<italic>lpxA</italic>, <italic>lpxC</italic>, and <italic>lpxD;</italic> <xref ref-type="bibr" rid="ref122">Moffatt et al., 2010</xref>; <xref ref-type="bibr" rid="ref20">Cafiso et al., 2019</xref>). LpxA, LpxC, and LpxD are three enzymes involved in the first main steps of LPS biosynthesis of <italic>A. baumannii</italic> occurring in the cytoplasm compartment (<xref ref-type="bibr" rid="ref164">Powers and Trent, 2018</xref>). Specifically, mutations in LpxA and LpxC can lead to modifications in the fatty acid chains of lipid A, while mutations in LpxD can affect the addition of PEtN groups to lipid A. These changes can reduce the outer membrane&#x2019;s net negative charge and permeability, decreasing colistin susceptibility (<xref ref-type="bibr" rid="ref145">Palmieri et al., 2020</xref>).</p>
</sec>
</sec>
<sec id="sec11">
<title>Bacterial attachment and biofilm formation</title>
<p><italic>A. baumannii</italic> forms biofilms on a wide range of surfaces, including medical and ventilator-associated pneumonia (VAP), as well as on host epithelial cells leading to meningitis, pneumonia, urinary tract infection, sepsis, and other conditions (<xref ref-type="bibr" rid="ref69">Greene et al., 2016a</xref>,<xref ref-type="bibr" rid="ref70">b</xref>; <xref ref-type="bibr" rid="ref222">Wong et al., 2017</xref>). Biofilm contributes to <italic>A. baumannii</italic> survival on surfaces and in dry and nutrient-deprived conditions for several weeks (<xref ref-type="bibr" rid="ref141">Orsinger-Jacobsen et al., 2013</xref>; <xref ref-type="bibr" rid="ref23">Chapartegui-Gonz&#x00E1;lez et al., 2018</xref>). The current understanding suggests biofilm formation in <italic>A. baumannii</italic> is a complex process mediated by a large repertoire of molecules and two-component systems (<xref ref-type="bibr" rid="ref120">Mcconnell et al., 2013</xref>; <xref ref-type="bibr" rid="ref222">Wong et al., 2017</xref>; <xref ref-type="bibr" rid="ref173">Roy et al., 2022</xref>).</p>
<sec id="sec12">
<title>Early surface colonization</title>
<p>Generally, biofilm production relies on the initial reversible bacterial attachment to a surface in response to environmental stimuli (<xref ref-type="bibr" rid="ref203">Toyofuku et al., 2016</xref>). Thus, early adhesion is essential in the colonization process and in establishing an <italic>A. baumannii</italic> infection. The CsuA/BABCDE chaperon-usher assembly system encodes for the bacterial pili that mediate the attachment of <italic>A. baumannii</italic> to various abiotic surfaces (<xref ref-type="bibr" rid="ref110">Longo et al., 2014</xref>). The Csu pili comprise four protein subunits, CsuA/B, CsuA, CsuB, and CsuE, assembled via the chaperone&#x2013;usher pathway (<xref ref-type="bibr" rid="ref202">Tomaras et al., 2008</xref>). The CsuC chaperone assists the CsuA/B polymerization in forming the major pilus subunit (<xref ref-type="bibr" rid="ref144">Pakharukova et al., 2015</xref>). In addition, CsuD functions as the usher, CsuE forms a tip adhesin, while CsuA and CsuB constitute minor pilin subunits (<xref ref-type="bibr" rid="ref201">Tomaras et al., 2003</xref>, <xref ref-type="bibr" rid="ref202">2008</xref>; <xref ref-type="bibr" rid="ref144">Pakharukova et al., 2015</xref>). Previous studies showed that the inactivation of the <italic>csuE</italic> gene abolishes pilus production and biofilm (<xref ref-type="bibr" rid="ref4">Amala Reena et al., 2017</xref>; <xref ref-type="bibr" rid="ref63">Ghasemi et al., 2018</xref>). However, a study conducted with 52 different clinical strains revealed that biofilm formation and the ability to attach host cells are independent abilities and not necessarily associated (<xref ref-type="bibr" rid="ref45">Eijkelkamp et al., 2011</xref>). Indeed, most <italic>A. baumannii</italic> carry the csuA/BABCDE locus; nevertheless, a subset of clinical isolates is <italic>csu</italic> deficient, indicating that these pili may be dispensable for biofilm formation and maintenance and that other pili systems may functionally replace them (<xref ref-type="bibr" rid="ref224">Wright et al., 2016</xref>). In <italic>A. baumannii,</italic> the expression of the <italic>csu</italic> operon is mainly regulated by the two-component system BfmRS where BfmS acts as a sensor kinase and BfmR functions as a response regulator (<xref ref-type="bibr" rid="ref202">Tomaras et al., 2008</xref>; <xref ref-type="bibr" rid="ref59">Gaddy and Actis, 2009</xref>). Indeed, the two-component system BfmRS is considered the master regulator of resistance to stress in <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="ref102">Law and Tan, 2022</xref>). BfmrR-P can act directly or indirectly on regulating genes for osmotic and oxidative stress, heat shock, the biosynthesis of siderophores, and the production of capsular polysaccharides, in addition to pili production. Furthermore, BfmR is also important for pellicle formation in <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="ref98">Krasauskas et al., 2019</xref>). A pellicle is an alternative biofilm growing at the air-liquid interface that may favor the colonization and persistence of <italic>A. baumannii</italic> in respiratory tracts, humidifiers, and moist surfaces (<xref ref-type="bibr" rid="ref118">Mart&#x00ED; et al., 2011</xref>; <xref ref-type="bibr" rid="ref127">Nait Chabane et al., 2014</xref>).</p>
</sec>
<sec id="sec13">
<title>Biofilm maturation</title>
<p>The two-component system BfmRS is also responsible for the subsequent irreversible adhesion starting with the production of factors under the control and early extracellular DNA (eDNA) release. An early eDNA release was demonstrated to be responsible for the first tridimensional biofilm formation. Notably, eDNA release is independent from the cell lysis in the early stage of biofilm formation and is mediated by membrane vesicles (<xref ref-type="bibr" rid="ref176">Sahu et al., 2012</xref>).</p>
<p>In <italic>A. baumannii,</italic> the AdeABC, AdeIJK, and AdeFGH RND-type efflux systems are critical in biofilm formation (<xref ref-type="bibr" rid="ref35">Coyne et al., 2011</xref>). Mutant strains of AdeABC, AdeIJK, and AdeFGH efflux pumps produce a significantly lower level of biofilm than the wild-type strain (<xref ref-type="bibr" rid="ref228">Yoon et al., 2015</xref>). Moreover, mutation of AdeABC and AdeIJK efflux pumps showed lower expression of several pilus system-encoding proteins, including CsuA/B, CsuC, and FimA. These proteins play a central role in the initial stages of adhesion, surface colonization, and biofilm maturation in <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="ref76">He et al., 2015</xref>; <xref ref-type="bibr" rid="ref181">Shadan et al., 2023</xref>).</p>
<p>The AdeRS two-component system regulates the AdeABC efflux pump&#x2019;s expression (<xref ref-type="bibr" rid="ref168">Richmond et al., 2016</xref>; <xref ref-type="bibr" rid="ref225">Xu et al., 2019</xref>). In particular, the deletions of <italic>adeRS</italic> and <italic>adeB</italic> reduced the biofilm growth of <italic>A. baumannii</italic> without affecting the number of adherent cells. This observation suggests that cells might be unable to produce a mature biofilm without this efflux pump (<xref ref-type="bibr" rid="ref168">Richmond et al., 2016</xref>). After the initial surface attachment, biofilm maturation occurs. During this process, individual cells produce the biofilm matrix entering the irreversible attachment stage. In <italic>A. baumannii,</italic> biofilm maturation is modulated by the Biofilm-associated proteins (Bap) and their interaction with the extracellular polymeric substances (EPS; <xref ref-type="bibr" rid="ref186">Soroosh et al., 2020</xref>; <xref ref-type="bibr" rid="ref206">Upmanyu et al., 2022</xref>). The main elements of the <italic>A. baumannii</italic> EPS are alginates and poly-&#x03B2;-(1-6)-N-acetylglucosamine (PNAG) compounds that interact with each other, with ions or heterologous molecules to form an elastic structure (<xref ref-type="bibr" rid="ref119">Marvasi et al., 2010</xref>). The <italic>pgaABCD</italic> locus is involved in the synthesis of PNAG, facilitating cell adhesion, promoting biofilm integrity, and limiting desiccation (<xref ref-type="bibr" rid="ref29">Choi et al., 2009</xref>; <xref ref-type="bibr" rid="ref124">Morris et al., 2019</xref>; <xref ref-type="bibr" rid="ref56">Flannery et al., 2020</xref>). Accordingly, deleting the pgaABC genes in <italic>A. baumannii</italic> impairs biofilm formation (<xref ref-type="bibr" rid="ref29">Choi et al., 2009</xref>). The Bap are large surface proteins orthologous to the <italic>Staphylococcus aureus</italic> Bap protein (<xref ref-type="bibr" rid="ref36">Cucarella et al., 2001</xref>; <xref ref-type="bibr" rid="ref109">Loehfelm et al., 2008</xref>). A type I secretion system secretes Bap. It is required in cell-to-cell adhesion and for developing higher-order structures on polystyrene and titanium (<xref ref-type="bibr" rid="ref109">Loehfelm et al., 2008</xref>; <xref ref-type="bibr" rid="ref74">Harding et al., 2017</xref>). Moreover, the Bap protein increases host colonization by facilitating <italic>A. baumannii</italic> adherence to human neonatal keratinocytes and bronchial epithelial cells (<xref ref-type="bibr" rid="ref19">Brossard and Campagnari, 2012</xref>). In addition to the Bap protein, the AdeABC efflux pump, normally related to antibiotic resistance, may also contribute to biofilm maturation (<xref ref-type="bibr" rid="ref168">Richmond et al., 2016</xref>). Notably, in mature <italic>A. baumannii</italic> biofilms, can be observed two types of colonies: the avirulent translucent (AV-T) colonies that produce dense biofilms and virulent opaque (VIR-O) colonies that exhibit low biomass but enhanced virulence in <italic>G. mellonella</italic>, increased surface motility an antibiotic resistance phenotype (<xref ref-type="bibr" rid="ref198">Tipton et al., 2015</xref>). Several genes are linked to different genomic expression profiles. Among them, ABUW_1132, a highly conserved gene that encodes a LysR-type transcriptional regulator (LTTR) that contributes to the passage of AV-T to VIR-O; its overexpression up-regulates <italic>abaI</italic> and activates the <italic>abaI/abaR</italic> quorum sensing (QS) signal (<xref ref-type="bibr" rid="ref195">Tierney et al., 2021</xref>). In <italic>A. baumannii</italic>, the QS system is regulated by the two-component system, AbaI/AbaR, which is homologous to the typical LuxI/LuxR system found in other Gram-negative bacteria. <italic>abaI</italic> encodes the autoinducer synthase, which catalyzes the synthesis of N-(3-hydroxy dodecanol)-L-HSL (AHL), which at high density interacts with the cognate receptor AbaR leading to downstream cellular responses (<xref ref-type="bibr" rid="ref135">Oh and Han, 2020</xref>). Previous studies have found that <italic>abaI</italic> and <italic>abaR</italic> disruption reduces biofilm formation (<xref ref-type="bibr" rid="ref131">Niu et al., 2008</xref>; <xref ref-type="bibr" rid="ref5">Anbazhagan et al., 2012</xref>). Moreover, <italic>A. baumannii</italic> cultured in the presence of AHL showed increased expression of Csu pili and biofilm formation (<xref ref-type="bibr" rid="ref111">Luo et al., 2015</xref>).</p>
</sec>
<sec id="sec14">
<title>Biofilm dispersion</title>
<p>In the final stage, the cells within the biofilm disperse and colonize new surfaces. Biofilm dispersal is induced prevalently under environmental stress, including the <italic>A. baumannii</italic> SOS response, and the activation of the UmuDAb RecA-dependent repressor inactivated by RecA cleavage when DNA damage occurs. As a result, the UmuDAb mutant cannot activate the transcription of <italic>bmfR.</italic> Thus, no Csu pili or biofilm is formed (<xref ref-type="bibr" rid="ref26">Ching et al., 2019</xref>). Notably, dispersed cells exhibit variable phenotypes, antibiotic susceptibility, transcriptomic patterns, and metabolic activities (<xref ref-type="bibr" rid="ref174">Rumbaugh and Sauer, 2020</xref>). For example, dispersed clinical isolates of <italic>A. baumannii</italic> are more hydrophobic and adhere more efficiently to the surface than the planktonic cells (<xref ref-type="bibr" rid="ref16">Berlanga et al., 2017</xref>). Moreover, the dispersed cells were more susceptible to ciprofloxacin and tetracycline than the same cells in the planktonic state (<xref ref-type="bibr" rid="ref16">Berlanga et al., 2017</xref>). In contrast, another <italic>A. baumannii</italic> clinical strain disseminating from ciprofloxacin-exposed biofilms is highly resistant to ciprofloxacin, erythromycin, and tetracycline (<xref ref-type="bibr" rid="ref156">Penesyan et al., 2019</xref>). These studies suggest that the ability of the dispersed cells to evolve, acquiring higher antibiotic resistance, could complicate the management and treatment of the infection (<xref ref-type="bibr" rid="ref102">Law and Tan, 2022</xref>).</p>
</sec>
<sec id="sec15">
<title>What is the clinical relevance of biofilm production among patients with <italic>Acinetobacter baumannii</italic> infection?</title>
<p>The ability of <italic>A. baumannii</italic> to form biofilms has been reported as an essential factor contributing to its persistence and tolerance to antimicrobial agents (<xref ref-type="bibr" rid="ref173">Roy et al., 2022</xref>). The proportion of <italic>A. baumannii</italic> clinical isolates that produce biofilms can vary significantly depending on the study and sample population. In a collection of 20 clinical isolates of <italic>A. baumannii</italic>, emerged that 80% of the strains formed biofilm, perhaps because of a dominant clone (<xref ref-type="bibr" rid="ref180">Sechi et al., 2004</xref>). Bardbari et al. compared biofilm-production ability between clinical and environmental <italic>A. baumannii</italic>. In this study emerged that the majority of both clinical and environmental isolates could form varying degrees of biofilm. Specifically, the prevalence of strong biofilm producers in clinical and environmental strains was 58.7 and 31.2%, respectively (<xref ref-type="bibr" rid="ref10">Bardbari et al., 2017</xref>). Others reported that among 154 <italic>A. baumannii</italic> isolated in Taiwan, 45.4% possessed strong biofilm formation ability (<xref ref-type="bibr" rid="ref227">Yang et al., 2019</xref>). Moreover, among 100 <italic>A. baumannii</italic> clinical isolates from three hospitals in Iran, 58% were strong biofilm producers (<xref ref-type="bibr" rid="ref229">Zeighami et al., 2019</xref>). Another study investigating 92 unrelated strains of <italic>A. baumannii</italic> isolated from two Spanish hospitals found that 63% of isolates formed biofilm, mainly from device-associated infections. Notably, these isolates were less frequently resistant to imipenem or ciprofloxacin than non-biofilm-forming isolates (<xref ref-type="bibr" rid="ref170">Rodr&#x0131;&#x0301;guez-Bano et al., 2008</xref>).</p>
<p>A study from 4 Chinese hospitals analyzed the contribution of biofilm formation in the epidemic spread of <italic>A. baumannii</italic> by comparing biofilm-forming abilities and genetic characteristics of international clonal lineage II (ICL II) and non-ICL II isolates. From a total of 114 clinical <italic>A. baumannii</italic> isolates, collected from various specimens, including blood, sputum, urine, and wound, emerged that 36% of the clinical isolates were able to form biofilm, but only 19.5% were strong biofilm producers. Of the <italic>A. baumannii</italic> isolates, the biofilm formation capacity of ICL II was significantly lower than that of non-ICL II isolates. The authors concluded that biofilm formation might not be a critical factor for the epidemic spread of <italic>A. baumannii</italic>, particularly for the ICL II lineage. They suggested that other factors, such as antimicrobial resistance and virulence, could play a more critical role in the epidemic potential of <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="ref78">Hu et al., 2016</xref>). Despite the propensity to produce biofilm, the clinical impact of biofilm in <italic>A. baumannii</italic> isolates is still debated. Indeed, a recent multicenter study in Taiwan including 711 patients showed that higher APACHE II score, shock status, lack of appropriate antimicrobial therapy, and carbapenem resistance were independent risk factors of 28-day mortality in the patients with <italic>A. baumannii</italic> bacteremia but not the level of biofilm formation. In addition, biofilm formation was most commonly observed in survivors than in non-survivors (38.4% vs. 31.9%; <xref ref-type="bibr" rid="ref25">Chiang et al., 2022</xref>). Similar results have been previously observed in a cohort of 273 patients with <italic>A. baumannii</italic> bacteremic pneumonia (<xref ref-type="bibr" rid="ref215">Wang et al., 2018</xref>). Accordingly, other studies have shown that infections caused by biofilm-producing <italic>A. baumannii</italic> are not necessarily associated with worse clinical outcomes (<xref ref-type="bibr" rid="ref170">Rodr&#x0131;&#x0301;guez-Bano et al., 2008</xref>; <xref ref-type="bibr" rid="ref215">Wang et al., 2018</xref>). Therefore, the impact and pathogenesis of biofilm production remain elusive and, in many cases, related to the patient&#x2019;s underlying condition or to the strain that causes the infection (<xref ref-type="bibr" rid="ref170">Rodr&#x0131;&#x0301;guez-Bano et al., 2008</xref>; <xref ref-type="bibr" rid="ref11">Barsoumian et al., 2015</xref>; <xref ref-type="bibr" rid="ref215">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="ref41">Di Domenico et al., 2020</xref>, <xref ref-type="bibr" rid="ref42">2021</xref>).</p>
<p><italic>A. baumannii</italic> is known for its ability to develop resistance to multiple antibiotics, making treatment of infections particularly challenging. In addition, the formation of biofilms further exacerbates this issue, as the extracellular matrix can act as a physical barrier, limiting the penetration of antibiotics and protecting the bacteria from the host&#x2019;s immune system (<xref ref-type="bibr" rid="ref158">Perez et al., 2007</xref>; <xref ref-type="bibr" rid="ref6">Antunes et al., 2011</xref>). Several antibiotics and antibiotic combinations have shown promise in combating <italic>A. baumannii</italic> biofilms. However, their effectiveness may vary depending on the strain and resistance profile. The use of two or more antibiotics with different mechanisms of action can enhance the therapeutic efficacy by affecting multiple bacterial targets. In particular, the combination of colistin and rifampicin was more effective at eradicating biofilms formed by multidrug-resistant <italic>A. baumannii</italic> isolates than either antibiotic alone (<xref ref-type="bibr" rid="ref14">Batoni et al., 2016</xref>). The antimicrobial combinations of colistin-levofloxacin, colistin-tigecycline, and tigecycline-levofloxacin or these combinations with clarithromycin were effective as lock solutions in the treatment of <italic>A. baumannii</italic> catheter-related infections (<xref ref-type="bibr" rid="ref143">Ozbek and Mataraci, 2013</xref>). Nevertheless, candidate antibiotics were active against biofilm-embedded <italic>A. baumannii</italic> cells at 400-fold the MIC. This concentration is unachievable in human serum, making those antimicrobials an undesirable option for systemic use in <italic>A. baumannii</italic> biofilm-associated infections (<xref ref-type="bibr" rid="ref143">Ozbek and Mataraci, 2013</xref>). Synergistic effects were also observed on biofilm-embedded carbapenem-resistant and carbapenem-susceptible <italic>A. baumannii</italic> strains. In particular, meropenem was active against biofilm-embedded carbapenem-susceptible <italic>A. baumannii</italic>, whereas meropenem plus sulbactam exhibited synergism against biofilm CRAB and caused significantly more damage to the biofilm architecture than colistin or tigecycline used alone (<xref ref-type="bibr" rid="ref216">Wang et al., 2016</xref>). Additionally, clinical isolates of MDRAB exhibited different degrees of biofilm formation in the presence of sub-minimum inhibitory concentrations of colistin and tigecycline (<xref ref-type="bibr" rid="ref179">Sato et al., 2018</xref>). A recent study showed that biofilm-embedded MDRAB had been eradicated with colistin but not tigecycline. Notably, the eradication increased with a combination of colistin and high concentrations of tigecycline (<xref ref-type="bibr" rid="ref178">Sato et al., 2021</xref>). Moreover, combining azithromycin and polymyxin B displayed synergistic activity against biofilm-producing <italic>A. baumannii</italic> clinical isolates, improving antimicrobial efficacy (<xref ref-type="bibr" rid="ref157">Peng et al., 2020</xref>). These data suggest that the effects of different antibiotics may depend on bacterial strains and the response of <italic>A. baumannii</italic> may vary under specific environmental stress conditions, such as in the presence of multiple antimicrobial agents. Nevertheless, one of the main challenges in analyzing these studies is the considerable heterogeneity in the design, methodologies, and patient populations examined (<xref rid="tab1" ref-type="table">Table 1</xref>). While reflecting the field&#x2019;s richness, such diversity can make it difficult to draw firm conclusions or compare findings directly across studies. Additionally, there is not yet a universally accepted definition or a standardized method for determining biofilm formation by <italic>A. baumannii</italic>. The absence of such standards introduces variability between studies and complicates the comparison of results. Furthermore, many of our findings are based on <italic>in vitro</italic> studies. While these studies provide valuable insights, they cannot fully capture the complexity of clinical infections. The behavior of <italic>A. baumannii</italic> in a real-world clinical setting can be influenced by myriad factors not present under laboratory conditions.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Activity of different antibiotics against carbapenem-resistant <italic>Acinetobacter baumannii</italic> (CRAB).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Drug</th>
<th align="left" valign="top">Mechanism of action</th>
<th align="left" valign="top">MIC breakpoint for CRAB (EUCAST)&#x00A7;</th>
<th align="left" valign="top">Side effects</th>
<th align="left" valign="top">Anti-biofilm activity vs. CRAB</th>
<th align="left" valign="top">Dosage for CRAB infections</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="3">Colistin</td>
<td align="left" valign="top">Colistin binds to LPS and phospholipids in the outer cell membrane of Gram-negative bacteria</td>
<td align="left" valign="top" rowspan="3">2&#x2009;&#x03BC;g/mL</td>
<td align="left" valign="top" rowspan="3">Nephrotoxicity, neurotoxicity</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top" rowspan="3">As per international consensus guidelines (<xref ref-type="bibr" rid="ref205">Tsuji et al., 2019</xref>)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">It competitively displaces divalent cations (Ca<sup>2+</sup> and Mg<sup>2+</sup>) from the phosphate groups of membrane lipids, which leads to disruption of the outer cell membrane, leakage of intracellular contents, and bacterial death</td>
<td align="left" valign="top">Absence of anti-biofilm activity also when combined with meropenem, ampicillin/sulbactam, and minocycline</td>
</tr>
<tr>
<td align="left" valign="top">Colistin plus rifampin retains anti-biofilm activity (<xref ref-type="bibr" rid="ref216">Wang et al., 2016</xref>; <xref ref-type="bibr" rid="ref1001">Wences et al., 2022</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Tigecycline</td>
<td align="left" valign="top">Tigecycline binds to the 30S ribosomal subunit and blocks the entry of amino-acyl tRNA molecules into the A site of the ribosome, inhibiting protein translation in bacteria.</td>
<td align="left" valign="top">IE</td>
<td align="left" valign="top">Nausea, vomiting, diarrhea, hepatotoxicity, pancreatitis</td>
<td align="left" valign="top">No (<xref ref-type="bibr" rid="ref216">Wang et al., 2016</xref>)</td>
<td align="left" valign="top">200&#x2009;mg loading dose followed by 100&#x2009;mg every 12&#x2009;h</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Ampicillin/sulbactam</td>
<td align="left" valign="top">Sulbactam is an irreversible competitive beta-lactamase inhibitor that can saturate Penicillin Binding Proteins (PBP) 1 and 3 in <italic>Acinetobacter</italic> spp. when given in high doses</td>
<td align="left" valign="top" rowspan="2">IE</td>
<td align="left" valign="top" rowspan="2">Hepatotoxicity</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">3&#x2013;9&#x2009;g every 8&#x2009;h (for ampicillin-sulbactam 2:1)</td>
</tr>
<tr>
<td align="left" valign="top">Anti-CRAB activity is exerted by sulbactam.</td>
<td align="left" valign="top">Meropenem plus sulbactam was synergistic against biofilm-embedded CRAB (<xref ref-type="bibr" rid="ref216">Wang et al., 2016</xref>; <xref ref-type="bibr" rid="ref1005">Chaiben et al., 2022</xref>)</td>
<td align="left" valign="top">A high dosage (9 g every 8&#x2009;h) is required for VAP (<xref ref-type="bibr" rid="ref1004">Jaruratanasirikul et al., 2019</xref>)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Cefiderocol</td>
<td align="left" valign="top" rowspan="2">Cefiderocol is a siderophore cephalosporin actively transported into the periplasmic space of Gram-negative bacteria through the bacterial siderophore iron uptake system, as well as through passive diffusion via outer membrane porin channels</td>
<td align="left" valign="top" rowspan="2">Zone diameters of &#x2265;17&#x2009;mm for the cefiderocol 30&#x2009;&#x03BC;g disk correspond to MIC values below the PK-PD breakpoint of S &#x2264; 2&#x2009;&#x03BC;g/mL</td>
<td align="left" valign="top" rowspan="2">Elevated liver tests, hypokalemia</td>
<td align="left" valign="top" rowspan="2">Yes (<xref ref-type="bibr" rid="ref1003">Pybus et al., 2021</xref>)</td>
<td align="left" valign="top">2&#x2009;g every 8&#x2009;h infused over 3&#x2009;h</td>
</tr>
<tr>
<td align="left" valign="top">2&#x2009;g every 6&#x2009;h infused over 3&#x2009;h if CrCl&#x2265;120&#x2009;mL/min</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Fosfomycin</td>
<td align="left" valign="top" rowspan="2">Fosfomycin interferes with the first cytoplasmic step of bacterial cell wall biosynthesis, the formation of the peptidoglycan precursor UDP N-acetylmuramic acid (UDP-MurNAc).</td>
<td align="left" valign="top" rowspan="2">No breakpoint available</td>
<td align="left" valign="top" rowspan="2">Hypernatremia, hypokalemia</td>
<td align="left" valign="top">Alone: no</td>
<td align="left" valign="top" rowspan="2">12&#x2013;24&#x2009;g/die (divided every 8&#x2013;12&#x2009;h)</td>
</tr>
<tr>
<td align="left" valign="top">In combination with colistin: yes (<xref ref-type="bibr" rid="ref1006">Boncompagni et al., 2022</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Eravacycline</td>
<td align="left" valign="top">Eravacycline binds reversibly to the 30S ribosomal subunit, inhibiting protein translation in bacteria.</td>
<td align="left" valign="top">IE</td>
<td align="left" valign="top">Gastrointestinal side effects</td>
<td align="left" valign="top">No data</td>
<td align="left" valign="top">1&#x2009;mg/kg/dose every 12&#x2009;h</td>
</tr>
<tr>
<td align="left" valign="top">Sulbactam/durlobactam</td>
<td align="left" valign="top">Durlobactam is a novel non-&#x00DF;-lactam diazabicyclooctane &#x00DF;-lactamase inhibitor with broad-spectrum activity against class A, C, and D &#x00DF;-lactamases.</td>
<td align="left" valign="top">No data</td>
<td align="left" valign="top">Gastrointestinal side effects</td>
<td align="left" valign="top">No data</td>
<td align="left" valign="top">1/1&#x2009;g every 6&#x2009;h, according to the ATTACK study (<ext-link xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link>: NCT03894046)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>CRAB, carbapenem-resistant <italic>A. baumannii</italic>; &#x00A7;, accessed on 7th March 2023; IE, insufficient evidence that the organism or group is a good target for therapy with the agent; CrCl, creatinine clearance.</p>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="sec16">
<title><italic>Acinetobacter baumannii</italic> infections and treatment options in critically ill patients</title>
<p>The two most common clinical manifestations of <italic>A. baumannii</italic> are nosocomial pneumonia, particularly VAP, and bacteremia (<xref ref-type="bibr" rid="ref222">Wong et al., 2017</xref>). While an endotracheal tube allows <italic>Acinetobacter</italic> spp. to establish biofilm facilitating its transmission and spread in the environment, the development of VAP occurs due to the aspiration of bacterial <italic>droplets</italic> directly into the alveoli. Likewise, bacteremia occurs as a hematogenous spread from pneumonia or in the presence of an infected central venous catheter. Less commonly, <italic>A. baumannii</italic> causes urinary tract infections (often associated with the presence of urinary catheters), central nervous system infections (often after neurosurgery or in the presence of external ventricular drain), wound or bone infections (often after surgery or trauma; <xref ref-type="bibr" rid="ref222">Wong et al., 2017</xref>). Typically, infections sustained by <italic>A. baumannii</italic> occur in intensive care units, where patients are characterized by critical illness, multimorbidity, prolonged hospital stay, exposure to multiple invasive procedures, and prolonged antibiotic therapy (<xref ref-type="bibr" rid="ref134">Ogutlu et al., 2014</xref>; <xref ref-type="bibr" rid="ref9">Ayobami et al., 2020</xref>; <xref ref-type="bibr" rid="ref81">Ibrahim et al., 2021</xref>).</p>
<p>During the COVID-19 pandemic, MDR organisms, particularly CRAB, have been increasingly reported as causative agents of secondary infections, especially in severe and critical diseases (<xref ref-type="bibr" rid="ref152">Patel et al., 2021</xref>; <xref ref-type="bibr" rid="ref31">Cogliati Dezza et al., 2022</xref>; <xref ref-type="bibr" rid="ref175">Russo et al., 2022</xref>; <xref ref-type="bibr" rid="ref101">Langford et al., 2023</xref>). Furthermore, CRAB acquisition increased during the hospital stay and accounted for high mortality rates in patients with COVID-19 (<xref ref-type="bibr" rid="ref52">Falcone et al., 2021</xref>; <xref ref-type="bibr" rid="ref80">Iacovelli et al., 2023</xref>). Increased antibiotic resistance, reported for clinical isolate, is even more significant in oncological patients (<xref ref-type="bibr" rid="ref128">&#x00D1;amendys-Silva et al., 2015</xref>; <xref ref-type="bibr" rid="ref129">Nazer et al., 2015</xref>; <xref ref-type="bibr" rid="ref33">Cornejo-Ju&#x00E1;rez et al., 2020</xref>). A previous report highlights that among 635 oncological patients, 6.1% were infected by <italic>A. baumannii</italic> MDR (<xref ref-type="bibr" rid="ref129">Nazer et al., 2015</xref>). An oncology department in China demonstrated that <italic>A. baumannii</italic> accounted for 9.8% of infections (<xref ref-type="bibr" rid="ref106">Li and Wang, 2018</xref>). Two studies have shown that 19% of patients died within 72&#x2009;h after <italic>A. baumannii</italic> isolation (<xref ref-type="bibr" rid="ref129">Nazer et al., 2015</xref>; <xref ref-type="bibr" rid="ref33">Cornejo-Ju&#x00E1;rez et al., 2020</xref>).</p>
<p>Therefore, CRAB represents a threat to the most vulnerable patients, contributing to the observed high mortality, which reaches values up to 50%&#x2013;70% in patients with septic shock and VAP (<xref ref-type="bibr" rid="ref85">Iovleva et al., 2022</xref>). Furthermore, despite sharing similar comorbidities and risk factors, patients infected with CRAB or XDR strains had a significantly higher mortality rate than those caused by susceptible strains (<xref ref-type="bibr" rid="ref103">Lee et al., 2014</xref>; <xref ref-type="bibr" rid="ref105">Lemos et al., 2014</xref>). A recent study further highlighted that the absolute excess 30-day mortality due to infection sustained by PDR <italic>A. baumannii</italic> compared to only PDR <italic>A. baumannii</italic> colonization was 34%, suggesting that one of every three treated patients would have been saved if effective drugs were available (<xref ref-type="bibr" rid="ref92">Karakonstantis et al., 2020</xref>).</p>
<p>Despite being a strong biofilm producer, it has been shown that biomass production was not an independent risk factor for 28-day mortality in patients with <italic>A. baumannii</italic> bacteremia (<xref ref-type="bibr" rid="ref25">Chiang et al., 2022</xref>). Indeed, one of the major drivers of mortality is the inappropriate initial effective therapy, which mainly depends on the high resistance level in <italic>A. baumannii</italic>. Currently, there is still no consensus on the optimal treatment of CRAB infections (<xref ref-type="bibr" rid="ref154">Paul et al., 2022</xref>; <xref ref-type="bibr" rid="ref199">Tiseo et al., 2022</xref>). Colistin has been considered the backbone of CRAB treatment for many years, mostly in combination with carbapenems, fosfomycin, tigecycline, or ampicillin/sulbactam or even with vancomycin and/or rifampin (<xref ref-type="bibr" rid="ref43">Durante-Mangoni et al., 2013</xref>; <xref ref-type="bibr" rid="ref21">Ceccarelli et al., 2015</xref>; <xref ref-type="bibr" rid="ref139">Oliva et al., 2017</xref>; <xref ref-type="bibr" rid="ref64">Giacobbe et al., 2020</xref>; <xref ref-type="bibr" rid="ref93">Katip et al., 2020</xref>). Colistin is administered as an inactive prodrug, colistimethate (also known as colistin methanesulfonate, CMS). International consensus guidelines and recent studies highly recommend administering CMS as a loading dose (LD) followed by a maintenance dose for the treatment of infections due to carbapenem-resistant Gram-negative bacilli, especially in critically ill patients (<xref ref-type="bibr" rid="ref205">Tsuji et al., 2019</xref>; <xref ref-type="bibr" rid="ref217">Wang et al., 2022</xref>). A recent study evaluated the efficacy and safety of using a CMS LD in the treatment of critically ill patients with CRAB infections and showed higher clinical, microbiological, and 30-day survival rates in patients receiving LD compared with patients not receiving LD; however, the administration of the LD was associated with a higher risk of nephrotoxicity (<xref ref-type="bibr" rid="ref94">Katip et al., 2021a</xref>,<xref ref-type="bibr" rid="ref95">b</xref>).</p>
<p>Colistin use is limited by the risk of nephrotoxicity if administered at clinically effective dosage (<xref ref-type="bibr" rid="ref140">Ordooei Javan et al., 2015</xref>) and the relatively poor lung epithelial lining fluid (ELF) penetration in critically ill patients (<xref ref-type="bibr" rid="ref83">Imberti et al., 2010</xref>). Furthermore, resistance to colistin may occur in up to 30% of CRAB strains (<xref ref-type="bibr" rid="ref85">Iovleva et al., 2022</xref>), rendering the treatment of CRAB infections even more challenging. In any case, the rate of colistin resistance is lower than that of tigecycline (45.5%; <xref ref-type="bibr" rid="ref22">Chang et al., 2012</xref>; <xref ref-type="bibr" rid="ref126">Muthusamy et al., 2016</xref>), suggesting this antibiotic still represents an effective antimicrobial agent against CRAB infections (<xref ref-type="bibr" rid="ref94">Katip et al., 2021a</xref>,<xref ref-type="bibr" rid="ref95">b</xref>).</p>
<p>Sulbactam is an irreversible competitive beta-lactamase inhibitor with direct antimicrobial activity thanks to its intrinsic affinity for the <italic>A. baumannii</italic> PBPs (<xref ref-type="bibr" rid="ref191">Tamma et al., 2022</xref>). In addition, when given in high doses, sulbactam has the ability to saturate PBP-1 and PBP-3 and may therefore overcome the increasing described rates of sulbactam resistance in CRAB (<xref ref-type="bibr" rid="ref12">Bartal et al., 2022</xref>).</p>
<p>In recent years, cefiderocol, a novel siderophore cephalosporin, has been approved by the Food and Drug Administration to treat serious infections caused by carbapenem-resistant Gram-negative bacteria (<xref ref-type="bibr" rid="ref209">US Food and Drug Administration, 2019</xref>) and represented an encouraging advancement, especially for the treatment of CRAB infections. While the phase 3 randomized clinical trial CREDIBLE-CR, which compared cefiderocol with the best available therapy, showed higher mortality in the subgroup of patients with CRAB treated with cefiderocol (<xref ref-type="bibr" rid="ref13">Bassetti et al., 2021</xref>), subsequent real-world observations from case series or observational studies showed promising results of cefiderocol in terms of efficacy (<xref ref-type="bibr" rid="ref138">Oliva et al., 2020</xref>; <xref ref-type="bibr" rid="ref15">Bavaro et al., 2021</xref>; <xref ref-type="bibr" rid="ref165">Rando et al., 2021</xref>; <xref ref-type="bibr" rid="ref53">Falcone et al., 2022</xref>) and safety (<xref ref-type="bibr" rid="ref151">Pascale et al., 2021</xref>). This advantage was more evident in patients with bloodstream infections than those with VAP (<xref ref-type="bibr" rid="ref53">Falcone et al., 2022</xref>), probably due to a sub-optimal penetration of cefiderocol in the ELF at current dosages (<xref ref-type="bibr" rid="ref62">Gatti et al., 2021</xref>). However, the possibility of developing resistance to this drug under treatment, associated with an observed higher microbiological failure than the best available therapy (<xref ref-type="bibr" rid="ref53">Falcone et al., 2022</xref>), requires caution and deserves further prospective studies to define cefiderocol optimal place in therapy toward CRAB infections (<xref ref-type="bibr" rid="ref213">Volpicelli et al., 2021</xref>).</p>
<p>Given the limited therapeutic options with conventional antibiotics, there is ongoing research on alternative or adjuvant strategies for treating CRAB infections. In particular, N-acetylcysteine (NAC) exhibited high <italic>in-vitro</italic> activity against both planktonic and biofilm CRAB (<xref ref-type="bibr" rid="ref162">Pollini et al., 2018</xref>; <xref ref-type="bibr" rid="ref38">De Angelis et al., 2022</xref>), while a recent clinical observation showed a survival benefit of intravenous NAC addition to antibiotics in critically ill patients with CRAB septic shock (<xref ref-type="bibr" rid="ref137">Oliva et al., 2021</xref>).</p>
</sec>
<sec id="sec17" sec-type="conclusions">
<title>Conclusion</title>
<p><italic>A. baumannii</italic> has emerged as an opportunistic pathogen responsible for a broad range of severe nosocomial infections. Much of <italic>A. baumannii</italic>&#x2019;s success can be directly attributed to its genome plasticity, which rapidly mutates under stress. The ability to resist most last-line antimicrobial agents poses a considerable challenge, especially in critically ill patients.</p>
<p>In particular, the dissemination of CRAB and the increase in the use of colistin has led to a critical emergence of resistant strains. However, several virulence mechanisms beyond canonical drug resistance were recently identified, enabling <italic>A. baumannii</italic> to thrive in the healthcare environment. Indeed, it has been observed that <italic>A. baumannii</italic> can contaminate hospital surfaces or devices, caregivers&#x2019; hands, and can be spread by asymptomatically colonized persons. In addition, desiccation resistance, surface adherence, and biofilm formation make <italic>A. baumannii</italic> outbreaks in acute care hospitals difficult to control.</p>
<p>The environmental persistence has probably contributed to the increase in the incidence of <italic>A. baumannii</italic> from COVID-19 patients highlighting the value of appropriate prevention and control practices, particularly in open-space ICUs. During the COVID-19 pandemic, decreased vigilance for MDR control of transmissions, suspension or limitation of the hospital infection control committees, reduced surveillance, and personnel numbers likely contributed to the increase in hospital-acquired infections caused by <italic>A. baumannii.</italic> Notably, this review focuses on critically ill patients, a population particularly vulnerable to <italic>A. baumannii</italic> infections. Nevertheless, these infections also occur in other patient populations, and some of the data and conclusions herein presented may not be universally applicable.</p>
<p>Therefore, rapid diagnostic tests to identify and track high-risk clones, and antibiotic resistance genes, together with appropriate antibiotic regimens and strict adherence to infection control measures, may represent priorities for effectively dealing with <italic>A. baumannii</italic> infections.</p>
</sec>
<sec id="sec18">
<title>Author contributions</title>
<p>IC, AO, FS, GF, MT, MP, and ED contributed to the review&#x2019;s conception and design. IC, AO, FS, RP, FP, and ED researched and wrote the review. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="sec19" sec-type="funding-information">
<title>Funding</title>
<p>This research was funded by the Italian Ministry of Health (RC 2023) and also supported by EU funding to AO within the NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (project no. PE00000007, INF-ACT).</p>
</sec>
<sec id="conf1" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="ref1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdul-Mutakabbir</surname> <given-names>J. C.</given-names></name> <name><surname>Nguyen</surname> <given-names>L.</given-names></name> <name><surname>Maassen</surname> <given-names>P. T.</given-names></name> <name><surname>Stamper</surname> <given-names>K. C.</given-names></name> <name><surname>Kebriaei</surname> <given-names>R.</given-names></name> <name><surname>Kaye</surname> <given-names>K. S.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>In VitroAntibacterial activity of Cefiderocol against multidrug-resistant <italic>Acinetobacter baumannii</italic></article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>65</volume>:<fpage>e0264620</fpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.02646-20</pub-id></citation></ref>
<ref id="ref2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>M. D.</given-names></name> <name><surname>Nickel</surname> <given-names>G. C.</given-names></name> <name><surname>Bajaksouzian</surname> <given-names>S.</given-names></name> <name><surname>Lavender</surname> <given-names>H.</given-names></name> <name><surname>Murthy</surname> <given-names>A. R.</given-names></name> <name><surname>Jacobs</surname> <given-names>M. R.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Resistance to Colistin in <italic>Acinetobacter baumannii</italic> associated with mutations in the PmrAB two-component system</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>53</volume>, <fpage>3628</fpage>&#x2013;<lpage>3634</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00284-09</pub-id></citation></ref>
<ref id="ref3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Kadmy</surname> <given-names>I. M. S.</given-names></name> <name><surname>Ibrahim</surname> <given-names>S. A.</given-names></name> <name><surname>Al-Saryi</surname> <given-names>N.</given-names></name> <name><surname>Aziz</surname> <given-names>S. N.</given-names></name> <name><surname>Besinis</surname> <given-names>A.</given-names></name> <name><surname>Hetta</surname> <given-names>H. F.</given-names></name></person-group> (<year>2020</year>). <article-title>Prevalence of genes involved in Colistin resistance in <italic>Acinetobacter baumannii</italic>: First report from Iraq</article-title>. <source>Microb. Drug Resist.</source> <volume>26</volume>, <fpage>616</fpage>&#x2013;<lpage>622</lpage>. doi: <pub-id pub-id-type="doi">10.1089/mdr.2019.0243</pub-id></citation></ref>
<ref id="ref4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amala Reena</surname> <given-names>A.</given-names></name> <name><surname>Subramaniyan</surname> <given-names>A.</given-names></name> <name><surname>Kanungo</surname> <given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>Biofilm formation as a virulence factor of <italic>Acinetobacter baumannii</italic>: an emerging pathogen in critical care units</article-title>. <source>J. Curr. Res. Sci. Med.</source> <volume>3</volume>, <fpage>74</fpage>&#x2013;<lpage>78</lpage>. doi: <pub-id pub-id-type="doi">10.4103/jcrsm.jcrsm_66_17</pub-id></citation></ref>
<ref id="ref5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anbazhagan</surname> <given-names>D.</given-names></name> <name><surname>Mansor</surname> <given-names>M.</given-names></name> <name><surname>Yan</surname> <given-names>G. O.</given-names></name> <name><surname>Md Yusof</surname> <given-names>M. Y.</given-names></name> <name><surname>Hassan</surname> <given-names>H.</given-names></name> <name><surname>Sekaran</surname> <given-names>S. D.</given-names></name></person-group> (<year>2012</year>). <article-title>Detection of quorum sensing signal molecules and identification of an autoinducer synthase gene among biofilm forming clinical isolates of <italic>Acinetobacter</italic> spp</article-title>. <source>PLoS One</source> <volume>7</volume>:<fpage>e36696</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0036696</pub-id></citation></ref>
<ref id="ref6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antunes</surname> <given-names>L. C.</given-names></name> <name><surname>Visca</surname> <given-names>P.</given-names></name> <name><surname>Towner</surname> <given-names>K. J.</given-names></name></person-group> (<year>2011</year>). <article-title><italic>Acinetobacter baumannii</italic>: evolution of a global pathogen</article-title>. <source>Pathogens Dis</source> <volume>71</volume>, <fpage>292</fpage>&#x2013;<lpage>301</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.2049-632X.2011.01264.x</pub-id></citation></ref>
<ref id="ref7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asaad</surname> <given-names>A. M.</given-names></name> <name><surname>Ansari</surname> <given-names>S.</given-names></name> <name><surname>Ajlan</surname> <given-names>S. E.</given-names></name> <name><surname>Awad</surname> <given-names>S. M.</given-names></name></person-group> (<year>2021</year>). <article-title>Epidemiology of biofilm producing <italic>Acinetobacter baumannii</italic> nosocomial isolates from a tertiary care hospital in Egypt: a cross-sectional study</article-title>. <source>Infect. Drug Resist.</source> <volume>14</volume>, <fpage>709</fpage>&#x2013;<lpage>717</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S261939</pub-id></citation></ref>
<ref id="ref8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Assimakopoulos</surname> <given-names>S. F.</given-names></name> <name><surname>Karamouzos</surname> <given-names>V.</given-names></name> <name><surname>Lefkaditi</surname> <given-names>A.</given-names></name> <name><surname>Sklavou</surname> <given-names>C.</given-names></name> <name><surname>Kolonitsiou</surname> <given-names>F.</given-names></name> <name><surname>Christofidou</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant <italic>Acinetobacter baumannii</italic>: a case series study</article-title>. <source>Infez. Med.</source> <volume>27</volume>, <fpage>11</fpage>&#x2013;<lpage>16</lpage>.</citation></ref>
<ref id="ref9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayobami</surname> <given-names>O.</given-names></name> <name><surname>Willrich</surname> <given-names>N.</given-names></name> <name><surname>Suwono</surname> <given-names>B.</given-names></name> <name><surname>Eckmanns</surname> <given-names>T.</given-names></name> <name><surname>Markwart</surname> <given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe: analysis of EARS-net data from 2013 to 2017</article-title>. <source>Antimicrob. Resist. Infect. Control</source> <volume>9</volume>:<fpage>89</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13756-020-00750-5</pub-id>, PMID: <pub-id pub-id-type="pmid">32560670</pub-id></citation></ref>
<ref id="ref10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bardbari</surname> <given-names>A. M.</given-names></name> <name><surname>Arabestani</surname> <given-names>M. R.</given-names></name> <name><surname>Karami</surname> <given-names>M.</given-names></name> <name><surname>Keramat</surname> <given-names>F.</given-names></name> <name><surname>Alikhani</surname> <given-names>M. Y.</given-names></name> <name><surname>Bagheri</surname> <given-names>K. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Correlation between ability of biofilm formation with their responsible genes and MDR patterns in clinical and environmental <italic>Acinetobacter baumannii</italic> isolates</article-title>. <source>Microb. Pathog.</source> <volume>108</volume>, <fpage>122</fpage>&#x2013;<lpage>128</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.micpath.2017.04.039</pub-id></citation></ref>
<ref id="ref11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barsoumian</surname> <given-names>A. E.</given-names></name> <name><surname>Mende</surname> <given-names>K.</given-names></name> <name><surname>Sanchez</surname> <given-names>C. J.</given-names></name> <name><surname>Beckius</surname> <given-names>M. L.</given-names></name> <name><surname>Wenke</surname> <given-names>J. C.</given-names></name> <name><surname>Murray</surname> <given-names>C. K.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Clinical infectious outcomes associated with biofilm-related bacterial infections: a retrospective chart review</article-title>. <source>BMC Infect. Dis.</source> <volume>15</volume>:<fpage>223</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12879-015-0972-2</pub-id></citation></ref>
<ref id="ref12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartal</surname> <given-names>C.</given-names></name> <name><surname>Rolston</surname> <given-names>K. V. I.</given-names></name> <name><surname>Nesher</surname> <given-names>L.</given-names></name></person-group> (<year>2022</year>). <article-title>Carbapenem-resistant <italic>Acinetobacter baumannii</italic>: colonization, infection, and current treatment options</article-title>. <source>Infect. Dis. Ther.</source> <volume>11</volume>, <fpage>683</fpage>&#x2013;<lpage>694</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40121-022-00597-w</pub-id>, PMID: <pub-id pub-id-type="pmid">35175509</pub-id></citation></ref>
<ref id="ref13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bassetti</surname> <given-names>M.</given-names></name> <name><surname>Echols</surname> <given-names>R.</given-names></name> <name><surname>Matsunaga</surname> <given-names>Y.</given-names></name> <name><surname>Ariyasu</surname> <given-names>M.</given-names></name> <name><surname>Doi</surname> <given-names>Y.</given-names></name> <name><surname>Ferrer</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial</article-title>. <source>Lancet Infect. Dis.</source> <volume>21</volume>, <fpage>226</fpage>&#x2013;<lpage>240</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30796-9</pub-id></citation></ref>
<ref id="ref14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Batoni</surname> <given-names>G.</given-names></name> <name><surname>Maisetta</surname> <given-names>G.</given-names></name> <name><surname>Esin</surname> <given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria</article-title>. <source>Biochim. Biophys. Acta Biomembr.</source> <volume>1858</volume>, <fpage>1044</fpage>&#x2013;<lpage>1060</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbamem.2015.10.013</pub-id></citation></ref>
<ref id="ref15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bavaro</surname> <given-names>D. F.</given-names></name> <name><surname>Belati</surname> <given-names>A.</given-names></name> <name><surname>Diella</surname> <given-names>L.</given-names></name> <name><surname>Stufano</surname> <given-names>M.</given-names></name> <name><surname>Romanelli</surname> <given-names>F.</given-names></name> <name><surname>Scalone</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Cefiderocol-based combination therapy for "difficult-to-treat" gram-negative severe infections: real-life case series and future perspectives</article-title>. <source>Antibiotics</source> <volume>10</volume>:<fpage>652</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics10060652</pub-id></citation></ref>
<ref id="ref16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berlanga</surname> <given-names>M.</given-names></name> <name><surname>Gomez-Perez</surname> <given-names>L.</given-names></name> <name><surname>Guerrero</surname> <given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>Biofilm formation and antibiotic susceptibility in dispersed cells versus planktonic cells from clinical, industry, and environmental origins</article-title>. <source>Antonie Van Leeuwenhoek</source> <volume>110</volume>, <fpage>1691</fpage>&#x2013;<lpage>1704</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10482-017-0919-2</pub-id></citation></ref>
<ref id="ref17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernhard</surname> <given-names>W.</given-names></name> <name><surname>Hoffmann</surname> <given-names>S.</given-names></name> <name><surname>Dombrowsky</surname> <given-names>H.</given-names></name> <name><surname>Rau</surname> <given-names>G. A.</given-names></name> <name><surname>Kamlage</surname> <given-names>A.</given-names></name> <name><surname>Kappler</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2001</year>). <article-title>Phosphatidylcholine molecular species in lung surfactant</article-title>. <source>Am. J. Respir. Cell Mol. Biol.</source> <volume>25</volume>, <fpage>725</fpage>&#x2013;<lpage>731</lpage>. doi: <pub-id pub-id-type="doi">10.1165/ajrcmb.25.6.4616</pub-id></citation></ref>
<ref id="ref1006"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boncompagni</surname> <given-names>S. R.</given-names></name> <name><surname>Micieli</surname> <given-names>M.</given-names></name> <name><surname>Di Maggio</surname> <given-names>T.</given-names></name> <name><surname>Aiezza</surname> <given-names>N.</given-names></name> <name><surname>Antonelli</surname> <given-names>A.</given-names></name> <name><surname>Giani</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Activity of fosfomycin/colistin combinations against planktonic and biofilm Gram-negative pathogens</article-title>. <source>J Antimicrob Chemother.</source> <volume>77</volume>, <fpage>2199</fpage>&#x2013;<lpage>2208</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkac142</pub-id></citation></ref>
<ref id="ref18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bou</surname> <given-names>G.</given-names></name> <name><surname>Mart&#x00ED;nez-Beltr&#x00E1;n</surname> <given-names>J.</given-names></name></person-group> (<year>2000</year>). <article-title>Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC b-lactamase in <italic>Acinetobacter baumannii</italic></article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>44</volume>, <fpage>428</fpage>&#x2013;<lpage>432</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.44.2.428-432.2000</pub-id></citation></ref>
<ref id="ref19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brossard</surname> <given-names>K. A.</given-names></name> <name><surname>Campagnari</surname> <given-names>A. A.</given-names></name></person-group> (<year>2012</year>). <article-title>The <italic>Acinetobacter baumannii</italic> biofilm-associated protein plays a role in adherence to human epithelial cells</article-title>. <source>Infect. Immun.</source> <volume>80</volume>, <fpage>228</fpage>&#x2013;<lpage>233</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.05913-11</pub-id></citation></ref>
<ref id="ref20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cafiso</surname> <given-names>V.</given-names></name> <name><surname>Stracquadanio</surname> <given-names>S.</given-names></name> <name><surname>Lo Verde</surname> <given-names>F.</given-names></name> <name><surname>Gabriele</surname> <given-names>G.</given-names></name> <name><surname>Mezzatesta</surname> <given-names>M. L.</given-names></name> <name><surname>Caio</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Colistin Resistant <italic>A. baumannii</italic>: genomic and transcriptomic traits acquired under Colistin therapy</article-title>. <source>Front. Microbiol.</source> <volume>9</volume>:<fpage>3195</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2018.03195</pub-id></citation></ref>
<ref id="ref21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ceccarelli</surname> <given-names>G.</given-names></name> <name><surname>Oliva</surname> <given-names>A.</given-names></name> <name><surname>D'Ettorre</surname> <given-names>G.</given-names></name> <name><surname>D'Abramo</surname> <given-names>A.</given-names></name> <name><surname>Caresta</surname> <given-names>E.</given-names></name> <name><surname>Barbara</surname> <given-names>C. S.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant <italic>Acinetobacter baumannii</italic> causing severe infections in a paediatric intensive care unit</article-title>. <source>BMC Infect. Dis.</source> <volume>15</volume>:<fpage>393</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12879-015-1133-3</pub-id>, PMID: <pub-id pub-id-type="pmid">26424078</pub-id></citation></ref>
<ref id="ref1005"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaiben</surname> <given-names>V.</given-names></name> <name><surname>Yamada</surname> <given-names>C. H.</given-names></name> <name><surname>Telles</surname> <given-names>J. P.</given-names></name> <name><surname>de Andrade</surname> <given-names>A. P.</given-names></name> <name><surname>Arend</surname> <given-names>L. N. V. S.</given-names></name> <name><surname>Ribeiro</surname> <given-names>V. S. T.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>A carbapenem-resistant Acinetobacter baumannii outbreak associated with a polymyxin shortage during the COVID pandemic: an in vitro and biofilm analysis of synergy between meropenem, gentamicin and sulbactam</article-title>. <source>J Antimicrob Chemother.</source> <volume>77</volume>, <fpage>1676</fpage>&#x2013;<lpage>1684</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkac102</pub-id></citation></ref>
<ref id="ref22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>K. C.</given-names></name> <name><surname>Lin</surname> <given-names>M. F.</given-names></name> <name><surname>Lin</surname> <given-names>N. T.</given-names></name> <name><surname>Wu</surname> <given-names>W. J.</given-names></name> <name><surname>Kuo</surname> <given-names>H. Y.</given-names></name> <name><surname>Lin</surname> <given-names>T. Y.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Clonal spread of multidrug-resistant <italic>Acinetobacter baumannii</italic> in eastern Taiwan</article-title>. <source>J. Microbiol. Immunol. Infect.</source> <volume>45</volume>, <fpage>37</fpage>&#x2013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jmii.2011.09.019</pub-id></citation></ref>
<ref id="ref23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chapartegui-Gonz&#x00E1;lez</surname> <given-names>I.</given-names></name> <name><surname>L&#x00E1;zaro-D&#x00ED;ez</surname> <given-names>M.</given-names></name> <name><surname>Bravo</surname> <given-names>Z.</given-names></name> <name><surname>Navas</surname> <given-names>J.</given-names></name> <name><surname>Icardo</surname> <given-names>J. M.</given-names></name> <name><surname>Ramos-Vivas</surname> <given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title><italic>Acinetobacter baumannii</italic> maintains its virulence after long-time starvation</article-title>. <source>PLoS One</source> <volume>13</volume>:<fpage>e0201961</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0201961</pub-id></citation></ref>
<ref id="ref24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>H. D.</given-names></name> <name><surname>Groisman</surname> <given-names>E. A.</given-names></name></person-group> (<year>2013</year>). <article-title>The PmrA/PmrB two-component system: the major regulator of LPS modifications</article-title>. <source>Annu. Rev. Microbiol.</source> <volume>67</volume>, <fpage>83</fpage>&#x2013;<lpage>112</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-micro-092412-155751</pub-id></citation></ref>
<ref id="ref25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname> <given-names>T. T.</given-names></name> <name><surname>Huang</surname> <given-names>T. W.</given-names></name> <name><surname>Sun</surname> <given-names>J. R.</given-names></name> <name><surname>Kuo</surname> <given-names>S. C.</given-names></name> <name><surname>Cheng</surname> <given-names>A.</given-names></name> <name><surname>Liu</surname> <given-names>C. P.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Biofilm formation is not an independent risk factor for mortality in patients with <italic>Acinetobacter baumannii</italic> bacteremia</article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>12</volume>:<fpage>964539</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2022.964539</pub-id></citation></ref>
<ref id="ref26"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Ching</surname> <given-names>C.</given-names></name> <name><surname>Muller</surname> <given-names>P. A.</given-names></name> <name><surname>Brychcy</surname> <given-names>M.</given-names></name> <name><surname>Reverdy</surname> <given-names>A.</given-names></name> <name><surname>Nguyen</surname> <given-names>B.</given-names></name> <name><surname>Downs</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2019</year>). RecA levels modulate biofilm development in <italic>Acinetobacter baumannii</italic>. BioRxiv.</citation></ref>
<ref id="ref27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>C. H.</given-names></name> <name><surname>Hyun</surname> <given-names>S. H.</given-names></name> <name><surname>Lee</surname> <given-names>J. Y.</given-names></name> <name><surname>Lee</surname> <given-names>J. S.</given-names></name> <name><surname>Lee</surname> <given-names>Y. S.</given-names></name> <name><surname>Kim</surname> <given-names>S. A.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title><italic>Acinetobacter baumannii</italic> outer membrane protein a targets the nucleus and induces cytotoxicity</article-title>. <source>Cell. Microbiol.</source> <volume>10</volume>, <fpage>309</fpage>&#x2013;<lpage>319</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1462-5822.2007.01041.x</pub-id></citation></ref>
<ref id="ref28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>C. H.</given-names></name> <name><surname>Lee</surname> <given-names>E. Y.</given-names></name> <name><surname>Lee</surname> <given-names>Y. C.</given-names></name> <name><surname>Park</surname> <given-names>T. I.</given-names></name> <name><surname>Kim</surname> <given-names>H. J.</given-names></name> <name><surname>Hyun</surname> <given-names>S. H.</given-names></name> <etal/></person-group>. (<year>2005</year>). <article-title>Outer membrane protein 38 of <italic>Acinetobacter baumannii</italic> localizes to the mitochondria and induces apoptosis of epithelial cells</article-title>. <source>Cell. Microbiol.</source> <volume>7</volume>, <fpage>1127</fpage>&#x2013;<lpage>1138</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1462-5822.2005.00538.x</pub-id></citation></ref>
<ref id="ref29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>A. H. K.</given-names></name> <name><surname>Slamti</surname> <given-names>L.</given-names></name> <name><surname>Avci</surname> <given-names>F. Y.</given-names></name> <name><surname>Pier</surname> <given-names>G. B.</given-names></name> <name><surname>Maira-Litr&#x00E1;n</surname> <given-names>T.</given-names></name></person-group> (<year>2009</year>). <article-title>The pgaABCD locus of <italic>Acinetobacter baumannii</italic> encodes the production of poly-&#x03B2;-1-6-N-Acetylglucosamine, which is critical for biofilm formation</article-title>. <source>J. Bacteriol.</source> <volume>191</volume>, <fpage>5953</fpage>&#x2013;<lpage>5963</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JB.00647-09</pub-id></citation></ref>
<ref id="ref30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cianfanelli</surname> <given-names>F. R.</given-names></name> <name><surname>Monlezun</surname> <given-names>L.</given-names></name> <name><surname>Coulthurst</surname> <given-names>S. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Aim, load, fire: the type VI secretion system, a bacterial nanoweapon</article-title>. <source>Trends Microbiol.</source> <volume>24</volume>, <fpage>51</fpage>&#x2013;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tim.2015.10.005</pub-id></citation></ref>
<ref id="ref31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cogliati Dezza</surname> <given-names>F.</given-names></name> <name><surname>Arcari</surname> <given-names>G.</given-names></name> <name><surname>Alessi</surname> <given-names>F.</given-names></name> <name><surname>Valeri</surname> <given-names>S.</given-names></name> <name><surname>Curtolo</surname> <given-names>A.</given-names></name> <name><surname>Sacco</surname> <given-names>F.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Clinical impact of COVID-19 on multi-drug-resistant gram-negative bacilli bloodstream infections in an intensive care unit setting: two pandemics compared</article-title>. <source>Antibiotics</source> <volume>11</volume>:<fpage>926</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics11070926</pub-id></citation></ref>
<ref id="ref32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Confer</surname> <given-names>A. W.</given-names></name> <name><surname>Ayalew</surname> <given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>The OmpA family of proteins: roles in bacterial pathogenesis and immunity</article-title>. <source>Vet. Microbiol.</source> <volume>163</volume>, <fpage>207</fpage>&#x2013;<lpage>222</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetmic.2012.08.019</pub-id></citation></ref>
<ref id="ref33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cornejo-Ju&#x00E1;rez</surname> <given-names>P.</given-names></name> <name><surname>Cevallos</surname> <given-names>M. A.</given-names></name> <name><surname>Castro-Jaimes</surname> <given-names>S.</given-names></name> <name><surname>Castillo-Ram&#x00ED;rez</surname> <given-names>S.</given-names></name> <name><surname>Vel&#x00E1;zquez-Acosta</surname> <given-names>C.</given-names></name> <name><surname>Mart&#x00ED;nez-Oliva</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>High mortality in an outbreak of multidrug resistant <italic>Acinetobacter baumannii</italic> infection introduced to an oncological hospital by a patient transferred from a general hospital</article-title>. <source>PLoS One</source> <volume>15</volume>:<fpage>e0234684</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0234684</pub-id></citation></ref>
<ref id="ref35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coyne</surname> <given-names>S.</given-names></name> <name><surname>Courvalin</surname> <given-names>P.</given-names></name> <name><surname>P&#x00E9;richon</surname> <given-names>B.</given-names></name></person-group> (<year>2011</year>). <article-title>Efflux-mediated antibiotic resistance in Acinetobacter spp</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>55</volume>, <fpage>947</fpage>&#x2013;<lpage>953</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01388-10</pub-id></citation></ref>
<ref id="ref36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cucarella</surname> <given-names>C.</given-names></name> <name><surname>Solano</surname> <given-names>C.</given-names></name> <name><surname>Valle</surname> <given-names>J.</given-names></name> <name><surname>Amorena</surname> <given-names>B.</given-names></name> <name><surname>Lasa</surname> <given-names>I.</given-names></name> <name><surname>Penad&#x00E9;s</surname> <given-names>J. R.</given-names></name></person-group> (<year>2001</year>). <article-title>Bap, a <italic>Staphylococcus aureus</italic> surface protein involved in biofilm formation</article-title>. <source>J. Bacteriol.</source> <volume>183</volume>, <fpage>2888</fpage>&#x2013;<lpage>2896</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10482-017-0919-2</pub-id></citation></ref>
<ref id="ref37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Darby</surname> <given-names>E. M.</given-names></name> <name><surname>Trampari</surname> <given-names>E.</given-names></name> <name><surname>Siasat</surname> <given-names>P.</given-names></name> <name><surname>Gaya</surname> <given-names>M. S.</given-names></name> <name><surname>Alav</surname> <given-names>I.</given-names></name> <name><surname>Webber</surname> <given-names>M. A.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Molecular mechanisms of antibiotic resistance revisited</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>21</volume>, <fpage>280</fpage>&#x2013;<lpage>295</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41579-022-00820-y</pub-id></citation></ref>
<ref id="ref38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Angelis</surname> <given-names>M.</given-names></name> <name><surname>Mascellino</surname> <given-names>M. T.</given-names></name> <name><surname>Miele</surname> <given-names>M. C.</given-names></name> <name><surname>Al Ismail</surname> <given-names>D.</given-names></name> <name><surname>Colone</surname> <given-names>M.</given-names></name> <name><surname>Stringaro</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>High activity of N-acetylcysteine in combination with Beta-lactams against Carbapenem-resistant Klebsiella pneumoniae and <italic>Acinetobacter baumannii</italic></article-title>. <source>Antibiotics</source> <volume>11</volume>:<fpage>225</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics11020225</pub-id></citation></ref>
<ref id="ref39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Decr&#x00E9;</surname> <given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title><italic>Acinetobacter baumannii</italic> et r&#x00E9;sistance aux antibiotiques: Un mod&#x00E8;le d&#x2019;adaptation</article-title>. <source>Revue Francophone des Laboratoires</source> <volume>2012</volume>, <fpage>43</fpage>&#x2013;<lpage>52</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1773-035X(12)71412-0</pub-id></citation></ref>
<ref id="ref40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deveson Lucas</surname> <given-names>D.</given-names></name> <name><surname>Crane</surname> <given-names>B.</given-names></name> <name><surname>Wright</surname> <given-names>A.</given-names></name> <name><surname>Han</surname> <given-names>M. L.</given-names></name> <name><surname>Moffatt</surname> <given-names>J.</given-names></name> <name><surname>Bulach</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Emergence of high-level Colistin resistance in an <italic>Acinetobacter baumannii</italic> clinical isolate mediated by inactivation of the global regulator H-NS</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>62</volume>, <fpage>e02442</fpage>&#x2013;<lpage>e02417</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.02442-17</pub-id></citation></ref>
<ref id="ref41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Domenico</surname> <given-names>E. G.</given-names></name> <name><surname>Cavallo</surname> <given-names>I.</given-names></name> <name><surname>Sivori</surname> <given-names>F.</given-names></name> <name><surname>Marchesi</surname> <given-names>F.</given-names></name> <name><surname>Prignano</surname> <given-names>G.</given-names></name> <name><surname>Pimpinelli</surname> <given-names>F.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Biofilm production by Carbapenem-resistant <italic>Klebsiella pneumoniae</italic> significantly increases the risk of death in oncological patients</article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>10</volume>:<fpage>561741</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2020.561741</pub-id></citation></ref>
<ref id="ref42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Domenico</surname> <given-names>E. G.</given-names></name> <name><surname>Marchesi</surname> <given-names>F.</given-names></name> <name><surname>Cavallo</surname> <given-names>I.</given-names></name> <name><surname>Toma</surname> <given-names>L.</given-names></name> <name><surname>Sivori</surname> <given-names>F.</given-names></name> <name><surname>Papa</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>The impact of bacterial biofilms on end-organ disease and mortality in patients with hematologic malignancies developing a bloodstream infection</article-title>. <source>Microbiol Spectr</source> <volume>9</volume>, <fpage>e00550</fpage>&#x2013;<lpage>e00521</lpage>. doi: <pub-id pub-id-type="doi">10.1128/Spectrum.00550-21</pub-id></citation></ref>
<ref id="ref43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Durante-Mangoni</surname> <given-names>E.</given-names></name> <name><surname>Signoriello</surname> <given-names>G.</given-names></name> <name><surname>Andini</surname> <given-names>R.</given-names></name> <name><surname>Mattei</surname> <given-names>A.</given-names></name> <name><surname>De Cristoforo</surname> <given-names>M.</given-names></name> <name><surname>Murino</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant <italic>Acinetobacter baumannii</italic>: a multicenter, randomized clinical trial</article-title>. <source>Clin. Infect. Dis.</source> <volume>57</volume>, <fpage>349</fpage>&#x2013;<lpage>358</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/cit253</pub-id>, PMID: <pub-id pub-id-type="pmid">23616495</pub-id></citation></ref>
<ref id="ref44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eijkelkamp</surname> <given-names>B. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Comparative analysis of surface-exposed virulence factors of <italic>Acinetobacter baumannii</italic></article-title>. <source>BMC Genomics</source> <volume>15</volume>:<fpage>1020</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2164-15-1020</pub-id></citation></ref>
<ref id="ref45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eijkelkamp</surname> <given-names>B. A.</given-names></name> <name><surname>Stroeher</surname> <given-names>U. H.</given-names></name> <name><surname>Hassan</surname> <given-names>K. A.</given-names></name> <name><surname>Papadimitrious</surname> <given-names>M. S.</given-names></name> <name><surname>Paulsen</surname> <given-names>I. T.</given-names></name> <name><surname>Brown</surname> <given-names>M. H.</given-names></name></person-group> (<year>2011</year>). <article-title>Adherence and motility characteristics of clinical <italic>Acinetobacter baumannii</italic> isolates</article-title>. <source>FEMS Microbiol. Lett.</source> <volume>323</volume>, <fpage>44</fpage>&#x2013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1574-6968.2011.02362.x</pub-id></citation></ref>
<ref id="ref46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elhosseiny</surname> <given-names>N. M.</given-names></name> <name><surname>Attia</surname> <given-names>A. S.</given-names></name></person-group> (<year>2018</year>). <article-title>Acinetobacter: an emerging pathogen with a versatile secretome</article-title>. <source>Emerg. Microb. Infect.</source> <volume>7</volume>, <fpage>1</fpage>&#x2013;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41426-018-0030-4</pub-id></citation></ref>
<ref id="ref47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname> <given-names>T. N.</given-names></name> <name><surname>Kuehn</surname> <given-names>M. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Virulence and immunomodulatory roles of bacterial outer membrane vesicles</article-title>. <source>Microbiol. Mol. Biol. Rev.</source> <volume>74</volume>, <fpage>81</fpage>&#x2013;<lpage>94</lpage>. doi: <pub-id pub-id-type="doi">10.1128/MMBR.00031-09</pub-id></citation></ref>
<ref id="ref48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Sayed Ahmed</surname> <given-names>M. A. E.</given-names></name> <name><surname>Zhong</surname> <given-names>L. L.</given-names></name> <name><surname>Shen</surname> <given-names>C.</given-names></name> <name><surname>Yang</surname> <given-names>Y.</given-names></name> <name><surname>Doi</surname> <given-names>Y.</given-names></name> <name><surname>Tian</surname> <given-names>G. B.</given-names></name></person-group> (<year>2020</year>). <article-title>Colistin and its role in the era of antibiotic resistance: an extended review (2000-2019)</article-title>. <source>Emerg Microbes Infect.</source> <volume>9</volume>, <fpage>868</fpage>&#x2013;<lpage>885</lpage>. doi: <pub-id pub-id-type="doi">10.1080/22221751.2020.1754133</pub-id></citation></ref>
<ref id="ref49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname> <given-names>B. A.</given-names></name> <name><surname>Hamouda</surname> <given-names>A.</given-names></name> <name><surname>Amyes</surname> <given-names>S. G. B.</given-names></name></person-group> (<year>2013</year>). <article-title>The rise of carbapenem-resistant <italic>Acinetobacter baumannii</italic></article-title>. <source>Curr. Pharm. Des.</source> <volume>19</volume>, <fpage>223</fpage>&#x2013;<lpage>238</lpage>.</citation></ref>
<ref id="ref50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ezadi</surname> <given-names>F.</given-names></name> <name><surname>Ardebili</surname> <given-names>A.</given-names></name> <name><surname>Mirnejad</surname> <given-names>R.</given-names></name></person-group> (<year>2019</year>). <article-title>Antimicrobial susceptibility testing for Polymyxins: challenges, issues, and recommendations</article-title>. <source>J. Clin. Microbiol.</source> <volume>57</volume>, <fpage>e01390</fpage>&#x2013;<lpage>e01318</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JCM.01390-18</pub-id></citation></ref>
<ref id="ref51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eze</surname> <given-names>E. C.</given-names></name> <name><surname>Chenia</surname> <given-names>H. Y.</given-names></name> <name><surname>El Zowalaty</surname> <given-names>M. E.</given-names></name></person-group> (<year>2018</year>). <article-title><italic>Acinetobacter baumannii</italic> biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments</article-title>. <source>Infect Drug Resist.</source> <volume>11</volume>, <fpage>2277</fpage>&#x2013;<lpage>2299</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S169894</pub-id></citation></ref>
<ref id="ref52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falcone</surname> <given-names>M.</given-names></name> <name><surname>Tiseo</surname> <given-names>G.</given-names></name> <name><surname>Giordano</surname> <given-names>C.</given-names></name> <name><surname>Leonildi</surname> <given-names>A.</given-names></name> <name><surname>Menichini</surname> <given-names>M.</given-names></name> <name><surname>Vecchione</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study</article-title>. <source>J. Antimicrob. Chemother.</source> <volume>76</volume>, <fpage>1078</fpage>&#x2013;<lpage>1084</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkaa530</pub-id></citation></ref>
<ref id="ref53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falcone</surname> <given-names>M.</given-names></name> <name><surname>Tiseo</surname> <given-names>G.</given-names></name> <name><surname>Leonildi</surname> <given-names>A.</given-names></name> <name><surname>Della Sala</surname> <given-names>L.</given-names></name> <name><surname>Vecchione</surname> <given-names>A.</given-names></name> <name><surname>Barnini</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Cefiderocol-compared to Colistin-based regimens for the treatment of severe infections caused by Carbapenem-resistant <italic>Acinetobacter baumannii</italic></article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>66</volume>:<fpage>e0214221</fpage>. doi: <pub-id pub-id-type="doi">10.1128/aac.02142-21</pub-id></citation></ref>
<ref id="ref54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname> <given-names>L.</given-names></name> <name><surname>Hancock</surname> <given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>25</volume>, <fpage>661</fpage>&#x2013;<lpage>681</lpage>. doi: <pub-id pub-id-type="doi">10.1128/CMR.00043-12</pub-id></citation></ref>
<ref id="ref55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fitzsimons</surname> <given-names>T. C.</given-names></name> <name><surname>Lewis</surname> <given-names>J. M.</given-names></name> <name><surname>Wright</surname> <given-names>A.</given-names></name> <name><surname>Kleifeld</surname> <given-names>O.</given-names></name> <name><surname>Schittenhelm</surname> <given-names>R. B.</given-names></name> <name><surname>Powell</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Identification of novel <italic>Acinetobacter baumannii</italic> type VI secretion system antibacterial effector and immunity pairs</article-title>. <source>Infect. Immun.</source> <volume>86</volume>, <fpage>e00297</fpage>&#x2013;<lpage>e00218</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.00297-18</pub-id></citation></ref>
<ref id="ref56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flannery</surname> <given-names>A.</given-names></name> <name><surname>le Berre</surname> <given-names>M.</given-names></name> <name><surname>Pier</surname> <given-names>G. B.</given-names></name> <name><surname>O&#x2019;Gara</surname> <given-names>J. P.</given-names></name> <name><surname>Kilcoyne</surname> <given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Glycomics microarrays reveal differential in situ presentation of the biofilm polysaccharide poly-N-acetylglucosamine on <italic>Acinetobacter baumannii</italic> and <italic>Staphylococcus aureus</italic> cell surfaces</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>:<fpage>2465</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21072465</pub-id></citation></ref>
<ref id="ref57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flores-D&#x00ED;az</surname> <given-names>M.</given-names></name> <name><surname>Monturiol-Gross</surname> <given-names>L.</given-names></name> <name><surname>Naylor</surname> <given-names>C.</given-names></name> <name><surname>Alape-Gir&#x00F3;n</surname> <given-names>A.</given-names></name> <name><surname>Flieger</surname> <given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Bacterial sphingomyelinases and phospholipases as virulence factors</article-title>. <source>Microbiol. Mol. Biol. Rev.</source> <volume>80</volume>, <fpage>597</fpage>&#x2013;<lpage>628</lpage>. doi: <pub-id pub-id-type="doi">10.1128/MMBR.00082-15</pub-id></citation></ref>
<ref id="ref58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fournier</surname> <given-names>P. E.</given-names></name> <name><surname>Vallenet</surname> <given-names>D.</given-names></name> <name><surname>Barbe</surname> <given-names>V.</given-names></name> <name><surname>Audic</surname> <given-names>S.</given-names></name> <name><surname>Ogata</surname> <given-names>H.</given-names></name> <name><surname>Poirel</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2006</year>). <article-title>Comparative genomics of multidrug resistance in <italic>Acinetobacter baumannii</italic></article-title>. <source>PLoS Genet.</source> <volume>2</volume>, <fpage>32</fpage>&#x2013;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pgen.0020007</pub-id></citation></ref>
<ref id="ref59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaddy</surname> <given-names>J. A.</given-names></name> <name><surname>Actis</surname> <given-names>L. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Regulation of <italic>Acinetobacter baumannii</italic> biofilm formation</article-title>. <source>Future Microbiol.</source> <volume>4</volume>, <fpage>273</fpage>&#x2013;<lpage>278</lpage>. doi: <pub-id pub-id-type="doi">10.2217/fmb.09.5</pub-id></citation></ref>
<ref id="ref60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaddy</surname> <given-names>J. A.</given-names></name> <name><surname>Tomaras</surname> <given-names>A. P.</given-names></name> <name><surname>Actis</surname> <given-names>L. A.</given-names></name></person-group> (<year>2009</year>). <article-title>The <italic>Acinetobacter baumannii</italic> 19606 OmpA protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells</article-title>. <source>Infect. Immun.</source> <volume>77</volume>, <fpage>3150</fpage>&#x2013;<lpage>3160</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.00096-09</pub-id></citation></ref>
<ref id="ref61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garnacho-Montero</surname> <given-names>J.</given-names></name> <name><surname>Amaya-Villar</surname> <given-names>R.</given-names></name> <name><surname>Ferr&#x00E1;ndiz-Mill&#x00F3;n</surname> <given-names>C.</given-names></name> <name><surname>D&#x00ED;az-Mart&#x00ED;n</surname> <given-names>A.</given-names></name> <name><surname>L&#x00F3;pez-S&#x00E1;nchez</surname> <given-names>J. M.</given-names></name> <name><surname>Guti&#x00E9;rrez-Pizarraya</surname> <given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Optimum treatment strategies for carbapenem-resistant <italic>Acinetobacter baumannii</italic> bacteremia</article-title>. <source>Expert Rev. Anti Infect. Ther.</source> <volume>13</volume>, <fpage>769</fpage>&#x2013;<lpage>777</lpage>. doi: <pub-id pub-id-type="doi">10.1586/14787210.2015.1032254</pub-id></citation></ref>
<ref id="ref62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gatti</surname> <given-names>M.</given-names></name> <name><surname>Bartoletti</surname> <given-names>M.</given-names></name> <name><surname>Cojutti</surname> <given-names>P. G.</given-names></name> <name><surname>Gaibani</surname> <given-names>P.</given-names></name> <name><surname>Conti</surname> <given-names>M.</given-names></name> <name><surname>Giannella</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant <italic>Acinetobacter baumannii</italic> bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol</article-title>. <source>J. Glob. Antimicrob. Resist.</source> <volume>27</volume>, <fpage>294</fpage>&#x2013;<lpage>298</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jgar.2021.10.014</pub-id></citation></ref>
<ref id="ref63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghasemi</surname> <given-names>E.</given-names></name> <name><surname>Ghalavand</surname> <given-names>Z.</given-names></name> <name><surname>Goudarzi</surname> <given-names>H.</given-names></name> <name><surname>Yeganeh</surname> <given-names>F.</given-names></name> <name><surname>Hashemi</surname> <given-names>A.</given-names></name> <name><surname>Dabiri</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Phenotypic and genotypic investigation of biofilm formation in clinical and environmental isolates of <italic>Acinetobacter baumannii</italic></article-title>. <source>Arch. Clin. Infect. Dis.</source> <volume>13</volume>:<fpage>e12914</fpage>. doi: <pub-id pub-id-type="doi">10.5812/archcid.12914</pub-id></citation></ref>
<ref id="ref64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giacobbe</surname> <given-names>D. R.</given-names></name> <name><surname>Saffioti</surname> <given-names>C.</given-names></name> <name><surname>Losito</surname> <given-names>A. R.</given-names></name> <name><surname>Rinaldi</surname> <given-names>M.</given-names></name> <name><surname>Aurilio</surname> <given-names>C.</given-names></name> <name><surname>Bolla</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Use of colistin in adult patients: a cross-sectional study</article-title>. <source>J Glob Antimicrob Resist.</source> <volume>20</volume>, <fpage>43</fpage>&#x2013;<lpage>49</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jgar.2019.06.009</pub-id></citation></ref>
<ref id="ref65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giammanco</surname> <given-names>A.</given-names></name> <name><surname>Cala</surname> <given-names>C.</given-names></name> <name><surname>Fasciana</surname> <given-names>T.</given-names></name> <name><surname>Dowzicky</surname> <given-names>M. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Global assessment of the activity of tigecycline against multidrug-resistant gram-negative pathogens between 2004 and 2014 as part of the tigecycline evaluation and surveillance trial</article-title>. <source>mSphere</source> <volume>2</volume>, <fpage>e00310</fpage>&#x2013;<lpage>e00316</lpage>. doi: <pub-id pub-id-type="doi">10.1128/mSphere.00310-16</pub-id></citation></ref>
<ref id="ref66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Girija</surname> <given-names>S.</given-names></name> <name><surname>Priyadharsini</surname> <given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>CLSI based antibiogram profile and the detection of MDR and XDR strains of <italic>Acinetobacter baumannii</italic> isolated from urine samples</article-title>. <source>Med. J. Islam Repub. Iran</source> <volume>33</volume>:<fpage>3</fpage>. doi: <pub-id pub-id-type="doi">10.34171/mjiri.33.3</pub-id></citation></ref>
<ref id="ref67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Girod</surname> <given-names>S.</given-names></name> <name><surname>Galabert</surname> <given-names>C.</given-names></name> <name><surname>Lecuire</surname> <given-names>A.</given-names></name> <name><surname>Zahm</surname> <given-names>J. M.</given-names></name> <name><surname>Puchelle</surname> <given-names>E.</given-names></name></person-group> (<year>1992</year>). <article-title>Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases</article-title>. <source>Pediatr. Pulmonol.</source> <volume>13</volume>, <fpage>22</fpage>&#x2013;<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ppul.1950130107</pub-id></citation></ref>
<ref id="ref68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Villoria</surname> <given-names>A. M.</given-names></name> <name><surname>Valverde-Garduno</surname> <given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Antibiotic-resistant <italic>Acinetobacter baumannii</italic> increasing success remains a challenge as a nosocomial pathogen</article-title>. <source>J Pathog</source> <volume>2016</volume>:<fpage>7318075</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2016/7318075</pub-id></citation></ref>
<ref id="ref69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greene</surname> <given-names>C.</given-names></name> <name><surname>Vadlamudi</surname> <given-names>G.</given-names></name> <name><surname>Newton</surname> <given-names>D.</given-names></name> <name><surname>Foxman</surname> <given-names>B.</given-names></name> <name><surname>Xi</surname> <given-names>C.</given-names></name></person-group> (<year>2016a</year>). <article-title>The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of <italic>Acinetobacter baumannii</italic></article-title>. <source>Am. J. Infect. Control</source> <volume>44</volume>, <fpage>e65</fpage>&#x2013;<lpage>e71</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajic.2015.12.012</pub-id></citation></ref>
<ref id="ref70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greene</surname> <given-names>C.</given-names></name> <name><surname>Wu</surname> <given-names>J.</given-names></name> <name><surname>Rickard</surname> <given-names>A. H.</given-names></name> <name><surname>Xi</surname> <given-names>C.</given-names></name></person-group> (<year>2016b</year>). <article-title>Evaluation of the ability of <italic>Acinetobacter baumannii</italic> to form biofilms on six different biomedical relevant surfaces</article-title>. <source>Lett. Appl. Microbiol.</source> <volume>63</volume>, <fpage>233</fpage>&#x2013;<lpage>239</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajic.2015.12.012</pub-id></citation></ref>
<ref id="ref71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamidian</surname> <given-names>M.</given-names></name> <name><surname>Nigro</surname> <given-names>S. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Emergence, molecular mechanisms and global spread of carbapenem-resistant <italic>Acinetobacter baumannii</italic></article-title>. <source>Microb Genom.</source> <volume>5</volume>:<fpage>e000306</fpage>. doi: <pub-id pub-id-type="doi">10.1099/mgen.0.000306</pub-id></citation></ref>
<ref id="ref72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname> <given-names>C. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Medically relevant Acinetobacter species require a type ii secretion system and specific membrane-associated chaperones for the export of multiple substrates and full virulence</article-title>. <source>PLoS Pathog.</source> <volume>12</volume>:<fpage>e1005391</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1005391</pub-id></citation></ref>
<ref id="ref73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname> <given-names>C. M.</given-names></name> <name><surname>Hennon</surname> <given-names>S. W.</given-names></name> <name><surname>Feldman</surname> <given-names>M. F.</given-names></name></person-group> (<year>2018</year>). <article-title>Uncovering the mechanisms of <italic>Acinetobacter baumannii</italic> virulence</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>16</volume>, <fpage>91</fpage>&#x2013;<lpage>102</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrmicro.2017.148</pub-id></citation></ref>
<ref id="ref74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname> <given-names>C. M.</given-names></name> <name><surname>Pulido</surname> <given-names>M. R.</given-names></name> <name><surname>Di Venanzio</surname> <given-names>G.</given-names></name> <name><surname>Kinsella</surname> <given-names>R. L.</given-names></name> <name><surname>Webb</surname> <given-names>A. I.</given-names></name> <name><surname>Scott</surname> <given-names>N. E.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Pathogenic Acinetobacter species have a functional type I secretion system and contact-dependent inhibition systems</article-title>. <source>J. Biol. Chem.</source> <volume>292</volume>, <fpage>9075</fpage>&#x2013;<lpage>9087</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M117.781575</pub-id></citation></ref>
<ref id="ref75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasani</surname> <given-names>A.</given-names></name> <name><surname>Sheikhalizadeh</surname> <given-names>V.</given-names></name> <name><surname>Ahangarzadeh Rezaee</surname> <given-names>M.</given-names></name> <name><surname>Rahmati-Yamchi</surname> <given-names>M.</given-names></name> <name><surname>Hasani</surname> <given-names>A.</given-names></name> <name><surname>Ghotaslou</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Frequency of aminoglycoside-modifying enzymes and ArmA among different sequence groups of <italic>Acinetobacter baumannii</italic> in Iran</article-title>. <source>Microb. Drug Resist.</source> <volume>22</volume>, <fpage>347</fpage>&#x2013;<lpage>353</lpage>. doi: <pub-id pub-id-type="doi">10.1089/mdr.2015.0254</pub-id></citation></ref>
<ref id="ref76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>X.</given-names></name> <name><surname>Lu</surname> <given-names>F.</given-names></name> <name><surname>Yuan</surname> <given-names>F.</given-names></name> <name><surname>Jiang</surname> <given-names>D.</given-names></name> <name><surname>Zhao</surname> <given-names>P.</given-names></name> <name><surname>Zhu</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Biofilm formation caused by clinical <italic>Acinetobacter baumannii</italic> isolates is associated with overexpression of the AdeFGH efflux pump</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>59</volume>, <fpage>4817</fpage>&#x2013;<lpage>4825</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00877-15</pub-id></citation></ref>
<ref id="ref77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heritier</surname> <given-names>C.</given-names></name> <name><surname>Poirel</surname> <given-names>L.</given-names></name> <name><surname>Nordmann</surname> <given-names>P.</given-names></name></person-group> (<year>2006</year>). <article-title>Cephalosporinase overexpression resulting from insertion of ISAba1 in <italic>Acinetobacter baumannii</italic></article-title>. <source>Clin. Microbiol. Infect.</source> <volume>12</volume>:<fpage>123e30</fpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1469-0691.2005.01320.x</pub-id></citation></ref>
<ref id="ref78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>Y.</given-names></name> <name><surname>He</surname> <given-names>L.</given-names></name> <name><surname>Tao</surname> <given-names>X.</given-names></name> <name><surname>Meng</surname> <given-names>F.</given-names></name> <name><surname>Zhang</surname> <given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Biofilm may not be necessary for the epidemic spread of <italic>Acinetobacter baumannii</italic></article-title>. <source>Sci. Rep.</source> <volume>6</volume>:<fpage>32066</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep32066</pub-id></citation></ref>
<ref id="ref79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname> <given-names>J.</given-names></name> <name><surname>Jia</surname> <given-names>X.</given-names></name> <name><surname>Zhang</surname> <given-names>L.</given-names></name> <name><surname>Li</surname> <given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>The characterization of two-component system PmrA/PmrB in Cronobacter sakazakii</article-title>. <source>Front. Microbiol.</source> <volume>11</volume>:<fpage>903</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2020.00903</pub-id></citation></ref>
<ref id="ref80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iacovelli</surname> <given-names>A.</given-names></name> <name><surname>Oliva</surname> <given-names>A.</given-names></name> <name><surname>Siccardi</surname> <given-names>G.</given-names></name> <name><surname>Tramontano</surname> <given-names>A.</given-names></name> <name><surname>Pellegrino</surname> <given-names>D.</given-names></name> <name><surname>Mastroianni</surname> <given-names>C. M.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Risk factors and effect on mortality of superinfections in a newly established COVID-19 respiratory sub-intensive care unit at University Hospital in Rome</article-title>. <source>BMC Pulm. Med.</source> <volume>23</volume>:<fpage>30</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12890-023-02315-9</pub-id></citation></ref>
<ref id="ref81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname> <given-names>S.</given-names></name> <name><surname>Al-Saryi</surname> <given-names>N.</given-names></name> <name><surname>Al-Kadmy</surname> <given-names>I. M. S.</given-names></name> <name><surname>Aziz</surname> <given-names>S. N.</given-names></name></person-group> (<year>2021</year>). <article-title>Multidrug-resistant <italic>Acinetobacter baumannii</italic> as an emerging concern in hospitals</article-title>. <source>Mol. Biol. Rep.</source> <volume>48</volume>, <fpage>6987</fpage>&#x2013;<lpage>6998</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11033-021-06690-6</pub-id></citation></ref>
<ref id="ref82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ilsan</surname> <given-names>N. A.</given-names></name> <name><surname>Lee</surname> <given-names>Y. J.</given-names></name> <name><surname>Kuo</surname> <given-names>S. C.</given-names></name> <name><surname>Lee</surname> <given-names>I. H.</given-names></name> <name><surname>Huang</surname> <given-names>T. W.</given-names></name></person-group> (<year>2021</year>). <article-title>Antimicrobial resistance mechanisms and virulence of Colistin- and Carbapenem-resistant <italic>Acinetobacter baumannii</italic> isolated from a teaching Hospital in Taiwan</article-title>. <source>Microorganisms</source> <volume>9</volume>:<fpage>1295</fpage>. doi: <pub-id pub-id-type="doi">10.3390/microorganisms9061295</pub-id></citation></ref>
<ref id="ref83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imberti</surname> <given-names>R.</given-names></name> <name><surname>Cusato</surname> <given-names>M.</given-names></name> <name><surname>Villani</surname> <given-names>P.</given-names></name> <name><surname>Carnevale</surname> <given-names>L.</given-names></name> <name><surname>Iotti</surname> <given-names>G. A.</given-names></name> <name><surname>Langer</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration</article-title>. <source>Chest</source> <volume>138</volume>, <fpage>1333</fpage>&#x2013;<lpage>1339</lpage>. doi: <pub-id pub-id-type="doi">10.1378/chest.10-0463</pub-id></citation></ref>
<ref id="ref84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ingti</surname> <given-names>B.</given-names></name> <name><surname>Upadhyay</surname> <given-names>S.</given-names></name> <name><surname>Hazarika</surname> <given-names>M.</given-names></name> <name><surname>Khyriem</surname> <given-names>A. B.</given-names></name> <name><surname>Paul</surname> <given-names>D.</given-names></name> <name><surname>Bhattacharya</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Distribution of carbapenem-resistant <italic>Acinetobacter baumannii</italic> with blaADC-30 and induction of ADC-30 in response to beta-lactam antibiotics</article-title>. <source>Res. Microbiol.</source> <volume>171</volume>, <fpage>128</fpage>&#x2013;<lpage>133</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.resmic.2020.01.002</pub-id></citation></ref>
<ref id="ref85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iovleva</surname> <given-names>A.</given-names></name> <name><surname>Mustapha</surname> <given-names>M. M.</given-names></name> <name><surname>Griffith</surname> <given-names>M. P.</given-names></name> <name><surname>Komarow</surname> <given-names>L.</given-names></name> <name><surname>Luterbach</surname> <given-names>C.</given-names></name> <name><surname>Evans</surname> <given-names>D. R.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Carbapenem-Resistant <italic>Acinetobacter baumannii</italic> in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance</article-title>. <source>MBio</source> <volume>13</volume>:<fpage>e0275921</fpage>. doi: <pub-id pub-id-type="doi">10.1128/mbio.02759-21</pub-id></citation></ref>
<ref id="ref86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iregui</surname> <given-names>A.</given-names></name> <name><surname>Khan</surname> <given-names>Z.</given-names></name> <name><surname>Landman</surname> <given-names>D.</given-names></name> <name><surname>Quale</surname> <given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Activity of Cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and <italic>Acinetobacter baumannii</italic> endemic to medical Centers in new York City</article-title>. <source>Microb. Drug Resist.</source> <volume>26</volume>, <fpage>722</fpage>&#x2013;<lpage>726</lpage>. doi: <pub-id pub-id-type="doi">10.1089/mdr.2019.0298</pub-id></citation></ref>
<ref id="ref87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname> <given-names>A. C.</given-names></name> <name><surname>Hood</surname> <given-names>I.</given-names></name> <name><surname>Boyd</surname> <given-names>K. L.</given-names></name> <name><surname>Olson</surname> <given-names>P. D.</given-names></name> <name><surname>Morrison</surname> <given-names>J. M.</given-names></name> <name><surname>Carson</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Inactivation of phospholipase D diminishes <italic>Acinetobacter baumannii</italic> pathogenesis</article-title>. <source>Infect. Immun.</source> <volume>78</volume>, <fpage>1952</fpage>&#x2013;<lpage>1962</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.00889-09</pub-id></citation></ref>
<ref id="ref88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacoby</surname> <given-names>G. A.</given-names></name> <name><surname>Strahilevitz</surname> <given-names>J.</given-names></name> <name><surname>Hooper</surname> <given-names>D. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Plasmid-mediated quinolone resistance</article-title>. <source>Microbiol Spectr</source> <volume>2</volume>:<fpage>10</fpage>. doi: <pub-id pub-id-type="doi">10.1128/microbiolspec.PLAS-0006-2013</pub-id></citation></ref>
<ref id="ref1004"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaruratanasirikul</surname> <given-names>S.</given-names></name> <name><surname>Vattanavanit</surname> <given-names>V.</given-names></name> <name><surname>Samaeng</surname> <given-names>M.</given-names></name> <name><surname>Nawakitrangsan</surname> <given-names>M.</given-names></name> <name><surname>Sriwiriyajan</surname> <given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Pharmacokinetics of imipenem in critically ill patients with life-threatening severe infections during support with extracorporeal membrane oxygenation</article-title>. <source>Clin. Drug Investig.</source> <volume>39</volume>, <fpage>787</fpage>&#x2013;<lpage>798</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40261-019-00796-3</pub-id></citation></ref>
<ref id="ref89"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeannot</surname> <given-names>K.</given-names></name> <name><surname>Bolard</surname> <given-names>A.</given-names></name> <name><surname>Pl&#x00E9;siat</surname> <given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Resistance to polymyxins in gram-negative organisms</article-title>. <source>Int. J. Antimicrob. Agents</source> <volume>49</volume>, <fpage>526</fpage>&#x2013;<lpage>535</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2016.11.029</pub-id></citation></ref>
<ref id="ref90"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>J. S.</given-names></name> <name><surname>Kwon</surname> <given-names>S. O.</given-names></name> <name><surname>Moon</surname> <given-names>D. C.</given-names></name> <name><surname>Gurung</surname> <given-names>M.</given-names></name> <name><surname>Lee</surname> <given-names>J. H.</given-names></name> <name><surname>Kim</surname> <given-names>S. I.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title><italic>Acinetobacter baumannii</italic> secretes cytotoxic outer membrane protein a via outer membrane vesicles</article-title>. <source>PLoS One</source> <volume>6</volume>:<fpage>e17027</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0017027</pub-id></citation></ref>
<ref id="ref91"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>T. L.</given-names></name> <name><surname>Waack</surname> <given-names>U.</given-names></name> <name><surname>Smith</surname> <given-names>S.</given-names></name> <name><surname>Mobley</surname> <given-names>H.</given-names></name> <name><surname>Sandkvist</surname> <given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title><italic>Acinetobacter baumannii</italic> is dependent on the type II secretion system and its substrate LipA for lipid utilization and in vivo fitness</article-title>. <source>J. Bacteriol.</source> <volume>198</volume>, <fpage>711</fpage>&#x2013;<lpage>719</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JB.00622-15</pub-id></citation></ref>
<ref id="ref92"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karakonstantis</surname> <given-names>S.</given-names></name> <name><surname>Gikas</surname> <given-names>A.</given-names></name> <name><surname>Astrinaki</surname> <given-names>E.</given-names></name> <name><surname>Kritsotakis</surname> <given-names>E. I.</given-names></name></person-group> (<year>2020</year>). <article-title>Excess mortality due to pandrug-resistant <italic>Acinetobacter baumannii</italic> infections in hospitalized patients</article-title>. <source>J. Hosp. Infect.</source> <volume>106</volume>, <fpage>447</fpage>&#x2013;<lpage>453</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jhin.2020.09.009</pub-id></citation></ref>
<ref id="ref93"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katip</surname> <given-names>W.</given-names></name> <name><surname>Uitrakul</surname> <given-names>S.</given-names></name> <name><surname>Oberdorfer</surname> <given-names>P. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Comparison of Colistin versus Colistin plus Meropenem for the treatment of Carbapenem-resistant <italic>Acinetobacter baumannii</italic> in critically ill patients: a propensity score-matched analysis</article-title>. <source>Antibiotics</source> <volume>9</volume>:<fpage>647</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics9100647</pub-id>, PMID: <pub-id pub-id-type="pmid">32998187</pub-id></citation></ref>
<ref id="ref94"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katip</surname> <given-names>W.</given-names></name> <name><surname>Uitrakul</surname> <given-names>S.</given-names></name> <name><surname>Oberdorfer</surname> <given-names>P.</given-names></name></person-group> (<year>2021a</year>). <article-title>Clinical efficacy and nephrotoxicity of the loading dose Colistin for the treatment of Carbapenem-resistant <italic>Acinetobacter baumannii</italic> in critically ill patients</article-title>. <source>Pharmaceutics.</source> <volume>14</volume>:<fpage>31</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pharmaceutics14010031</pub-id>, PMID: <pub-id pub-id-type="pmid">35056926</pub-id></citation></ref>
<ref id="ref95"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katip</surname> <given-names>W.</given-names></name> <name><surname>Uitrakul</surname> <given-names>S.</given-names></name> <name><surname>Oberdorfer</surname> <given-names>P.</given-names></name></person-group> (<year>2021b</year>). <article-title>Short-course versus long-course Colistin for treatment of Carbapenem-Resistant <italic>A. baumannii</italic> in cancer patient</article-title>. <source>Antibiotics</source> <volume>10</volume>:<fpage>484</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics10050484</pub-id></citation></ref>
<ref id="ref96"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>S. W.</given-names></name> <name><surname>Choi</surname> <given-names>C. H.</given-names></name> <name><surname>Moon</surname> <given-names>D. C.</given-names></name> <name><surname>Jin</surname> <given-names>J. S.</given-names></name> <name><surname>Lee</surname> <given-names>J. H.</given-names></name> <name><surname>Shin</surname> <given-names>J. H.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Serum resistance of <italic>Acinetobacter baumannii</italic> through the binding of factor H to outer membrane proteins</article-title>. <source>FEMS Microbiol. Lett.</source> <volume>301</volume>, <fpage>224</fpage>&#x2013;<lpage>231</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1574-6968.2009.01820.x</pub-id></citation></ref>
<ref id="ref97"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kohira</surname> <given-names>N.</given-names></name> <name><surname>Hackel</surname> <given-names>M. A.</given-names></name> <name><surname>Ishioka</surname> <given-names>Y.</given-names></name> <name><surname>Kuroiwa</surname> <given-names>M.</given-names></name> <name><surname>Sahm</surname> <given-names>D. F.</given-names></name> <name><surname>Sato</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance program (SIDERO-WT-2014)</article-title>. <source>J. Glob. Antimicrob. Resist.</source> <volume>22</volume>, <fpage>738</fpage>&#x2013;<lpage>741</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jgar.2020.07.009</pub-id></citation></ref>
<ref id="ref98"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krasauskas</surname> <given-names>R.</given-names></name> <name><surname>Skerni&#x0161;kyt&#x0117;</surname> <given-names>J.</given-names></name> <name><surname>Armalyt&#x0117;</surname> <given-names>J.</given-names></name> <name><surname>Su&#x017E;ied&#x0117;lien&#x0117;</surname> <given-names>E.</given-names></name></person-group> (<year>2019</year>). <article-title>The role of <italic>Acinetobacter baumannii</italic> response regulator BfmR in pellicle formation and competitiveness via contact-dependent inhibition system</article-title>. <source>BMC Microbiol.</source> <volume>19</volume>:<fpage>241</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12866-019-1621-5</pub-id></citation></ref>
<ref id="ref99"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kulp</surname> <given-names>A.</given-names></name> <name><surname>Kuehn</surname> <given-names>M. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Biological functions and biogenesis of secreted bacterial outer membrane vesicles</article-title>. <source>Annu. Rev. Microbiol.</source> <volume>64</volume>, <fpage>163</fpage>&#x2013;<lpage>184</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev.micro.091208.073413</pub-id></citation></ref>
<ref id="ref100"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname> <given-names>S. C.</given-names></name> <name><surname>Lee</surname> <given-names>Y. T.</given-names></name> <name><surname>Yang Lauderdale</surname> <given-names>T. L.</given-names></name> <name><surname>Huang</surname> <given-names>W. C.</given-names></name> <name><surname>Chuang</surname> <given-names>M. F.</given-names></name> <name><surname>Chen</surname> <given-names>C. P.</given-names></name></person-group> (<year>2015</year>). <article-title>Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in <italic>Acinetobacter baumannii</italic></article-title>. <source>Front. Microbiol.</source> <volume>6</volume>:<fpage>231</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2015.00231</pub-id></citation></ref>
<ref id="ref101"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langford</surname> <given-names>B. J.</given-names></name> <name><surname>So</surname> <given-names>M.</given-names></name> <name><surname>Simeonova</surname> <given-names>M.</given-names></name> <name><surname>Leung</surname> <given-names>V.</given-names></name> <name><surname>Lo</surname> <given-names>J.</given-names></name> <name><surname>Kan</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis</article-title>. <source>Lancet Microbe</source> <volume>4</volume>:<fpage>e179</fpage>. doi: <pub-id pub-id-type="doi">10.2139/ssrn.4099404</pub-id></citation></ref>
<ref id="ref102"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Law</surname> <given-names>S. K. K.</given-names></name> <name><surname>Tan</surname> <given-names>H. S.</given-names></name></person-group> (<year>2022</year>). <article-title>The role of quorum sensing, biofilm formation, and iron acquisition as key virulence mechanisms in <italic>Acinetobacter baumannii</italic> and the corresponding anti-virulence strategies</article-title>. <source>Microbiol. Res.</source> <volume>260</volume>:<fpage>127032</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.micres.2022.127032</pub-id></citation></ref>
<ref id="ref103"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>H. Y.</given-names></name> <name><surname>Chen</surname> <given-names>C. L.</given-names></name> <name><surname>Wu</surname> <given-names>S. R.</given-names></name> <name><surname>Huang</surname> <given-names>C. W.</given-names></name> <name><surname>Chiu</surname> <given-names>C. H.</given-names></name></person-group> (<year>2014</year>). <article-title>Risk factors and outcome analysis of <italic>Acinetobacter baumannii</italic> complex bacteremia in critical patients</article-title>. <source>Crit. Care Med.</source> <volume>42</volume>, <fpage>1081</fpage>&#x2013;<lpage>1088</lpage>. doi: <pub-id pub-id-type="doi">10.1097/CCM.0000000000000125</pub-id></citation></ref>
<ref id="ref104"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>C. R.</given-names></name> <name><surname>Lee</surname> <given-names>J. H.</given-names></name> <name><surname>Park</surname> <given-names>M.</given-names></name> <name><surname>Park</surname> <given-names>K. S.</given-names></name> <name><surname>Bae</surname> <given-names>I. K.</given-names></name> <name><surname>Kim</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Biology of <italic>Acinetobacter baumannii</italic>: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options</article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>7</volume>:<fpage>55</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2017.00055</pub-id></citation></ref>
<ref id="ref105"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lemos</surname> <given-names>E. V.</given-names></name> <name><surname>de la Hoz</surname> <given-names>F. P.</given-names></name> <name><surname>Einarson</surname> <given-names>T. R.</given-names></name> <name><surname>McGhan</surname> <given-names>W. F.</given-names></name> <name><surname>Quevedo</surname> <given-names>E.</given-names></name> <name><surname>Casta&#x00F1;eda</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Carbapenem resistance and mortality in patients with <italic>Acinetobacter baumannii</italic> infection: systematic review and meta-analysis</article-title>. <source>Clin. Microbiol. Infect.</source> <volume>20</volume>, <fpage>416</fpage>&#x2013;<lpage>423</lpage>. doi: <pub-id pub-id-type="doi">10.1111/1469-0691.12363</pub-id></citation></ref>
<ref id="ref106"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>F.</given-names></name> <name><surname>Wang</surname> <given-names>Z.</given-names></name></person-group> (<year>2018</year>). <article-title>Increasing rates of <italic>Acinetobacter baumannii</italic> infection and resistance in an oncology department</article-title>. <source>J. Cancer Res. Ther.</source> <volume>14</volume>, <fpage>68</fpage>&#x2013;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.4103/jcrt.JCRT_737_17</pub-id></citation></ref>
<ref id="ref107"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Llewellyn</surname> <given-names>A. C.</given-names></name> <name><surname>Zhao</surname> <given-names>J.</given-names></name> <name><surname>Song</surname> <given-names>F.</given-names></name> <name><surname>Parvathareddy</surname> <given-names>J.</given-names></name> <name><surname>Xu</surname> <given-names>Q.</given-names></name> <name><surname>Napier</surname> <given-names>B. A.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>NaxD is a deacetylase required for lipid a modification and Francisella pathogenesis</article-title>. <source>Mol. Microbiol.</source> <volume>86</volume>, <fpage>611</fpage>&#x2013;<lpage>627</lpage>. doi: <pub-id pub-id-type="doi">10.1111/mmi.12004</pub-id></citation></ref>
<ref id="ref108"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lob</surname> <given-names>S. H.</given-names></name> <name><surname>Hoban</surname> <given-names>D. J.</given-names></name> <name><surname>Sahm</surname> <given-names>D. F.</given-names></name> <name><surname>Badal</surname> <given-names>R. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Regional differences and trends in antimicrobial susceptibility of <italic>Acinetobacter baumannii</italic></article-title>. <source>Int. J. Antimicrob. Agents</source> <volume>47</volume>, <fpage>317</fpage>&#x2013;<lpage>323</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2016.01.015</pub-id></citation></ref>
<ref id="ref109"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loehfelm</surname> <given-names>T. W.</given-names></name> <name><surname>Luke</surname> <given-names>N. R.</given-names></name> <name><surname>Campagnari</surname> <given-names>A. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Identification and characterization of an <italic>Acinetobacter baumannii</italic> biofilm-associated protein</article-title>. <source>J. Bacteriol.</source> <volume>190</volume>, <fpage>1036</fpage>&#x2013;<lpage>1044</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JB.01416-07</pub-id></citation></ref>
<ref id="ref110"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Longo</surname> <given-names>F.</given-names></name> <name><surname>Vuotto</surname> <given-names>C.</given-names></name> <name><surname>Donelli</surname> <given-names>G.</given-names></name></person-group> (<year>2014</year>). <article-title>Biofilm formation in <italic>Acinetobacter baumannii</italic></article-title>. <source>New Microbiol.</source> <volume>37</volume>, <fpage>119</fpage>&#x2013;<lpage>127</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S332051</pub-id></citation></ref>
<ref id="ref111"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>L. M.</given-names></name> <name><surname>Wu</surname> <given-names>L. J.</given-names></name> <name><surname>Xiao</surname> <given-names>Y. L.</given-names></name> <name><surname>Zhao</surname> <given-names>D.</given-names></name> <name><surname>Chen</surname> <given-names>Z. X.</given-names></name> <name><surname>Kang</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Enhancing pili assembly and biofilm formation in <italic>Acinetobacter baumannii</italic> ATCC19606 using non-native acyl-homoserine lactones</article-title>. <source>BMC Microbiol.</source> <volume>15</volume>:<fpage>62</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12866-015-0397-5</pub-id></citation></ref>
<ref id="ref112"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>C.</given-names></name> <name><surname>McClean</surname> <given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Mapping global prevalence of <italic>Acinetobacter baumannii</italic> and recent vaccine development to tackle it</article-title>. <source>Vaccine</source> <volume>9</volume>:<fpage>570</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines9060570</pub-id></citation></ref>
<ref id="ref113"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>F.</given-names></name> <name><surname>Shen</surname> <given-names>C.</given-names></name> <name><surname>Zheng</surname> <given-names>X.</given-names></name> <name><surname>Liu</surname> <given-names>Y.</given-names></name> <name><surname>Chen</surname> <given-names>H.</given-names></name> <name><surname>Zhong</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Identification of a novel plasmid carrying mcr-4.3 in an <italic>Acinetobacter baumannii</italic> strain in China</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>63</volume>, <fpage>e00133</fpage>&#x2013;<lpage>e00119</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00133-19</pub-id></citation></ref>
<ref id="ref114"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magill</surname> <given-names>S. S.</given-names></name> <name><surname>Edwards</surname> <given-names>J. R.</given-names></name> <name><surname>Bamberg</surname> <given-names>W.</given-names></name> <name><surname>Beldavs</surname> <given-names>Z. G.</given-names></name> <name><surname>Dumyati</surname> <given-names>G.</given-names></name> <name><surname>Kainer</surname> <given-names>M. A.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Multistate point-prevalence survey of health care-associated infections</article-title>. <source>N. Engl. J. Med.</source> <volume>370</volume>, <fpage>1198</fpage>&#x2013;<lpage>1208</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1306801</pub-id></citation></ref>
<ref id="ref115"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magnet</surname> <given-names>S.</given-names></name> <name><surname>Courvalin</surname> <given-names>P.</given-names></name> <name><surname>Lambert</surname> <given-names>T. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in <italic>Acinetobacter baumannii</italic> strain BM4454</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>45</volume>, <fpage>3375</fpage>&#x2013;<lpage>3380</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.45.12.3375-3380.2001</pub-id></citation></ref>
<ref id="ref116"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname> <given-names>S.</given-names></name> <name><surname>Kaminski</surname> <given-names>M.</given-names></name> <name><surname>Landman</surname> <given-names>D.</given-names></name> <name><surname>Quale</surname> <given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Cefiderocol resistance in <italic>Acinetobacter baumannii</italic>: roles of the &#x00DF;-lactamases, siderophore receptors, and penicillin-binding protein 3</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>64</volume>, <fpage>e01221</fpage>&#x2013;<lpage>e01220</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01221-20</pub-id></citation></ref>
<ref id="ref117"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mangioni</surname> <given-names>D.</given-names></name> <name><surname>Fox</surname> <given-names>V.</given-names></name> <name><surname>Chatenoud</surname> <given-names>L.</given-names></name> <name><surname>Bolis</surname> <given-names>M.</given-names></name> <name><surname>Bottino</surname> <given-names>N.</given-names></name> <name><surname>Cariani</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Genomic characterization of Carbapenem-resistant <italic>Acinetobacter baumannii</italic> (CRAB) in mechanically ventilated COVID-19 patients and impact of infection control measures on reducing CRAB circulation during the second wave of the SARS-CoV-2 pandemic in Milan, Italy</article-title>. <source>Microbiol Spectr.</source> <volume>11</volume>:<fpage>e0020923</fpage>. doi: <pub-id pub-id-type="doi">10.1128/spectrum.00209-23</pub-id></citation></ref>
<ref id="ref118"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x00ED;</surname> <given-names>S.</given-names></name> <name><surname>Rodr&#x00ED;guez-Bano</surname> <given-names>J.</given-names></name> <name><surname>Catel-Ferreira</surname> <given-names>M.</given-names></name> <name><surname>Jouenne</surname> <given-names>T.</given-names></name> <name><surname>Vila</surname> <given-names>J.</given-names></name> <name><surname>Seifert</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Biofilm formation at the solid-liquid and air-liquid interfaces by Acinetobacter species</article-title>. <source>BMC. Res. Notes</source> <volume>4</volume>:<fpage>5</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1756-0500-4-5</pub-id></citation></ref>
<ref id="ref119"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marvasi</surname> <given-names>M.</given-names></name> <name><surname>Visscher</surname> <given-names>P. T.</given-names></name> <name><surname>Casillas Martinez</surname> <given-names>L.</given-names></name></person-group> (<year>2010</year>). <article-title>Exopolymeric substances (EPS) from Bacillus subtilis: polymers and genes encoding their synthesis</article-title>. <source>FEMS Microbiol. Lett.</source> <volume>313</volume>, <fpage>1</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1574-6968.2010.02085.x</pub-id></citation></ref>
<ref id="ref120"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McConnell</surname> <given-names>M. J.</given-names></name> <name><surname>Actis</surname> <given-names>L.</given-names></name> <name><surname>Pachon</surname> <given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title><italic>Acinetobacter baumannii</italic>: human infections, factors contributing to pathogenesis and animal models</article-title>. <source>FEMS Microbiol. Rev.</source> <volume>37</volume>, <fpage>130</fpage>&#x2013;<lpage>155</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1574-6976.2012.00344.x</pub-id></citation></ref>
<ref id="ref121"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meletis</surname> <given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Carbapenem resistance: overview of the problem and future perspectives</article-title>. <source>Ther Adv Infect Dis</source> <volume>3</volume>, <fpage>15</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1177/2049936115621709</pub-id></citation></ref>
<ref id="ref122"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moffatt</surname> <given-names>J. H.</given-names></name> <name><surname>Harper</surname> <given-names>M.</given-names></name> <name><surname>Harrison</surname> <given-names>P.</given-names></name> <name><surname>Hale</surname> <given-names>J. D. F.</given-names></name> <name><surname>Vinogradov</surname> <given-names>E.</given-names></name> <name><surname>Seemann</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Colistin resistance in <italic>Acinetobacter baumannii</italic> is mediated by complete loss of lipopolysaccharide production</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>54</volume>, <fpage>4971</fpage>&#x2013;<lpage>4977</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00834-10</pub-id></citation></ref>
<ref id="ref123"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname> <given-names>D. C.</given-names></name> <name><surname>Choi</surname> <given-names>C. H.</given-names></name> <name><surname>Lee</surname> <given-names>J. H.</given-names></name> <name><surname>Choi</surname> <given-names>C. W.</given-names></name> <name><surname>Kim</surname> <given-names>H. Y.</given-names></name> <name><surname>Park</surname> <given-names>J. S.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title><italic>Acinetobacter baumannii</italic> outer membrane protein a modulates the biogenesis of outer membrane vesicles</article-title>. <source>J. Microbiol.</source> <volume>50</volume>, <fpage>155</fpage>&#x2013;<lpage>160</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12275-012-1589-4</pub-id></citation></ref>
<ref id="ref124"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname> <given-names>F. C.</given-names></name> <name><surname>Dexter</surname> <given-names>C.</given-names></name> <name><surname>Kostoulias</surname> <given-names>X.</given-names></name> <name><surname>Uddin</surname> <given-names>M. I.</given-names></name> <name><surname>Peleg</surname> <given-names>A. Y.</given-names></name></person-group> (<year>2019</year>). <article-title>The mechanisms of disease caused by <italic>Acinetobacter baumannii</italic></article-title>. <source>Front. Microbiol.</source> <volume>10</volume>:<fpage>1601</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2019.01601</pub-id></citation></ref>
<ref id="ref125"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moyni&#x00E9;</surname> <given-names>L.</given-names></name> <name><surname>Luscher</surname> <given-names>A.</given-names></name> <name><surname>Rolo</surname> <given-names>D.</given-names></name> <name><surname>Pletzer</surname> <given-names>D.</given-names></name> <name><surname>Tortajada</surname> <given-names>A.</given-names></name> <name><surname>Weingart</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Structure and function of the PiuA and PirA Siderophore-drug receptors from Pseudomonas aeruginosa and <italic>Acinetobacter baumannii</italic></article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>61</volume>, <fpage>e02531</fpage>&#x2013;<lpage>e02516</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.02531-16</pub-id></citation></ref>
<ref id="ref126"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muthusamy</surname> <given-names>D.</given-names></name> <name><surname>Sudhishnaa</surname> <given-names>S.</given-names></name> <name><surname>Boppe</surname> <given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Invitro activities of Polymyxins and rifampicin against Carbapenem resistant <italic>Acinetobacter baumannii</italic> at a tertiary care hospital from South India</article-title>. <source>J. Clin. Diagn. Res.</source> <volume>10</volume>, <fpage>DC15</fpage>&#x2013;<lpage>DC18</lpage>. doi: <pub-id pub-id-type="doi">10.7860/JCDR/2016/19968.8535</pub-id></citation></ref>
<ref id="ref127"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nait Chabane</surname> <given-names>Y.</given-names></name> <name><surname>Marti</surname> <given-names>S.</given-names></name> <name><surname>Rihouey</surname> <given-names>C.</given-names></name> <name><surname>Alexandre</surname> <given-names>S.</given-names></name> <name><surname>Hardouin</surname> <given-names>J.</given-names></name> <name><surname>Lesouhaitier</surname> <given-names>O.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Characterisation of pellicles formed by <italic>Acinetobacter baumannii</italic> at the air-liquid interface</article-title>. <source>PLoS One</source> <volume>9</volume>:<fpage>660</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0111660</pub-id></citation></ref>
<ref id="ref128"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>&#x00D1;amendys-Silva</surname> <given-names>S. A.</given-names></name> <name><surname>Correa-Garc&#x00ED;a</surname> <given-names>P.</given-names></name> <name><surname>Garc&#x00ED;a-Guill&#x00E9;n</surname> <given-names>F. J.</given-names></name> <name><surname>Gonz&#x00E1;lez-Herrera</surname> <given-names>M. O.</given-names></name> <name><surname>P&#x00E9;rez-Alonso</surname> <given-names>A.</given-names></name> <name><surname>Texcocano-Becerra</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Outcomes of critically ill cancer patients with <italic>Acinetobacter baumannii</italic> infection</article-title>. <source>World J Crit Care Med</source> <volume>4</volume>, <fpage>258</fpage>&#x2013;<lpage>264</lpage>. doi: <pub-id pub-id-type="doi">10.5492/wjccm.v4.i3.258</pub-id></citation></ref>
<ref id="ref129"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nazer</surname> <given-names>L. H.</given-names></name> <name><surname>Kharabsheh</surname> <given-names>A.</given-names></name> <name><surname>Rimawi</surname> <given-names>D.</given-names></name> <name><surname>Mubarak</surname> <given-names>S.</given-names></name> <name><surname>Hawari</surname> <given-names>F.</given-names></name></person-group> (<year>2015</year>). <article-title>Characteristics and outcomes of <italic>Acinetobacter baumannii</italic> infections in critically ill patients with cancer: a matched case&#x2013;control study</article-title>. <source>Microb. Drug Resist.</source> <volume>21</volume>, <fpage>556</fpage>&#x2013;<lpage>561</lpage>. doi: <pub-id pub-id-type="doi">10.1089/mdr.2015.0032</pub-id></citation></ref>
<ref id="ref130"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname> <given-names>L.</given-names></name> <name><surname>Lv</surname> <given-names>Y.</given-names></name> <name><surname>Yuan</surname> <given-names>M.</given-names></name> <name><surname>Hu</surname> <given-names>X.</given-names></name> <name><surname>Nie</surname> <given-names>T.</given-names></name> <name><surname>Yang</surname> <given-names>X.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Genetic basis of high-level aminoglycoside resistance in <italic>Acinetobacter baumannii</italic> from Beijing, China</article-title>. <source>Acta Pharm. Sin. B</source> <volume>4</volume>, <fpage>295</fpage>&#x2013;<lpage>300</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.apsb.2014.06.004</pub-id></citation></ref>
<ref id="ref131"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname> <given-names>C.</given-names></name> <name><surname>Clemmer</surname> <given-names>K. M.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name> <name><surname>Rather</surname> <given-names>P. N.</given-names></name></person-group> (<year>2008</year>). <article-title>Isolation and characterization of an autoinducer synthase from <italic>Acinetobacter baumannii</italic></article-title>. <source>J. Bacteriol.</source> <volume>190</volume>, <fpage>3386</fpage>&#x2013;<lpage>3392</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JB.01929-07</pub-id></citation></ref>
<ref id="ref132"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Novovi&#x0107;</surname> <given-names>K.</given-names></name> <name><surname>Jov&#x010D;i&#x0107;</surname> <given-names>B.</given-names></name></person-group> (<year>2023</year>). <article-title>Colistin resistance in <italic>Acinetobacter baumannii</italic>: molecular mechanisms and epidemiology</article-title>. <source>Antibiotics</source> <volume>12</volume>:<fpage>516</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics12030516</pub-id></citation></ref>
<ref id="ref133"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname> <given-names>J.</given-names></name> <name><surname>Zander</surname> <given-names>E.</given-names></name> <name><surname>Stefanik</surname> <given-names>D.</given-names></name> <name><surname>Higgins</surname> <given-names>P. G.</given-names></name> <name><surname>Roca</surname> <given-names>I.</given-names></name> <name><surname>Vila</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>High incidence of pandrug-resistant <italic>Acinetobacter baumannii</italic> isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial</article-title>. <source>J. Antimicrob. Chemother.</source> <volume>72</volume>, <fpage>3277</fpage>&#x2013;<lpage>3282</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkx322</pub-id></citation></ref>
<ref id="ref134"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ogutlu</surname> <given-names>A.</given-names></name> <name><surname>Guclu</surname> <given-names>E.</given-names></name> <name><surname>Karabay</surname> <given-names>O.</given-names></name> <name><surname>Utku</surname> <given-names>A. C.</given-names></name> <name><surname>Tuna</surname> <given-names>N.</given-names></name> <name><surname>Yahyaoglu</surname> <given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients</article-title>. <source>Ann. Clin. Microbiol. Antimicrob.</source> <volume>13</volume>:<fpage>7</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1476-0711-13-7</pub-id></citation></ref>
<ref id="ref135"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname> <given-names>M. H.</given-names></name> <name><surname>Han</surname> <given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>AbaR is a LuxR type regulator essential for motility and the formation of biofilm and pellicle in <italic>Acinetobacter baumannii</italic></article-title>. <source>Genes Genomics.</source> <volume>42</volume>, <fpage>1339</fpage>&#x2013;<lpage>1346</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13258-020-01005-8</pub-id></citation></ref>
<ref id="ref136"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olaitan</surname> <given-names>A. O.</given-names></name> <name><surname>Morand</surname> <given-names>S.</given-names></name> <name><surname>Rolain</surname> <given-names>J. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria</article-title>. <source>Front. Microbiol.</source> <volume>5</volume>:<fpage>643</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2014.00643</pub-id></citation></ref>
<ref id="ref137"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliva</surname> <given-names>A.</given-names></name> <name><surname>Bianchi</surname> <given-names>A.</given-names></name> <name><surname>Russo</surname> <given-names>A.</given-names></name> <name><surname>Ceccarelli</surname> <given-names>G.</given-names></name> <name><surname>Cancelli</surname> <given-names>F.</given-names></name> <name><surname>Aloj</surname> <given-names>F.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Effect of N-acetylcysteine Administration on 30-day mortality in critically ill patients with septic shock caused by Carbapenem-resistant Klebsiella pneumoniae and <italic>Acinetobacter baumannii</italic>: a retrospective case-control study</article-title>. <source>Antibiotics</source> <volume>10</volume>:<fpage>271</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics10030271</pub-id></citation></ref>
<ref id="ref138"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliva</surname> <given-names>A.</given-names></name> <name><surname>Ceccarelli</surname> <given-names>G.</given-names></name> <name><surname>De Angelis</surname> <given-names>M.</given-names></name> <name><surname>Sacco</surname> <given-names>F.</given-names></name> <name><surname>Miele</surname> <given-names>M. C.</given-names></name> <name><surname>Mastroianni</surname> <given-names>C. M.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant <italic>Acinetobacter baumannii</italic></article-title>. <source>J. Glob. Antimicrob. Resist.</source> <volume>23</volume>, <fpage>292</fpage>&#x2013;<lpage>296</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jgar.2020.09.019</pub-id></citation></ref>
<ref id="ref139"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliva</surname> <given-names>A.</given-names></name> <name><surname>Cipolla</surname> <given-names>A.</given-names></name> <name><surname>Vullo</surname> <given-names>V.</given-names></name> <name><surname>Venditti</surname> <given-names>M.</given-names></name> <name><surname>Mastroianni</surname> <given-names>C. M.</given-names></name> <name><surname>Falcone</surname> <given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant <italic>Acinetobacter baumannii</italic> causing ventilator-associated pneumonia</article-title>. <source>New Microbiol.</source> <volume>40</volume>, <fpage>205</fpage>&#x2013;<lpage>207</lpage>. PMID: <pub-id pub-id-type="pmid">28675246</pub-id></citation></ref>
<ref id="ref140"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ordooei Javan</surname> <given-names>A.</given-names></name> <name><surname>Shokouhi</surname> <given-names>S.</given-names></name> <name><surname>Sahraei</surname> <given-names>Z.</given-names></name></person-group> (<year>2015</year>). <article-title>A review on colistin nephrotoxicity</article-title>. <source>Eur. J. Clin. Pharmacol.</source> <volume>71</volume>, <fpage>801</fpage>&#x2013;<lpage>810</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00228-015-1865-4</pub-id></citation></ref>
<ref id="ref141"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orsinger-Jacobsen</surname> <given-names>S. J.</given-names></name> <name><surname>Patel</surname> <given-names>S. S.</given-names></name> <name><surname>Vellozzi</surname> <given-names>E. M.</given-names></name> <name><surname>Gialanella</surname> <given-names>P.</given-names></name> <name><surname>Nimrichter</surname> <given-names>L.</given-names></name> <name><surname>Miranda</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Use of a stainless-steel washer platform to study <italic>Acinetobacter baumannii</italic> adhesion and biofilm formation on abiotic surfaces</article-title>. <source>Microbiology</source> <volume>159</volume>, <fpage>2594</fpage>&#x2013;<lpage>2604</lpage>. doi: <pub-id pub-id-type="doi">10.1099/mic.0.068825-0</pub-id></citation></ref>
<ref id="ref142"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>&#x00D6;zarslan</surname> <given-names>T. O.</given-names></name> <name><surname>Sirmatel</surname> <given-names>F.</given-names></name> <name><surname>Karab&#x00F6;rk</surname> <given-names>S. O.</given-names></name> <name><surname>D&#x00FC;zc&#x00FC;</surname> <given-names>S. E.</given-names></name> <name><surname>Astarci</surname> <given-names>H. M.</given-names></name></person-group> (<year>2023</year>). <article-title><italic>Acinetobacter baumannii</italic> pneumonia increases surfactant proteins SP-A, SP-B, and SP-D levels, while decreasing SP-C level in bronchoalveolar lavage in rats</article-title>. <source>Microbes Infect.</source> <volume>25</volume>:<fpage>105064</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.micinf.2022.105064</pub-id></citation></ref>
<ref id="ref143"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozbek</surname> <given-names>B.</given-names></name> <name><surname>Mataraci</surname> <given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>In vitro effectiveness of colistin, tigecycline, and levofloxacin alone and combined with clarithromycin and/or heparin as lock solutions against embedded <italic>Acinetobacter baumannii</italic> strains</article-title>. <source>J. Antimicrob. Chemother.</source> <volume>68</volume>, <fpage>827</fpage>&#x2013;<lpage>830</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dks472</pub-id></citation></ref>
<ref id="ref144"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pakharukova</surname> <given-names>N.</given-names></name> <name><surname>Tuittila</surname> <given-names>M.</given-names></name> <name><surname>Paavilainen</surname> <given-names>S.</given-names></name> <name><surname>Zavialov</surname> <given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Crystallization and preliminary X-ray diffraction analysis of the Csu pili CsuC-CsuA/B chaperone-major subunit pre-assembly complex from <italic>Acinetobacter baumannii</italic></article-title>. <source>Acta Crystallogr. F. Struct. Biol. Commun.</source> <volume>71</volume>, <fpage>770</fpage>&#x2013;<lpage>774</lpage>. doi: <pub-id pub-id-type="doi">10.1107/S2053230X15007955</pub-id></citation></ref>
<ref id="ref145"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palmieri</surname> <given-names>M.</given-names></name> <name><surname>D&#x2019;Andrea</surname> <given-names>M. M.</given-names></name> <name><surname>Pelegrin</surname> <given-names>A. C.</given-names></name> <name><surname>Perrot</surname> <given-names>N.</given-names></name> <name><surname>Mirande</surname> <given-names>C.</given-names></name> <name><surname>Blanc</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Abundance of Colistin-resistant, OXA-23- and ArmA-producing <italic>Acinetobacter baumannii</italic> belonging to international clone 2 in Greece</article-title>. <source>Front. Microbiol.</source> <volume>11</volume>:<fpage>668</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2020.00668</pub-id></citation></ref>
<ref id="ref146"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Pandey</surname> <given-names>N.</given-names></name> <name><surname>Cascella</surname> <given-names>M.</given-names></name></person-group> (<year>2022</year>). &#x201C;<article-title>Beta lactam antibiotics</article-title>&#x201D; in <source>StatPearls</source> (Treasure Island (FL): <publisher-name>StatPearls Publishing</publisher-name>).</citation></ref>
<ref id="ref147"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papathanakos</surname> <given-names>G.</given-names></name> <name><surname>Andrianopoulos</surname> <given-names>I.</given-names></name> <name><surname>Papathanasiou</surname> <given-names>A.</given-names></name> <name><surname>Priavali</surname> <given-names>E.</given-names></name> <name><surname>Koulenti</surname> <given-names>D.</given-names></name> <name><surname>Koulouras</surname> <given-names>V.</given-names></name></person-group> (<year>2020</year>). <article-title>Colistin-resistant <italic>Acinetobacter Baumannii</italic> Bacteremia: a serious threat for critically ill patients</article-title>. <source>Microorganisms</source> <volume>8</volume>:<fpage>287</fpage>. doi: <pub-id pub-id-type="doi">10.3390/microorganisms8020287</pub-id></citation></ref>
<ref id="ref148"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>J. S.</given-names></name> <name><surname>Lee</surname> <given-names>W. C.</given-names></name> <name><surname>Choi</surname> <given-names>S.</given-names></name> <name><surname>Yeo</surname> <given-names>K. J.</given-names></name> <name><surname>Song</surname> <given-names>J. H.</given-names></name> <name><surname>Han</surname> <given-names>Y. H.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Overexpression, purification, crystallization and preliminary X-ray crystallographic analysis of the periplasmic domain of outer membrane protein a from <italic>Acinetobacter baumannii</italic></article-title>. <source>Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.</source> <volume>67</volume>, <fpage>1531</fpage>&#x2013;<lpage>1533</lpage>. doi: <pub-id pub-id-type="doi">10.1107/S1744309111038401</pub-id></citation></ref>
<ref id="ref149"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>J. S.</given-names></name> <name><surname>Lee</surname> <given-names>W. C.</given-names></name> <name><surname>Yeo</surname> <given-names>K. J.</given-names></name> <name><surname>Ryu</surname> <given-names>K. S.</given-names></name> <name><surname>Kumarasiri</surname> <given-names>M.</given-names></name> <name><surname>Hesek</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Mechanism of anchoring of OmpA protein to the cell wall peptidoglycan of the gram-negative bacterial outer membrane</article-title>. <source>FASEB J.</source> <volume>26</volume>, <fpage>219</fpage>&#x2013;<lpage>228</lpage>. doi: <pub-id pub-id-type="doi">10.1096/fj.11-188425</pub-id></citation></ref>
<ref id="ref150"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Partridge</surname> <given-names>S. R.</given-names></name> <name><surname>Di Pilato</surname> <given-names>V.</given-names></name> <name><surname>Doi</surname> <given-names>Y.</given-names></name> <name><surname>Feldgarden</surname> <given-names>M.</given-names></name> <name><surname>Haft</surname> <given-names>D. H.</given-names></name> <name><surname>Klimke</surname> <given-names>W.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Proposal for assignment of allele numbers for mobile colistin resistance (mcr) genes</article-title>. <source>J. Antimicrob. Chemother.</source> <volume>73</volume>, <fpage>2625</fpage>&#x2013;<lpage>2630</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dky262</pub-id></citation></ref>
<ref id="ref151"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pascale</surname> <given-names>R.</given-names></name> <name><surname>Pasquini</surname> <given-names>Z.</given-names></name> <name><surname>Bartoletti</surname> <given-names>M.</given-names></name> <name><surname>Caiazzo</surname> <given-names>L.</given-names></name> <name><surname>Fornaro</surname> <given-names>G.</given-names></name> <name><surname>Bussini</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Cefiderocol treatment for carbapenem-resistant <italic>Acinetobacter baumannii</italic> infection in the ICU during the COVID-19 pandemic: a multicentre cohort study</article-title>. <source>JAC Antimicrob. Resist.</source> <volume>3</volume>:<fpage>dlab174</fpage>. doi: <pub-id pub-id-type="doi">10.1093/jacamr/dlab174</pub-id></citation></ref>
<ref id="ref152"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname> <given-names>A.</given-names></name> <name><surname>Emerick</surname> <given-names>M.</given-names></name> <name><surname>Cabunoc</surname> <given-names>M. K.</given-names></name> <name><surname>Williams</surname> <given-names>M. H.</given-names></name> <name><surname>Preas</surname> <given-names>M. A.</given-names></name> <name><surname>Schrank</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Rapid spread and control of multidrug-resistant gram-negative bacteria in COVID-19 patient care units</article-title>. <source>Emerg. Infect. Dis.</source> <volume>27</volume>, <fpage>1234</fpage>&#x2013;<lpage>1237</lpage>. doi: <pub-id pub-id-type="doi">10.3201/eid2704.204036</pub-id></citation></ref>
<ref id="ref153"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paton</surname> <given-names>R.</given-names></name> <name><surname>Miles</surname> <given-names>R. S.</given-names></name> <name><surname>Hood</surname> <given-names>J.</given-names></name> <name><surname>Amyes</surname> <given-names>S. G.</given-names></name> <name><surname>Miles</surname> <given-names>R. S.</given-names></name> <name><surname>Amyes</surname> <given-names>S. G.</given-names></name></person-group> (<year>1993</year>). <article-title>ARI 1: b-lactamase-mediated imipenem resistance in <italic>Acinetobacter baumannii</italic></article-title>. <source>Int. J. Antimicrob. Agents</source> <volume>2</volume>:<fpage>81e7</fpage>. doi: <pub-id pub-id-type="doi">10.1016/0924-8579(93)90045-7</pub-id></citation></ref>
<ref id="ref154"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname> <given-names>M.</given-names></name> <name><surname>Carrara</surname> <given-names>E.</given-names></name> <name><surname>Retamar</surname> <given-names>P.</given-names></name> <name><surname>T&#x00E4;ngd&#x00E9;n</surname> <given-names>T.</given-names></name> <name><surname>Bitterman</surname> <given-names>R.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)</article-title>. <source>Clin. Microbiol. Infect.</source> <volume>28</volume>, <fpage>521</fpage>&#x2013;<lpage>547</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmi.2021.11.025</pub-id></citation></ref>
<ref id="ref155"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peleg</surname> <given-names>A. Y.</given-names></name> <name><surname>Seifert</surname> <given-names>H.</given-names></name> <name><surname>Paterson</surname> <given-names>D. L.</given-names></name></person-group> (<year>2008</year>). <article-title><italic>Acinetobacter baumannii</italic>: emergence of a successful pathogen</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>21</volume>, <fpage>538</fpage>&#x2013;<lpage>582</lpage>. doi: <pub-id pub-id-type="doi">10.1128/CMR.00058-07</pub-id></citation></ref>
<ref id="ref156"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Penesyan</surname> <given-names>A.</given-names></name> <name><surname>Nagy</surname> <given-names>S. S.</given-names></name> <name><surname>Kjelleberg</surname> <given-names>S.</given-names></name> <name><surname>Gillings</surname> <given-names>M. R.</given-names></name> <name><surname>Paulsen</surname> <given-names>I. T.</given-names></name></person-group> (<year>2019</year>). <article-title>Rapid microevolution of biofilm cells in response to antibiotics</article-title>. <source>NPJ Biofilms Microbiomes</source> <volume>5</volume>:<fpage>34</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41522-019-0108-3</pub-id></citation></ref>
<ref id="ref157"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname> <given-names>Q.</given-names></name> <name><surname>Lin</surname> <given-names>F.</given-names></name> <name><surname>Ling</surname> <given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>In vitro activity of biofilm inhibitors in combination with antibacterial drugs against extensively drug-resistant <italic>Acinetobacter baumannii</italic></article-title>. <source>Sci. Rep.</source> <volume>10</volume>:<fpage>18097</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-75218-y</pub-id></citation></ref>
<ref id="ref158"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname> <given-names>F.</given-names></name> <name><surname>Hujer</surname> <given-names>A. M.</given-names></name> <name><surname>Hujer</surname> <given-names>K. M.</given-names></name> <name><surname>Decker</surname> <given-names>B. K.</given-names></name> <name><surname>Rather</surname> <given-names>P. N.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Global challenge of multidrug-resistant <italic>Acinetobacter baumannii</italic></article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>51</volume>, <fpage>3471</fpage>&#x2013;<lpage>3484</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01464-06</pub-id></citation></ref>
<ref id="ref159"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piperaki</surname> <given-names>E. T.</given-names></name> <name><surname>Tzouvelekis</surname> <given-names>L. S.</given-names></name> <name><surname>Miriagou</surname> <given-names>V.</given-names></name> <name><surname>Daikos</surname> <given-names>G. L.</given-names></name></person-group> (<year>2019</year>). <article-title>Carbapenem-resistant <italic>Acinetobacter baumannii</italic>: in pursuit of an effective treatment</article-title>. <source>Clin. Microbiol. Infect.</source> <volume>25</volume>, <fpage>951</fpage>&#x2013;<lpage>957</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmi.2019.03.014</pub-id></citation></ref>
<ref id="ref160"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poirel</surname> <given-names>L.</given-names></name> <name><surname>Jayol</surname> <given-names>A.</given-names></name> <name><surname>Nordmann</surname> <given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>30</volume>, <fpage>557</fpage>&#x2013;<lpage>596</lpage>. doi: <pub-id pub-id-type="doi">10.1128/CMR.00064-16</pub-id></citation></ref>
<ref id="ref161"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poirel</surname> <given-names>L.</given-names></name> <name><surname>Sadek</surname> <given-names>M.</given-names></name> <name><surname>Nordmann</surname> <given-names>P.</given-names></name></person-group> (<year>2021</year>). <article-title>Contribution of PER-type and NDM-type &#x03B2;-lactamases to Cefiderocol resistance in <italic>Acinetobacter baumannii</italic></article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>65</volume>:<fpage>e0087721</fpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00877-21</pub-id></citation></ref>
<ref id="ref162"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pollini</surname> <given-names>S.</given-names></name> <name><surname>Boncompagni</surname> <given-names>S.</given-names></name> <name><surname>Di Maggio</surname> <given-names>T.</given-names></name> <name><surname>Di Pilato</surname> <given-names>V.</given-names></name> <name><surname>Spanu</surname> <given-names>T.</given-names></name> <name><surname>Fiori</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>In vitro synergism of colistin in combination with N-acetylcysteine against <italic>Acinetobacter baumannii</italic> grown in planktonic phase and in biofilms</article-title>. <source>J. Antimicrob. Chemother.</source> <volume>73</volume>, <fpage>2388</fpage>&#x2013;<lpage>2395</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dky185</pub-id></citation></ref>
<ref id="ref163"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pour</surname> <given-names>N. K.</given-names></name> <name><surname>Dusane</surname> <given-names>D. H.</given-names></name> <name><surname>Dhakephalkar</surname> <given-names>P. K.</given-names></name> <name><surname>Zamin</surname> <given-names>F. R.</given-names></name> <name><surname>Zinjarde</surname> <given-names>S. S.</given-names></name> <name><surname>Chopade</surname> <given-names>B. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Biofilm formation by <italic>Acinetobacter baumannii</italic> strains isolated from urinary tract infection and urinary catheters</article-title>. <source>FEMS Immunol. Med. Microbiol.</source> <volume>62</volume>, <fpage>328</fpage>&#x2013;<lpage>338</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1574-695X.2011.00818.x</pub-id></citation></ref>
<ref id="ref164"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname> <given-names>M. J.</given-names></name> <name><surname>Trent</surname> <given-names>M. S.</given-names></name></person-group> (<year>2018</year>). <article-title>Expanding the paradigm for the outer membrane: <italic>Acinetobacter baumannii</italic> in the absence of endotoxin</article-title>. <source>Mol. Microbiol.</source> <volume>107</volume>, <fpage>47</fpage>&#x2013;<lpage>56</lpage>. doi: <pub-id pub-id-type="doi">10.1111/mmi.13872</pub-id></citation></ref>
<ref id="ref1003"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pybus</surname> <given-names>C. A.</given-names></name> <name><surname>Felder-Scott</surname> <given-names>C.</given-names></name> <name><surname>Obuekwe</surname> <given-names>V.</given-names></name> <name><surname>Greenberg</surname> <given-names>D. E.</given-names></name></person-group> (<year>2021</year>). <article-title>Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens</article-title>. <source>Antimicrob Agents Chemother.</source> <volume>65</volume>, <fpage>e01194</fpage>&#x2013;<lpage>e01120</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01194-20</pub-id></citation></ref>
<ref id="ref165"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rando</surname> <given-names>E.</given-names></name> <name><surname>Segala</surname> <given-names>F. V.</given-names></name> <name><surname>Vargas</surname> <given-names>J.</given-names></name> <name><surname>Seguiti</surname> <given-names>C.</given-names></name> <name><surname>De Pascale</surname> <given-names>G.</given-names></name> <name><surname>Murri</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Cefiderocol for severe Carbapenem-Resistant <italic>A. baumannii</italic> pneumonia: towards the comprehension of its place in therapy</article-title>. <source>Antibiotics</source> <volume>11</volume>:<fpage>3</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics11010003</pub-id></citation></ref>
<ref id="ref166"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Repizo</surname> <given-names>G. D.</given-names></name> <name><surname>Gagn&#x00E9;</surname> <given-names>S.</given-names></name> <name><surname>Foucault-Grunenwald</surname> <given-names>M. L.</given-names></name> <name><surname>Borges</surname> <given-names>V.</given-names></name> <name><surname>Charpentier</surname> <given-names>X.</given-names></name> <name><surname>Limansky</surname> <given-names>A. S.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Differential role of the T6SS in <italic>Acinetobacter baumannii</italic> virulence</article-title>. <source>PLoS One</source> <volume>10</volume>:<fpage>e0138265</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0138265</pub-id></citation></ref>
<ref id="ref167"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhouma</surname> <given-names>M.</given-names></name> <name><surname>Beaudry</surname> <given-names>F.</given-names></name> <name><surname>Th&#x00E9;riault</surname> <given-names>W.</given-names></name> <name><surname>Letellier</surname> <given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Colistin in pig production: chemistry, mechanism of antibacterial action, microbial resistance emergence, and one health perspectives</article-title>. <source>Front. Microbiol.</source> <volume>7</volume>:<fpage>1789</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2016.01789</pub-id></citation></ref>
<ref id="ref168"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richmond</surname> <given-names>G. E.</given-names></name> <name><surname>Evans</surname> <given-names>L. P.</given-names></name> <name><surname>Anderson</surname> <given-names>M. J.</given-names></name> <name><surname>Wand</surname> <given-names>M. E.</given-names></name> <name><surname>Bonney</surname> <given-names>L. C.</given-names></name> <name><surname>Ivens</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>The <italic>Acinetobacter baumannii</italic> two-component system AdeRS regulates genes required for multidrug efflux, biofilm formation, and virulence in a strain-specific manner</article-title>. <source>MBio</source> <volume>7</volume>:<fpage>e00430</fpage>. doi: <pub-id pub-id-type="doi">10.1128/mBio.00430-16</pub-id></citation></ref>
<ref id="ref169"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roca</surname> <given-names>I.</given-names></name> <name><surname>Espinal</surname> <given-names>P.</given-names></name> <name><surname>Vila-Farres</surname> <given-names>X.</given-names></name> <name><surname>Vila</surname> <given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>The <italic>Acinetobacter baumannii</italic> oxymoron: commensal hospital dweller turned pan-drug-resistant menace</article-title>. <source>Front. Microbiol.</source> <volume>3</volume>:<fpage>148</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2012.00148</pub-id></citation></ref>
<ref id="ref170"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x0131;&#x0301;guez-Bano</surname> <given-names>J.</given-names></name> <name><surname>Mart&#x0131;&#x0301;</surname> <given-names>S.</given-names></name> <name><surname>Soto</surname> <given-names>S.</given-names></name> <name><surname>Fern&#x00E1;ndez-Cuenca</surname> <given-names>F.</given-names></name> <name><surname>Cisneros</surname> <given-names>J. M.</given-names></name> <name><surname>Pach&#x00F3;n</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>Biofilm formation in <italic>Acinetobacter baumannii</italic>: associated features and clinical implications</article-title>. <source>Clin. Microbiol. Infect.</source> <volume>14</volume>, <fpage>276</fpage>&#x2013;<lpage>278</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1469-0691.2007.01916.x</pub-id></citation></ref>
<ref id="ref171"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x00ED;guez-Mart&#x00ED;nez</surname> <given-names>J. M.</given-names></name> <name><surname>Nordmann</surname> <given-names>P.</given-names></name> <name><surname>Ronco</surname> <given-names>E.</given-names></name> <name><surname>Poirel</surname> <given-names>L.</given-names></name></person-group> (<year>2010</year>). <article-title>Extended-spectrum cephalosporinase in <italic>Acinetobacter baumannii</italic></article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>54</volume>:<fpage>3484e8</fpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00050-10</pub-id></citation></ref>
<ref id="ref172"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname> <given-names>S.</given-names></name> <name><surname>Chatterjee</surname> <given-names>S.</given-names></name> <name><surname>Bhattacharjee</surname> <given-names>A.</given-names></name> <name><surname>Chattopadhyay</surname> <given-names>P.</given-names></name> <name><surname>Saha</surname> <given-names>B.</given-names></name> <name><surname>Dutta</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Overexpression of efflux pumps, mutations in the pumps&#x2019; regulators, chromosomal mutations, and AAC(6&#x2032;)-Ib-cr are associated with fluoroquinolone resistance in diverse sequence types of neonatal Septicaemic <italic>Acinetobacter baumannii</italic>: a 7-year single Center study</article-title>. <source>Front. Microbiol.</source> <volume>12</volume>:<fpage>602724</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2021.602724</pub-id></citation></ref>
<ref id="ref173"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname> <given-names>S.</given-names></name> <name><surname>Chowdhury</surname> <given-names>G.</given-names></name> <name><surname>Mukhopadhyay</surname> <given-names>A. K.</given-names></name> <name><surname>Dutta</surname> <given-names>S.</given-names></name> <name><surname>Basu</surname> <given-names>S.</given-names></name></person-group> (<year>2022</year>). <article-title>Convergence of biofilm formation and antibiotic resistance in <italic>Acinetobacter baumannii</italic> infection</article-title>. <source>Front. Med.</source> <volume>9</volume>:<fpage>793615</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmed.2022.793615</pub-id></citation></ref>
<ref id="ref174"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rumbaugh</surname> <given-names>K. P.</given-names></name> <name><surname>Sauer</surname> <given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>Biofilm dispersion</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>18</volume>, <fpage>571</fpage>&#x2013;<lpage>586</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41579-020-0385-0</pub-id></citation></ref>
<ref id="ref175"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname> <given-names>A.</given-names></name> <name><surname>Gavaruzzi</surname> <given-names>F.</given-names></name> <name><surname>Ceccarelli</surname> <given-names>G.</given-names></name> <name><surname>Borrazzo</surname> <given-names>C.</given-names></name> <name><surname>Oliva</surname> <given-names>A.</given-names></name> <name><surname>Alessandri</surname> <given-names>F.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Multidrug-resistant <italic>Acinetobacter baumannii</italic> infections in COVID-19 patients hospitalized in intensive care unit</article-title>. <source>Infection</source> <volume>50</volume>, <fpage>83</fpage>&#x2013;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s15010-021-01643-4</pub-id></citation></ref>
<ref id="ref176"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sahu</surname> <given-names>P. K.</given-names></name> <name><surname>Iyer</surname> <given-names>P. S.</given-names></name> <name><surname>Oak</surname> <given-names>A. M.</given-names></name> <name><surname>Pardesi</surname> <given-names>K. R.</given-names></name> <name><surname>Chopade</surname> <given-names>B. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Characterization of eDNA from the clinical strain <italic>Acinetobacter baumannii</italic> AIIMS 7 and its role in biofilm formation</article-title>. <source>Sci. World J.</source> <volume>2012</volume>:<fpage>973436</fpage>. doi: <pub-id pub-id-type="doi">10.1100/2012/973436</pub-id></citation></ref>
<ref id="ref177"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>S&#x00E1;nchez-Encinales</surname> <given-names>V.</given-names></name> <name><surname>&#x00C1;lvarez-Mar&#x00ED;n</surname> <given-names>R.</given-names></name> <name><surname>Pach&#x00F3;n-Ib&#x00E1;&#x00F1;ez</surname> <given-names>M. E.</given-names></name> <name><surname>Fern&#x00E1;ndez-Cuenca</surname> <given-names>F.</given-names></name> <name><surname>Pascual</surname> <given-names>A.</given-names></name> <name><surname>Garnacho-Montero</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Overproduction of outer membrane protein a by <italic>Acinetobacter baumannii</italic> as a risk factor for nosocomial pneumonia, Bacteremia, and mortality rate increase</article-title>. <source>J Infect Dis</source> <volume>215</volume>, <fpage>966</fpage>&#x2013;<lpage>974</lpage>. doi: <pub-id pub-id-type="doi">10.1093/infdis/jix010</pub-id></citation></ref>
<ref id="ref178"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname> <given-names>Y.</given-names></name> <name><surname>Ubagai</surname> <given-names>T.</given-names></name> <name><surname>Tansho-Nagakawa</surname> <given-names>S.</given-names></name> <name><surname>Yoshino</surname> <given-names>Y.</given-names></name> <name><surname>Ono</surname> <given-names>Y.</given-names></name></person-group> (<year>2021</year>). <article-title>Effects of colistin and tigecycline on multidrug-resistant <italic>Acinetobacter baumannii</italic> biofilms: advantages and disadvantages of their combination</article-title>. <source>Sci. Rep.</source> <volume>11</volume>:<fpage>11700</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-021-90732-3</pub-id></citation></ref>
<ref id="ref179"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname> <given-names>Y.</given-names></name> <name><surname>Unno</surname> <given-names>Y.</given-names></name> <name><surname>Ubagai</surname> <given-names>T.</given-names></name> <name><surname>Ono</surname> <given-names>Y.</given-names></name></person-group> (<year>2018</year>). <article-title>Sub-minimum inhibitory concentrations of colistin and polymyxin B promote <italic>Acinetobacter baumannii</italic> biofilm formation</article-title>. <source>PLoS One</source> <volume>13</volume>, <volume>e0194556</volume>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0194556</pub-id></citation></ref>
<ref id="ref180"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sechi</surname> <given-names>L. A.</given-names></name> <name><surname>Karadenizli</surname> <given-names>A.</given-names></name> <name><surname>Deriu</surname> <given-names>A.</given-names></name> <name><surname>Zanetti</surname> <given-names>S.</given-names></name> <name><surname>Kolayli</surname> <given-names>F.</given-names></name> <name><surname>Balikci</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2004</year>). <article-title>PER-1 type beta-lactamase production in <italic>Acinetobacter baumannii</italic> is related to cell adhesion</article-title>. <source>Med. Sci. Monit.</source> <volume>10</volume>, <fpage>CR180</fpage>&#x2013;<lpage>CR184</lpage>.</citation></ref>
<ref id="ref181"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shadan</surname> <given-names>A.</given-names></name> <name><surname>Pathak</surname> <given-names>A.</given-names></name> <name><surname>Ma</surname> <given-names>Y.</given-names></name> <name><surname>Pathania</surname> <given-names>R.</given-names></name> <name><surname>Singh</surname> <given-names>R. P.</given-names></name></person-group> (<year>2023</year>). <article-title>Deciphering the virulence factors, regulation, and immune response to <italic>Acinetobacter baumannii</italic> infection</article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>13</volume>:<fpage>1053968</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2023.1053968</pub-id></citation></ref>
<ref id="ref182"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname> <given-names>J. H.</given-names></name> <name><surname>Lee</surname> <given-names>H. W.</given-names></name> <name><surname>Kim</surname> <given-names>S. M.</given-names></name> <name><surname>Kim</surname> <given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>Proteomic analysis of <italic>Acinetobacter baumannii</italic> in biofilm and planktonic growth mode</article-title>. <source>J. Microbiol.</source> <volume>47</volume>, <fpage>728</fpage>&#x2013;<lpage>735</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12275-009-0158-y</pub-id></citation></ref>
<ref id="ref183"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smani</surname> <given-names>Y.</given-names></name> <name><surname>Fabrega</surname> <given-names>A.</given-names></name> <name><surname>Roca</surname> <given-names>I.</given-names></name> <name><surname>Sanchez-Encinales</surname> <given-names>V.</given-names></name> <name><surname>Vila</surname> <given-names>J.</given-names></name> <name><surname>Pachon</surname> <given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Role of OmpA in the multidrug resistance phenotype of <italic>Acinetobacter baumannii</italic></article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>58</volume>, <fpage>1806</fpage>&#x2013;<lpage>1808</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.02101-13</pub-id></citation></ref>
<ref id="ref184"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smani</surname> <given-names>Y.</given-names></name> <name><surname>McConnell</surname> <given-names>M. J.</given-names></name> <name><surname>Pach&#x00F3;n</surname> <given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Role of fibronectin in the adhesion of <italic>Acinetobacter baumannii</italic> to host cells</article-title>. <source>PLoS One</source> <volume>7</volume>:<fpage>e33073</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0033073</pub-id></citation></ref>
<ref id="ref185"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smet</surname> <given-names>A.</given-names></name> <name><surname>Martel</surname> <given-names>A.</given-names></name> <name><surname>Persoons</surname> <given-names>D.</given-names></name> <name><surname>Dewulf</surname> <given-names>J.</given-names></name> <name><surname>Heyndrickx</surname> <given-names>M.</given-names></name> <name><surname>Catry</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>Diversity of extended-Spectrum &#x03B2;-lactamases and class C &#x03B2;-lactamases among cloacal <italic>Escherichia coli</italic> isolates in Belgian broiler farms</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>52</volume>, <fpage>1238</fpage>&#x2013;<lpage>1243</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01285-07</pub-id></citation></ref>
<ref id="ref186"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soroosh</surname> <given-names>M.</given-names></name> <name><surname>Furmanek-Blaszk</surname> <given-names>B.</given-names></name> <name><surname>&#x0141;upkowska</surname> <given-names>A.</given-names></name> <name><surname>Kuczynska-Wisnik</surname> <given-names>D.</given-names></name> <name><surname>Stojowska-Swedrzynska</surname> <given-names>K.</given-names></name> <name><surname>Laskowsk</surname> <given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Mechanisms protecting <italic>Acinetobacter baumannii</italic> against multiple stresses triggered by the host immune response, antibiotics and outside-host environment</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>:<fpage>5498</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21155498</pub-id></citation></ref>
<ref id="ref187"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname> <given-names>J.</given-names></name> <name><surname>Bergmann</surname> <given-names>H.</given-names></name> <name><surname>G&#x00F6;ttig</surname> <given-names>S.</given-names></name> <name><surname>Ebersberger</surname> <given-names>I.</given-names></name> <name><surname>Averhoff</surname> <given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title><italic>Acinetobacter baumannii</italic> virulence is mediated by the concerted action of three phospholipases D</article-title>. <source>PLoS One</source> <volume>10</volume>:<fpage>e0138360</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0138360</pub-id></citation></ref>
<ref id="ref188"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sugawara</surname> <given-names>E.</given-names></name> <name><surname>Nikaido</surname> <given-names>H.</given-names></name></person-group> (<year>2012</year>). <article-title>OmpA is the principal nonspecific slow porin of <italic>Acinetobacter baumannii</italic></article-title>. <source>J. Bacteriol.</source> <volume>194</volume>, <fpage>4089</fpage>&#x2013;<lpage>4096</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JB.00435-12</pub-id></citation></ref>
<ref id="ref189"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>Z.</given-names></name> <name><surname>Kang</surname> <given-names>Y.</given-names></name> <name><surname>Norris</surname> <given-names>M. H.</given-names></name> <name><surname>Troyer</surname> <given-names>R. M.</given-names></name> <name><surname>Son</surname> <given-names>M. S.</given-names></name> <name><surname>Schweizer</surname> <given-names>H. P.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Blocking phosphatidylcholine utilization in <italic>Pseudomonas aeruginosa</italic> via mutagenesis of fatty acid, glycerol, and choline degradation pathways, confirms the importance of this nutrient source in vivo</article-title>. <source>PLoS One</source> <volume>9</volume>:<fpage>e103778</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0103778</pub-id></citation></ref>
<ref id="ref190"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>B.</given-names></name> <name><surname>Liu</surname> <given-names>H.</given-names></name> <name><surname>Jiang</surname> <given-names>Y.</given-names></name> <name><surname>Shao</surname> <given-names>L.</given-names></name> <name><surname>Yang</surname> <given-names>S.</given-names></name> <name><surname>Chen</surname> <given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>New mutations involved in Colistin resistance in <italic>Acinetobacter baumannii</italic></article-title>. <source>MSphere</source> <volume>5</volume>, <fpage>e00895</fpage>&#x2013;<lpage>e00819</lpage>. doi: <pub-id pub-id-type="doi">10.1128/mSphere.00895-19</pub-id></citation></ref>
<ref id="ref1002"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tacconelli</surname> <given-names>E.</given-names></name> <name><surname>Carrara</surname> <given-names>E.</given-names></name> <name><surname>Savoldi</surname> <given-names>A.</given-names></name> <name><surname>Harbarth</surname> <given-names>S.</given-names></name> <name><surname>Mendelson</surname> <given-names>M.</given-names></name> <name><surname>Monnet</surname> <given-names>D. L.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis</article-title>. <source>Lancet Infect Dis.</source> <volume>18</volume>, <fpage>318</fpage>&#x2013;<lpage>327</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(17)30753-3</pub-id></citation></ref>
<ref id="ref191"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tamma</surname> <given-names>P. D.</given-names></name> <name><surname>Aitken</surname> <given-names>S. L.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name> <name><surname>Mathers</surname> <given-names>A. J.</given-names></name> <name><surname>van Duin</surname> <given-names>D.</given-names></name> <name><surname>Clancy</surname> <given-names>C. J.</given-names></name></person-group> (<year>2022</year>). <article-title>Infectious Diseases Society of America guidance on the treatment of AmpC &#x03B2;-lactamase-producing Enterobacterales, Carbapenem-resistant <italic>Acinetobacter baumannii</italic>, and <italic>Stenotrophomonas maltophilia</italic> infections</article-title>. <source>Clin. Infect. Dis.</source> <volume>74</volume>, <fpage>2089</fpage>&#x2013;<lpage>2114</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/ciab1013</pub-id></citation></ref>
<ref id="ref192"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tayabali</surname> <given-names>A. F.</given-names></name> <name><surname>Nguyen</surname> <given-names>K. C.</given-names></name> <name><surname>Shwed</surname> <given-names>P. S.</given-names></name> <name><surname>Crosthwait</surname> <given-names>J.</given-names></name> <name><surname>Coleman</surname> <given-names>G.</given-names></name> <name><surname>Seligy</surname> <given-names>V. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Comparison of the virulence potential of Acinetobacter strains from clinical and environmental sources</article-title>. <source>PLoS One</source> <volume>7</volume>:<fpage>e37024</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0037024</pub-id></citation></ref>
<ref id="ref193"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname> <given-names>M. G.</given-names></name> <name><surname>Black</surname> <given-names>C. C.</given-names></name> <name><surname>Pavlicek</surname> <given-names>R. L.</given-names></name> <name><surname>Honnold</surname> <given-names>C. L.</given-names></name> <name><surname>Wise</surname> <given-names>M. C.</given-names></name> <name><surname>Alamneh</surname> <given-names>Y. A.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Validation of a novel murine wound model of <italic>Acinetobacter baumannii</italic> infection</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>58</volume>, <fpage>1332</fpage>&#x2013;<lpage>1342</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01944-13</pub-id></citation></ref>
<ref id="ref194"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname> <given-names>G. B.</given-names></name> <name><surname>Adams-Haduch</surname> <given-names>J. M.</given-names></name> <name><surname>Taracila</surname> <given-names>M.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name> <name><surname>Wang</surname> <given-names>H. N.</given-names></name> <name><surname>Doi</surname> <given-names>Y.</given-names></name></person-group> (<year>2011</year>). <article-title>Extended-spectrum AmpC cephalosporinase in <italic>Acinetobacter baumannii</italic>: ADC-56 confers resistance to cefepime</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>55</volume>:<fpage>4922e5</fpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00704-11</pub-id></citation></ref>
<ref id="ref195"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tierney</surname> <given-names>A. R. P.</given-names></name> <name><surname>Chin</surname> <given-names>C. Y.</given-names></name> <name><surname>Weiss</surname> <given-names>D. S.</given-names></name> <name><surname>Rather</surname> <given-names>P. N.</given-names></name></person-group> (<year>2021</year>). <article-title>A LysR-type transcriptional regulator controls multiple phenotypes in <italic>Acinetobacter baumannii</italic></article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>11</volume>:<fpage>778331</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2021.778331</pub-id></citation></ref>
<ref id="ref196"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tiku</surname> <given-names>V.</given-names></name></person-group> (<year>2022</year>). <article-title><italic>Acinetobacter baumannii</italic>: virulence strategies and host Defense mechanisms</article-title>. <source>DNA Cell Biol.</source> <volume>41</volume>, <fpage>43</fpage>&#x2013;<lpage>48</lpage>. doi: <pub-id pub-id-type="doi">10.1089/dna.2021.0588</pub-id></citation></ref>
<ref id="ref197"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tiku</surname> <given-names>V.</given-names></name> <name><surname>Kofoed</surname> <given-names>E. M.</given-names></name> <name><surname>Yan</surname> <given-names>D.</given-names></name> <name><surname>Kang</surname> <given-names>J.</given-names></name> <name><surname>Xu</surname> <given-names>M.</given-names></name> <name><surname>Reichelt</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Outer membrane vesicles containing OmpA induce mitochondrial fragmentation to promote pathogenesis of <italic>Acinetobacter baumannii</italic></article-title>. <source>Sci. Rep.</source> <volume>11</volume>:<fpage>618</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-79966-9</pub-id></citation></ref>
<ref id="ref198"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tipton</surname> <given-names>K. A.</given-names></name> <name><surname>Dimitrova</surname> <given-names>D.</given-names></name> <name><surname>Rather</surname> <given-names>P. N.</given-names></name></person-group> (<year>2015</year>). <article-title>Phase-variable control of multiple phenotypes in <italic>Acinetobacter baumannii</italic> strain AB5075</article-title>. <source>J. Bacteriol.</source> <volume>197</volume>, <fpage>2593</fpage>&#x2013;<lpage>2599</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JB.00188-15</pub-id></citation></ref>
<ref id="ref199"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tiseo</surname> <given-names>G.</given-names></name> <name><surname>Brigante</surname> <given-names>G.</given-names></name> <name><surname>Giacobbe</surname> <given-names>D. R.</given-names></name> <name><surname>Maraolo</surname> <given-names>A. E.</given-names></name> <name><surname>Gona</surname> <given-names>F.</given-names></name> <name><surname>Falcone</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM)</article-title>. <source>Int. J. Antimicrob. Agents</source> <volume>60</volume>:<fpage>106611</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2022.106611</pub-id></citation></ref>
<ref id="ref200"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toker</surname> <given-names>A.</given-names></name></person-group> (<year>2005</year>). <article-title>The biology and biochemistry of diacylglycerol signalling</article-title>. <source>EMBO Rep.</source> <volume>6</volume>, <fpage>310</fpage>&#x2013;<lpage>314</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.embor.7400378</pub-id></citation></ref>
<ref id="ref201"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomaras</surname> <given-names>A. P.</given-names></name> <name><surname>Dorsey</surname> <given-names>C. W.</given-names></name> <name><surname>Edelmann</surname> <given-names>R. E.</given-names></name> <name><surname>Actis</surname> <given-names>L. A.</given-names></name></person-group> (<year>2003</year>). <article-title>Attachment to and biofilm formation on abiotic surfaces by <italic>Acinetobacter baumannii</italic>: involvement of a novel chaperone-usher pili assembly system</article-title>. <source>Microbiology</source> <volume>149</volume>, <fpage>3473</fpage>&#x2013;<lpage>3484</lpage>. doi: <pub-id pub-id-type="doi">10.1099/mic.0.26541-0</pub-id></citation></ref>
<ref id="ref202"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomaras</surname> <given-names>A. P.</given-names></name> <name><surname>Flagler</surname> <given-names>M. J.</given-names></name> <name><surname>Dorsey</surname> <given-names>C. W.</given-names></name> <name><surname>Gaddy</surname> <given-names>J. A.</given-names></name> <name><surname>Actis</surname> <given-names>L. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Characterization of a two-component regulatory system from <italic>Acinetobacter baumannii</italic> that controls biofilm formation and cellular morphology</article-title>. <source>Microbiology</source> <volume>154</volume>, <fpage>3398</fpage>&#x2013;<lpage>3409</lpage>. doi: <pub-id pub-id-type="doi">10.1099/mic.0.2008/019471-0</pub-id></citation></ref>
<ref id="ref203"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toyofuku</surname> <given-names>M.</given-names></name> <name><surname>Inaba</surname> <given-names>T.</given-names></name> <name><surname>Kiyokawa</surname> <given-names>T.</given-names></name> <name><surname>Obana</surname> <given-names>N.</given-names></name> <name><surname>Yawata</surname> <given-names>Y.</given-names></name> <name><surname>Nomura</surname> <given-names>N.</given-names></name></person-group> (<year>2016</year>). <article-title>Environmental factors that shape biofilm formation</article-title>. <source>Biosci. Biotechnol. Biochem.</source> <volume>80</volume>:<fpage>1058701</fpage>. doi: <pub-id pub-id-type="doi">10.1080/09168451.2015.1058701</pub-id></citation></ref>
<ref id="ref204"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trebosc</surname> <given-names>V.</given-names></name> <name><surname>Gartenmann</surname> <given-names>S.</given-names></name> <name><surname>T&#x00F6;tzl</surname> <given-names>M.</given-names></name> <name><surname>Lucchini</surname> <given-names>V.</given-names></name> <name><surname>Schellhorn</surname> <given-names>B.</given-names></name> <name><surname>Pieren</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Dissecting Colistin resistance mechanisms in extensively drug-resistant <italic>Acinetobacter baumannii</italic> clinical isolates</article-title>. <source>MBio</source> <volume>10</volume>, <fpage>e01083</fpage>&#x2013;<lpage>e01019</lpage>. doi: <pub-id pub-id-type="doi">10.1128/mBio.01083-19</pub-id></citation></ref>
<ref id="ref205"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsuji</surname> <given-names>B. T.</given-names></name> <name><surname>Pogue</surname> <given-names>J. M.</given-names></name> <name><surname>Zavascki</surname> <given-names>A. P.</given-names></name> <name><surname>Paul</surname> <given-names>M.</given-names></name> <name><surname>Daikos</surname> <given-names>G. L.</given-names></name> <name><surname>Forrest</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>International consensus guidelines for the optimal use of the Polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)</article-title>. <source>Pharmacotherapy</source> <volume>39</volume>, <fpage>10</fpage>&#x2013;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1002/phar.2209</pub-id></citation></ref>
<ref id="ref206"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Upmanyu</surname> <given-names>K.</given-names></name> <name><surname>Haq</surname> <given-names>Q. M.</given-names></name> <name><surname>Singh</surname> <given-names>R.</given-names></name></person-group> (<year>2022</year>). <article-title>Factors mediating <italic>Acinetobacter baumannii</italic> biofilm formation: opportunities for developing therapeutics</article-title>. <source>Curr Res Microbial Sci</source> <volume>3</volume>:<fpage>100131</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.crmicr.2022.100131</pub-id></citation></ref>
<ref id="ref207"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uppalapati</surname> <given-names>S. R.</given-names></name> <name><surname>Sett</surname> <given-names>A.</given-names></name> <name><surname>Pathania</surname> <given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>The outer membrane proteins OmpA, CarO, and OprD of <italic>Acinetobacter baumannii</italic> Confer a two-pronged Defense in facilitating its success as a potent human pathogen</article-title>. <source>Front. Microbiol.</source> <volume>11</volume>:<fpage>589234</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2020.589234</pub-id></citation></ref>
<ref id="ref208"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Urusova</surname> <given-names>D. V.</given-names></name> <name><surname>Kinsella</surname> <given-names>R. L.</given-names></name> <name><surname>Salinas</surname> <given-names>N. D.</given-names></name> <name><surname>Haurat</surname> <given-names>M. F.</given-names></name> <name><surname>Feldman</surname> <given-names>M. F.</given-names></name> <name><surname>Tolia</surname> <given-names>N. H.</given-names></name></person-group> (<year>2019</year>). <article-title>The structure of Acinetobacter-secreted protease CpaA complexed with its chaperone CpaB reveals a novel mode of a T2SS chaperone&#x2013;substrate interaction</article-title>. <source>J. Biol. Chem.</source> <volume>294</volume>, <fpage>13344</fpage>&#x2013;<lpage>13354</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.RA119.009805</pub-id></citation></ref>
<ref id="ref209"><citation citation-type="other"><person-group person-group-type="author"><collab id="coll1">US Food and Drug Administration</collab></person-group>. (<year>2019</year>). Highlights of prescribing information: Fetroja (Cefiderocol). Available at: <ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209445s000lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209445s000lbl.pdf</ext-link>.</citation></ref>
<ref id="ref210"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van der Meer-Janssen</surname> <given-names>Y. P.</given-names></name> <name><surname>Van Galen</surname> <given-names>J.</given-names></name> <name><surname>Batenburg</surname> <given-names>J. J.</given-names></name> <name><surname>Helms</surname> <given-names>J. B.</given-names></name></person-group> (<year>2010</year>). <article-title>Lipids in host-pathogen interactions: pathogens exploit the complexity of the host cell lipidome</article-title>. <source>Prog. Lipid Res.</source> <volume>49</volume>, <fpage>1</fpage>&#x2013;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.plipres.2009.07.003</pub-id></citation></ref>
<ref id="ref211"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Venkataramana</surname> <given-names>G. P.</given-names></name> <name><surname>Lalitha</surname> <given-names>A. K. V.</given-names></name> <name><surname>Mariappan</surname> <given-names>S.</given-names></name> <name><surname>Sekar</surname> <given-names>U.</given-names></name></person-group> (<year>2022</year>). <article-title>Plasmid-mediated fluoroquinolone resistance in Pseudomonas aeruginosa and <italic>Acinetobacter baumannii</italic></article-title>. <source>J Lab Physicians.</source> <volume>14</volume>, <fpage>271</fpage>&#x2013;<lpage>277</lpage>. doi: <pub-id pub-id-type="doi">10.1055/s-0042-1742636</pub-id></citation></ref>
<ref id="ref212"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vila</surname> <given-names>J.</given-names></name> <name><surname>Mart&#x00ED;</surname> <given-names>S.</given-names></name> <name><surname>Sanchez-C&#x00E9;spedes</surname> <given-names>J. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Porins, efflux pumps and multidrug resistance in <italic>Acinetobacter baumannii</italic></article-title>. <source>J. Antimicrob. Chemother.</source> <volume>59</volume>, <fpage>1210</fpage>&#x2013;<lpage>1215</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkl509</pub-id></citation></ref>
<ref id="ref213"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Volpicelli</surname> <given-names>L.</given-names></name> <name><surname>Venditti</surname> <given-names>M.</given-names></name> <name><surname>Ceccarelli</surname> <given-names>G.</given-names></name> <name><surname>Oliva</surname> <given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Place in therapy of the newly available armamentarium for multi-drug-resistant gram-negative pathogens: proposal of a prescription algorithm</article-title>. <source>Antibiotics</source> <volume>10</volume>:<fpage>1475</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics10121475</pub-id></citation></ref>
<ref id="ref214"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waack</surname> <given-names>U.</given-names></name> <name><surname>Warnock</surname> <given-names>M.</given-names></name> <name><surname>Yee</surname> <given-names>A.</given-names></name> <name><surname>Huttinger</surname> <given-names>Z.</given-names></name> <name><surname>Smith</surname> <given-names>S.</given-names></name> <name><surname>Kumar</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>CpaA is a glycan-specific Adamalysin-like protease secreted by <italic>Acinetobacter baumannii</italic> that inactivates coagulation factor XII</article-title>. <source>MBio</source> <volume>9</volume>, <fpage>e01606</fpage>&#x2013;<lpage>e01618</lpage>. doi: <pub-id pub-id-type="doi">10.1128/mBio.01606-18</pub-id></citation></ref>
<ref id="ref215"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y. C.</given-names></name> <name><surname>Huang</surname> <given-names>T. W.</given-names></name> <name><surname>Yang</surname> <given-names>Y. S.</given-names></name> <name><surname>Kuo</surname> <given-names>S. C.</given-names></name> <name><surname>Chen</surname> <given-names>C. T.</given-names></name> <name><surname>Liu</surname> <given-names>C. P.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Biofilm formation is not associated with worse outcome in <italic>Acinetobacter baumannii</italic> bacteraemic pneumonia</article-title>. <source>Sci. Rep.</source> <volume>8</volume>:<fpage>7289</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-018-25661-9</pub-id></citation></ref>
<ref id="ref216"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y. C.</given-names></name> <name><surname>Kuo</surname> <given-names>S. C.</given-names></name> <name><surname>Yang</surname> <given-names>Y. S.</given-names></name> <name><surname>Lee</surname> <given-names>Y. T.</given-names></name> <name><surname>Chiu</surname> <given-names>C. H.</given-names></name> <name><surname>Chuang</surname> <given-names>M. F.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Individual or combined effects of meropenem, imipenem, sulbactam, colistin, and tigecycline on biofilm-embedded <italic>Acinetobacter baumannii</italic> and biofilm architecture</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>60</volume>, <fpage>4670</fpage>&#x2013;<lpage>4676</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00551-16</pub-id></citation></ref>
<ref id="ref217"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>S. H.</given-names></name> <name><surname>Yang</surname> <given-names>K. Y.</given-names></name> <name><surname>Sheu</surname> <given-names>C. C.</given-names></name> <name><surname>Chen</surname> <given-names>W. C.</given-names></name> <name><surname>Chan</surname> <given-names>M. C.</given-names></name> <name><surname>Feng</surname> <given-names>J. Y.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>The necessity of a loading dose when prescribing intravenous colistin in critically ill patients with CRGNB-associated pneumonia: a multi-center observational study</article-title>. <source>Crit. Care</source> <volume>26</volume>:<fpage>91</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13054-022-03947-9</pub-id>, PMID: <pub-id pub-id-type="pmid">35379303</pub-id></citation></ref>
<ref id="ref218"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>C.</given-names></name> <name><surname>Yang</surname> <given-names>D.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Ni</surname> <given-names>W.</given-names></name></person-group> (<year>2022</year>). <article-title>Cefiderocol for the treatment of multidrug-resistant gram-negative bacteria: a systematic review of currently available evidence</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>:<fpage>896971</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2022.896971</pub-id></citation></ref>
<ref id="ref219"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname> <given-names>B. S.</given-names></name> <name><surname>Kinsella</surname> <given-names>R. L.</given-names></name> <name><surname>Harding</surname> <given-names>C. M.</given-names></name> <name><surname>Feldman</surname> <given-names>M. F.</given-names></name></person-group> (<year>2017</year>). <article-title>The secrets of Acinetobacter secretion</article-title>. <source>Trends Microbiol.</source> <volume>25</volume>, <fpage>532</fpage>&#x2013;<lpage>545</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tim.2017.01.005</pub-id></citation></ref>
<ref id="ref220"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weinberg</surname> <given-names>S. E.</given-names></name> <name><surname>Villedieu</surname> <given-names>A.</given-names></name> <name><surname>Bagdasarian</surname> <given-names>N.</given-names></name> <name><surname>Karah</surname> <given-names>N.</given-names></name> <name><surname>Teare</surname> <given-names>L.</given-names></name> <name><surname>Elamin</surname> <given-names>W. F.</given-names></name></person-group> (<year>2020</year>). <article-title>Control and management of multidrug resistant <italic>Acinetobacter baumannii</italic>: a review of the evidence and proposal of novel approaches</article-title>. <source>Infect Prev Pract.</source> <volume>2</volume>:<fpage>100077</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.infpip.2020.100077</pub-id></citation></ref>
<ref id="ref1001"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wences</surname> <given-names>M.</given-names></name> <name><surname>Wolf</surname> <given-names>E. R.</given-names></name> <name><surname>Li</surname> <given-names>C.</given-names></name> <name><surname>Singh</surname> <given-names>N.</given-names></name> <name><surname>Bah</surname> <given-names>N.</given-names></name> <name><surname>Tan</surname> <given-names>X.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Combatting Planktonic and Biofilm Populations of Carbapenem-Resistant Acinetobacter baumannii with Polymyxin-Based Combinations</article-title>. <source>Antibiotics (Basel).</source> <volume>11</volume>:<fpage>959</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics11070959</pub-id></citation></ref>
<ref id="ref221"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whiteway</surname> <given-names>C.</given-names></name> <name><surname>Breine</surname> <given-names>A.</given-names></name> <name><surname>Philippe</surname> <given-names>C.</given-names></name> <name><surname>Van der Henst</surname> <given-names>C.</given-names></name></person-group> (<year>2022</year>). <article-title>Acinetobacter baumannii</article-title>. <source>Trends Microbiol.</source> <volume>30</volume>, <fpage>199</fpage>&#x2013;<lpage>200</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tim.2021.11.008</pub-id></citation></ref>
<ref id="ref222"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname> <given-names>D.</given-names></name> <name><surname>Nielsen</surname> <given-names>T. B.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name> <name><surname>Pantapalangkoor</surname> <given-names>P.</given-names></name> <name><surname>Luna</surname> <given-names>B.</given-names></name> <name><surname>Spellberg</surname> <given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>30</volume>, <fpage>409</fpage>&#x2013;<lpage>447</lpage>. doi: <pub-id pub-id-type="doi">10.1128/CMR.00058-16</pub-id></citation></ref>
<ref id="ref224"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname> <given-names>M. S.</given-names></name> <name><surname>Iovleva</surname> <given-names>A.</given-names></name> <name><surname>Jacobs</surname> <given-names>M. R.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name> <name><surname>Adams</surname> <given-names>M. D.</given-names></name></person-group> (<year>2016</year>). <article-title>Genome dynamics of multidrug-resistant <italic>Acinetobacter baumannii</italic> during infection and treatment</article-title>. <source>Genome Med.</source> <volume>8</volume>:<fpage>26</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13073-016-0279-y</pub-id></citation></ref>
<ref id="ref225"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>C. F.</given-names></name> <name><surname>Bilya</surname> <given-names>S. R.</given-names></name> <name><surname>Xu</surname> <given-names>W.</given-names></name></person-group> (<year>2019</year>). <article-title>adeABC efflux gene in <italic>Acinetobacter baumannii</italic></article-title>. <source>N. Microbes N. Infect.</source> <volume>30</volume>:<fpage>100549</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nmni.2019.100549</pub-id></citation></ref>
<ref id="ref226"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamano</surname> <given-names>Y.</given-names></name> <name><surname>Ishibashi</surname> <given-names>N.</given-names></name> <name><surname>Kuroiwa</surname> <given-names>M.</given-names></name> <name><surname>Takemura</surname> <given-names>M.</given-names></name> <name><surname>Sheng</surname> <given-names>W. H.</given-names></name> <name><surname>Hsueh</surname> <given-names>P. R.</given-names></name></person-group> (<year>2021</year>). <article-title>Characterisation of cefiderocol-non-susceptible <italic>Acinetobacter baumannii</italic> isolates from Taiwan</article-title>. <source>J. Glob. Antimicrob. Resist.</source> <volume>28</volume>, <fpage>120</fpage>&#x2013;<lpage>124</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nmni.2019.100549</pub-id></citation></ref>
<ref id="ref227"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>C. H.</given-names></name> <name><surname>Su</surname> <given-names>P. W.</given-names></name> <name><surname>Moi</surname> <given-names>S. H.</given-names></name> <name><surname>Chuang</surname> <given-names>L. Y.</given-names></name></person-group> (<year>2019</year>). <article-title>Biofilm formation in <italic>Acinetobacter baumannii</italic>: genotype-phenotype correlation</article-title>. <source>Molecules</source> <volume>24</volume>:<fpage>1849</fpage>. doi: <pub-id pub-id-type="doi">10.3390/molecules24101849</pub-id></citation></ref>
<ref id="ref228"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname> <given-names>E. J.</given-names></name> <name><surname>Chabane</surname> <given-names>Y. N.</given-names></name> <name><surname>Goussard</surname> <given-names>S.</given-names></name> <name><surname>Snesrud</surname> <given-names>E.</given-names></name> <name><surname>Courvalin</surname> <given-names>P.</given-names></name> <name><surname>D&#x00E9;</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Contribution of resistance-nodulation-cell division efflux systems to antibiotic resistance and biofilm formation in <italic>Acinetobacter baumannii</italic></article-title>. <source>MBio</source> <volume>6</volume>, <fpage>e00309</fpage>&#x2013;<lpage>e00315</lpage>. doi: <pub-id pub-id-type="doi">10.1128/mBio.00309-15</pub-id></citation></ref>
<ref id="ref229"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeighami</surname> <given-names>H.</given-names></name> <name><surname>Valadkhani</surname> <given-names>F.</given-names></name> <name><surname>Shapouri</surname> <given-names>R.</given-names></name> <name><surname>Samadi</surname> <given-names>E.</given-names></name> <name><surname>Haghi</surname> <given-names>F.</given-names></name></person-group> (<year>2019</year>). <article-title>Virulence characteristics of multidrug resistant biofilm forming <italic>Acinetobacter baumannii</italic> isolated from intensive care unit patients</article-title>. <source>BMC Infect. Dis.</source> <volume>19</volume>:<fpage>629</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12879-019-4272-0</pub-id></citation></ref>
<ref id="ref230"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>X.</given-names></name> <name><surname>Tian</surname> <given-names>J.</given-names></name> <name><surname>Wu</surname> <given-names>N.</given-names></name> <name><surname>Fan</surname> <given-names>Y.</given-names></name></person-group> (<year>2013</year>). <article-title>Probing the molecular determinant of the lipase-specific foldase Lif26 for the interaction with its cognate Lip26</article-title>. <source>Int. J. Biol. Macromol.</source> <volume>53</volume>, <fpage>54</fpage>&#x2013;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2012.11.007</pub-id></citation></ref>
</ref-list>
</back>
</article>